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Zusammenfassung 
Vesikulärer Transport ist ein hochgradig regulierter Prozess. Eine Schlüsselfunktion 
übernehmen hierbei Proteine der Rab Familie, die mit 60 Mitgliedern die größte Gruppe 
innerhalb der Ras Superfamilie kleiner monomerer GTPasen darstellt. Rabs rekrutieren als 
Effektoren bezeichnete Proteine zur Membran von Organellen, deren Identität sie hierdurch 
definieren. Rabs können sowohl in einer aktiven, GTP gebundenen, als auch in einer 
inaktiven Gestalt, gebunden an GDP, auftreten. Eine Schlüsselfunktion in ihrer Regulation 
kommt RabGAPs zu, die katalytisch die Hydrolyse gebundenen GTPs beschleunigen.  
Durch Datenbankanalyse wurden im humanen Genom 40 dieser GAPs, die durch 
eine TBC Domäne charakterisiert sind, identifiziert. Um spezifische Rab-RabGAP Paare 
erkennen zu können, wurde ein neuartiges Hefe-Hybrid Verfahren entwickelt. Mittels dieses 
Verfahrens wurde ein RabGAP-5 benanntes GAP identifiziert, das spezifisch die GTP 
Hydrolyse durch Rab5 stimulierte. Die Expression von RabGAP-5 führte zur Inaktivierung 
von Rab5 und dem Verlust des Rab5 Effektors EEA1 von Endosomen. RabGAP-5 war des 
Weiteren in der Lage, die von Rab5 abhängige Aufnahme von EGF und Transferrin zu 
blockieren. Die Depletion von RabGAP-5 führte durch die erhöhte Menge von GTP 
gebundenem Rab5 zu vergrößerten Endosomen und blockierte den Transport von EGF. 
 Um im Weiteren an der Regulation der Sekretion beteiligte Rabs und ihre GAPs zu 
identifizieren, wurde eine neue Methode etabliert, die es, basierend auf der Inaktivierung von 
endogenen Rabs durch Expression ihrer GAPs, ermöglicht, beide Partner zugleich zu 
erkennen. 
 Mittels dieses Verfahrens wurde der Einfluss von RabGAPs auf den Golgi Apparat, 
das ERGIC und die Sekretion untersucht. Dies führte zur Identifikation von TBC1D20 als 
alleinigem gemeinsamem Regulator dieser Prozesse und Organellen, einem hochgradig 
konservierten Protein. Dieses Protein stimulierte die GTP Hydrolyse sowohl durch Rab1 als 
auch durch Rab2, und reguliert in vivo in erster Linie Rab1. Als einziges RabGAP besitzt 
TBC1D20 eine Transmembran-Domäne, durch die es im ER verankert wird. Hier interagiert 
TBC1D20 mit RTN-1, welches seine Aktivität moduliert. 
Diese Ergebnisse zeigen eine bisher unbekannt Funktion von Rab1 bei der 
Regulation von Prozessen auf der Ebene des ER auf. Des Weiteren wird das klassische Bild 
von RabGAPs als Regulatoren der Lebensspanne aktiver, GTP gebundener Rab GTPasen, 
durch diese Ergebnisse erweitert. 
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Abstract 
Vesicle traffic in eukaryotic cells is a tightly organized process involving a multitude of 
regulatory proteins. Key regulators of this traffic are small GTPases called Rabs. With about 
60 members in the human genome, they constitute the largest subgroup in the superfamily of 
Ras like monomeric GTPases. They recruit effector proteins to specific membranes and thus 
define the identity of organelles. Rabs switch between an active, GTP bound state and an 
inactive GDP bound state. Key regulators of this conversion are RabGAPs, which accelerate 
the hydrolysis of bound GTP. All RabGAPs are characterized by the presence of a TBC 
domain. 
In the human genome 40 RabGAPs were identified, most of which had not been 
studied so far. To assign them to their specific Rab proteins, a novel reverse yeast two-
hybrid screening method was developed. This identified a GAP for Rab5 termed RabGAP-5. 
RabGAP-5 stimulated the GTPase activity of Rab5. Its expression inactivated Rab5 and 
redistributed the Rab5 effector EEA1 from early endosomes to the cytoplasm. RabGAP-5 
also blocked the Rab5 dependent uptake of EGF and transferrin from the plasma membrane. 
When RabGAP-5 was depleted, the size of endosomes was increased, indicating elevated 
Rab5-GTP levels. Endocytosed EGF was unable to exit the endosome, indicating that 
trafficking through endosomes was also blocked. 
To identify GAPs and Rabs implicated in the regulation of early secretory events 
simultaneously, a second novel screening method was established. It involved the analysis of 
phenotypes caused by the inactivation of endogenous target Rabs via the overexpression of 
RabGAPs. 
Changes in Golgi morphology, ERGIC organisation and the proceeding of secretion 
were only observed with one candidate RabGAP, the highly conserved protein TBC1D20. 
TBC1D20 showed activity towards Rab1 and Rab2 in vitro, and acted primarily on Rab1 in 
vivo. In contrast to all other RabGAPs it has a transmembrane domain, which localises it to 
the ER. TBC1D20 interacts with RTN-1 on ER membranes. This interaction modulates the 
activity of TBC1D20. 
These data indicate a novel function for Rab1 in regulating ER exit, and thus extend the 
classical view of RabGAPs as regulators of active Rab lifetime. 
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1 Introduction 
1.1 Intracellular membrane trafficking 
1.1.1 Organelles and vesicle trafficking  
Eukaryotic cells are compartmentalised into membrane bound organelles that establish and 
maintain functionally discrete environments. Organelles therefore differ in their protein and 
lipid composition as well as in their luminal content. 
To equip the organelles with their unique protein and lipid composition as well as to 
exchange material between them, membrane trafficking is required. Membrane traffic 
describes a series of steps by which proteins and lipids are exchanged between 
compartments in the form of small membrane bound carriers termed vesicles. This exchange 
is a highly organised and tightly regulated process generating and maintaining the different 
properties of each organelle. 
To organise the various steps along the route of a vesicle from one to the other 
compartment, many regulatory and accessory proteins are required at each step. Even though 
the understanding of these proteins and the processes needed for proper vesicle mediated 
transport has made great progress in recent years (Jahn and Scheller, 2006; van Vliet et al., 
2003), many questions still remain to be answered. 
1.1.2 Trafficking pathways 
Membrane trafficking can be divided into two general pathways (Figure 1-1). Material taken 
up from the plasma membrane and transported towards the inside of the cell follows the 
endocytic pathway. Proteins and lipids produced by the cell that traffic to destinations within 
the cell or become secreted, follow the secretory pathway. 
Proteins trafficking through the secretory pathway are synthesised at the 
endoplasmatic reticulum (ER) by ER attached ribosomes. They leave the ER at ER exit sites 
(ERES) in vesicles coated with the Coat Protein Complex II (COPII) (Tang et al., 2005). 
These vesicles fuse with each other and form the ER-Golgi intermediate compartment 
(ERGIC) (Appenzeller-Herzog and Hauri, 2006). The next stage is the Golgi apparatus 
where cargo is modified and sorted. ER resident proteins recycle back to the ER in COPI 
vesicles. The Golgi is divided in functionally discrete sub-compartments termed cis-, medial- 
and trans-Golgi. The final compartment of the Golgi is called the trans-Golgi network 
(TGN) (Griffiths and Simons, 1986). Here cargo is sorted into clathrin-coated vesicles 
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(McNiven and Thompson, 2006), which traffic to the plasma membrane (PM) or other sub-
cellular compartments (Gu et al., 2001). The TGN also receives vesicles from organelles of 
the endocytic pathway (Bonifacino and Rojas, 2006), and thus functions as an integrator of 
both the secretory and the endocytic pathway. 
 
 
Figure 1-1 Mammalian membrane compartments and trafficking pathways. Left hand side: The 
secretory pathway is initiated at the endoplasmatic reticulum (ER). Cargo proteins (*) are produced 
by ER associated ribosomes. Cargo leaves the ER in COPII (orange coat) vesicles at ER exit sites 
(ERES). Cargo traffics via the ER-Golgi intermediate compartment (ERGIC) to the cis- medial- and 
trans-Golgi (CG, MG, TG). ER resident proteins are recycled in COPI (green coat) vesicles. The final 
stage of the Golgi is the trans-Golgi network (TGN) that functions as an integrator of secretory and 
endocytic traffic. Cargo can undergo regulated secretion (RS) and traffic to the plasma membrane 
(PM) via secretory granules (SG) or directly traffic to the PM via the constitutive secretory pathway 
(CS). Right hand side: The endocytic pathway is initiated at the PM. Activated receptors (T) are 
endocytosed via clathrin-coated (blue coat) pits (CCP) and clathrin-coated vesicles (CCV) to early 
endosomes (EE). Cargo can be recycled via recycling endosomes (RE). Cargo destined for 
degradation traffics via late endosomes or multi vesiculated bodies (LE/MVB) to lysosomes (LY). 
Drawing is not to scale. 
 
Multiple parallel endocytic pathways are initiated at the PM (Mayor and Pagano, 
2007). In clathrin dependent endocytosis, activated receptors accumulate in clathrin-coated 
pits (CCP), which are pinched off and form clathrin-coated vesicles (CCV) (McNiven and 
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Thompson, 2006). These vesicles fuse with early endosomes (EEs). Cargo designated to be 
recycled traffics through the recycling endosome (RE) back to the PM (Maxfield and 
McGraw, 2004). Cargo designated for degradation remains in the EE, which matures into the 
late endosome (LE) or multivesicular body (MVB). Internal vesicles are generated at the 
MVB that remove the active receptors from the cytoplasm and stop signalling events 
(Katzmann et al., 2002). MVBs finally fuse with lysosomes (LY) and degrade their content 
(Futter et al., 1996). 
1.1.3 Vesicle trafficking has defined stages 
Vesicle trafficking is initiated from a donor compartment at specific vesicle formation sites 
that are enriched in cargo (Figure 1-2A). Cytosolic coat components are recruited to these 
sites and promote vesicle formation. Coats are supra-molecular assemblies of proteins that 
cover vesicles. Three main coat complexes can be distinguished in mammalian cells: the 
clathrin coats, associated with trafficking between the PM, the TGN and endosomal 
compartments; the COPI coat which functions in intra-Golgi and Golgi to ER traffic; and the 
COPII coat that is involved in anterograde trafficking from the ER to the Golgi. 
As coats or coat associated proteins recognize sorting signals, their association leads 
to further concentration of cargo at the vesicle formation site. The addition of further coat 
components leads to the polymerisation of the coat into a regulatory lattice. This 
polymerisation deforms flat membrane patches into buds (Figure 1-2B) and ultimately 
vesicles (Bonifacino and Lippincott-Schwartz, 2003). The neck still connecting the budding 
vesicle to the donor membrane (Figure 1-2C) is then severed either directly by the action of 
the coat (Matsuoka et al., 1998) or by accessory proteins like dynamin (McNiven and 
Thompson, 2006). After abscission from the donor membrane, the newly formed vesicles 
un-coat (Figure 1-2D). The coat is lost from vesicles either by the direct activity of the coat 
(Bi et al., 2002) or accessory proteins triggering uncoating (Lafer, 2002). The coat proteins 
then recycle to the vesicle formation site and participate in the formation of further vesicles. 
Motor proteins are recruited to the vesicle and mediate its transport along 
cytoskeletal structures such as actin fibres or microtubules (Figure 1-2E). This ensures long-
distance movement, and may not be essential for short distance traffic. 
Long distance docking and target recognition of the vesicle (Figure 1-2F) requires 
cytosolic proteins called tethers (Sztul and Lupashin, 2006). Tethers are proteins or protein 
complexes that usually form elongated rod like structures and bind to proteins on both the 
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vesicle and the target. The proximity generated by tethers is thought to enhance the 
efficiency of vesicle transport and facilitate the subsequent fusion (Pfeffer, 1999). 
The docking (Figure 1-2G) of vesicles to their acceptor membranes requires specific 
soluble NSF attachment protein receptors (SNAREs) (Jahn and Scheller, 2006). Specific 
SNAREs are found on both the vesicle and the donor membrane. All these SNAREs have a 
SNARE motif. Four SNARE motifs associate into a complex of four intertwined parallel α-
helices, in with each helix is provided by a different SNARE motif. This complex of 
extraordinary stability is called a SNAREpin (Weber et al., 1998). The SNAREpin assembly 
is thought to exert mechanical force on membranes, and thus causes fusion (Figure 1-2H). 
The fusion leads to the release of the cargo into the lumen of the acceptor compartment. The 
SNAREpin is then unwound by the combined action of the NEM-sensitive factor (NSF) 
(Block et al., 1988) and the soluble NSF attachment protein (SNAP) (Clary et al., 1990). The 
SNAREs and cargo receptor molecules are then recycled (Figure 1-2I) in vesicles to the 
donor membrane. 
 
 
Figure 1-2 Overview of vesicle transport. (A) Initiation of coat assembly at the donor membrane. 
(B) Budding and (C) abscission of the newly formed vesicle. (D) Uncoating of the vesicle and 
recycling of coat proteins. (E) Movement of the vesicle along cytoskeletal structures. (F) Tethering of 
the vesicle to the target membrane. (G) Docking and trans-SNARE complex formation. (H) 
SNAREpin formation driven membrane fusion and cargo release. (I) SNAREs and cargo receptors 
recycle to the donor compartment. Drawing is not to scale. 
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1.2 Small GTPases and membrane traffic 
1.2.1 The G domain 
Small monomeric GTPases belong to the so-called Ras superfamily. The family members, 
usually about 25 kDa in size, make one of the largest protein families in the human genome. 
Sequence analysis has revealed about 200 members (Wennerberg et al., 2005). This 
superfamily is divided into the five mayor groups Ras, Rho, Ran, Arf and Rab. 
The members of this family are characterised by a G domain that binds to guanine 
nucleotides. This domain is built by six β-strands surrounded by five α-helices (Figure 1-3), 
a typical conformation for nucleotide-binding domains. The nucleotide-interacting portion of 
the G domain, the G box, consists of five sequence elements, G1 to G5 (Bourne et al., 1991). 
Nucleotide binding is mediated by interactions of both the nucleotide base with an N/TKxD 
motif in G4 and the β- and γ-phosphates with the G1 phosphate-binding loop (P-loop), a 
GxxxxGKS/T motif. The G domain also coordinates a magnesium ion that is required for 
binding nucleotides. The DxxGQ motif in G3 is involved in GTP hydrolysis. Specificity for 
guanine nucleotides is due to an aspartate that forms hydrogen bonds with the guanine ring 
and hinders binding of adenine by the GTPase (Vetter and Wittinghofer, 2001). 
 
 
Figure 1-3 The G-domain. Protein in ribbon representation bound to GTP in ball and stick 
representation. The switch-I region is in green, the switch-II in lavender. Magnesium is represented 
as a blue sphere. Adapted from Vetter, 2001. 
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1.2.2 GTPases function as molecular switches 
A conserved characteristic of these GTPases is their ability to form stable complexes with 
both GTP and GDP. Two regions of the G-domain called switch-I and switch-II (Figure 1-3) 
undergo conformational changes dependent on the state of the bound nucleotide. The ability 
of small GTPases to exist in two conformations makes them molecular switches (Figure 
1-4). In the active, GTP-bound form, two hydrogen bonds from the γ-phosphate are formed 
to invariant threonine and glycine residues in switch-I and switch-II. These hydrogen bonds 
are lost when hydrolysis from GTP to GDP occurs and the switch regions relax into the 
inactive GDP bound conformation. The conformational change therefore works like a loaded 
spring (Vetter and Wittinghofer, 2001). 
To activate the GTPases, GTP is exchanged to GDP by guanine nucleotide exchange 
factors (GEFs). Even though different domains catalyse nucleotide exchange, they use 
similar mechanisms. GEFs open the nucleotide-binding cleft by destabilising it. This 
destabilisation reduces the nucleotide affinity and leads to dissociation of GDP (Vetter and 
Wittinghofer, 2001). There is no preference which nucleotide will be inserted by the GEF 
reaction. As the cellular GTP concentration is higher than the concentration of GDP and the 
interaction of the active GTPases their with downstream interacting proteins sequesters 
them, the equilibrium is shifted into the GDP-to-GTP direction (Cherfils and Chardin, 1999). 
GTPase activating proteins (GAPs) stimulate the weak basal GTP hydrolysis activity 
of the GTPases and thus inactivate them. The mechanism of GAP accelerated GTP 
hydrolysis will be discussed in more detail later. 
 
 
Figure 1-4 The GTPase cycle. GTPases cycle between an active conformation bound to GTP (red) 
and a inactive conformation (green) bound to GDP. Hydrolysis of GTP to GDP is stimulated by 
GAPs. The exchange of GDP to GTP is catalysed by GEFs. 
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The downstream interacting proteins of small GTPases, so-called effectors have 
much higher affinity to the GTPases in their active GTP bound conformation (Vetter and 
Wittinghofer, 2001). They bind to surfaces of the GTPases including the switch regions. The 
switch regions also contribute to the specificity of this interaction (Pereira-Leal and Seabra, 
2000). When the switch regions change their conformation upon hydrolysis from GTP to 
GDP, the interaction of the effector with the GTPase is lost. 
1.2.3 GTPases in vesicle trafficking 
Most tethers and coat subunits are recruited to membranes by the action of small GTPases 
(Munro, 2002). COPII requires Sar1 to associate with membranes and initiate the coat 
formation. Sar1 also functions as the timer for coat release, as a subunit of the coat also 
functions as a GAP for Sar1 (Bi et al., 2002). COPI on the other hands requires the small 
GTPase ARF (Serafini et al., 1991) that is closely related to Sar1. One group of Golgi 
associated tethers and structural elements termed Golgins (Short et al., 2005) have a so-
called GRIP domain (Munro and Nichols, 1999) that specifically binds to small GTPases of 
the Arl family (Panic et al., 2003). The related GRAB domain present in another group of 
golgins binds Arf1 (Gillingham et al., 2004). The exocyst, a huge multi subunit complex 
involved in exocytosis (Short and Barr, 2002), requires Rho and CDC42 for its proper spatial 
regulation (Guo et al., 2001; Zhang et al., 2001). 
1.2.4 Rab GTPases 
Many proteins or protein complexes involved in membrane trafficking require a member of 
the Rab family of small GTPases to be recruited to specific membranes. Rab GTPases were 
first identified as Ras-like from brain, (Gallwitz et al., 1983) and soon after shown to be 
involved in trafficking (Salminen and Novick, 1987). 
While coat proteins and SNARE machineries have only diversified modestly in the 
course of eukaryotic evolution, the Rab GTPase family expanded substantially during the 
specialization of the endomembrane system (Gurkan et al., 2007). With more than 60 
members (Wennerberg et al., 2005) in the human genome, the Rab family is the largest 
group of the Ras superfamily. S.cerevisiae has only eleven Rabs (Lazar et al., 1997) called 
Ypts (yeast protein transport). However, alignments of Rab and Ypt proteins show a high 
degree of conservation, and human and yeast Rab proteins can be grouped according to their 
segregation pattern in a phylogenetic tree (Figure 1-5). These groups that reflect similarity of 
sequence also represent shared ancestry (Pereira-Leal and Seabra, 2001). 
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Most Rabs that co-segregate in the phylogenetic tree share similar sub-cellular 
localisation and function. Ypt51/52/53 regulates endocytic events in yeast (Lazar et al., 
1997). It falls into one group with the mammalian Rabs Rab5a,b,c, Rab22a and Rab31 
(Figure 1-5). These Rabs regulate endocytosis in mammalian cells (Zerial and McBride, 
2001). Other Rabs of this group like Rab17, which are less closely related to Ypt51/52/53, 
are also involved in regulation of endosome associated trafficking (Zacchi et al., 1998). This 
suggests that specialised Rabs for different sorting events arose early in evolution. The 
increase in number of regulatory proteins reflects the increased complexity of higher 
eukaryotic cells. On the other hand, yeast Ypt1 is in a group with only two almost identical 
isoforms, Rab1a and Rab1b. This suggests that ER to Golgi trafficking, which is regulated 
by these Rabs was not subject to diversification throughout evolution. 
Some groups in this phylogenetic tree, like the Rab3/Rab27 group that is involved in 
regulated secretion (Zerial and McBride, 2001) do not have a yeast member. This suggests 
that these Rabs regulate trafficking events that are specific for higher eukaryotic cells. 
 
 
Figure 1-5 A phylogenetic tree of human and S.cerevisiae Rabs. S.cerevisiae Ypt proteins are 
depicted in red for easier discrimination. A blue background highlights one group of Rabs regulating 
endocytosis that are related to Ypt51/52/53. Length of lines represents similarity of amino acid 
sequence. 
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Many Rabs have isoforms with almost identical sequences. The differences between 
these isoforms are so far poorly studied. Most probably they regulate the same process 
redundantly or are tissue or developmental stage specific in their expression. Without 
isoforms, approximately 40 independent Rab proteins with a distinct function are found in 
the human genome. 
1.2.5 Rabs define membrane compartments 
Rabs localise to specific sub-cellular compartments (Figure 1-6) (Zerial and McBride, 2001). 
Every membrane compartment and trafficking step necessary to make a functioning cell is 
identified by a specific set of Rabs. 
Rabs tightly associate to membranes with two highly hydrophobic geranyl-geranly 
moieties that are covalently linked to cysteine residues at their very C-terminus. Active Rabs 
recruit effectors to specific membranes (Grosshans et al., 2006). Rab effectors can be 
integral and peripheral membrane proteins as well as cytosolic proteins and complexes. Rabs 
usually have multiple effectors but most effectors are specific for one Rab. Rabs provide 
identity to the membrane they are localising to by specifically concentrating these effector 
molecules (Pfeffer, 2001). This mechanism is not limited to entire organelles, as Rabs also 
define sub-domains (Pfeffer, 2003). Recycling endosomes for example are characterised by 
both Rab4 and Rab11 (Figure 1-6). 
Rabs define membrane compartments in combination with their effectors. Rab9 for 
example generates a functional sub-domain on late endosomes (Pfeffer, 2001). Rab9 is 
involved in the transport of MPRs from late endosomes to the TGN. The tail interacting 
protein of 47 kDa (TIP47) is a Rab9 effector that binds to MPRs. TIP47 preferentially binds 
to MPRs in the presence of Rab9. Its interaction with Rab9 enhances the affinity of TIP47 
for MPRs (Carroll et al., 2001). Active Rab9 therefore generates membrane domain enriched 
in MPRs and TIP47 designated to traffic to the TGN. 
Rabs can act in combination with specific lipids, mostly phosphoinositides. 
Phosphoinositides are generated by phosphorylation of PtdIns on specific inositol ring 
positions by PtdIns-kinases (Behnia and Munro, 2005). The Rab5 effector EEA1 for 
example requires both PtdIns(3)P and Rab5 to be recruited to early endosomes (Simonsen et 
al., 1998). 
Hypervariable sequences at the C-terminus of Rabs were previously thought to 
confer the membrane specificity (Chavrier et al., 1991). More recent findings challenge this 
view and show that a cooperative mode of Rabs and their effectors (Aivazian et al., 2006) 
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ensures proper membrane localisation. This suggests a model in which effectors need Rabs 
as much as Rabs need their effectors for specific localization. 
 
 
Figure 1-6 Rab proteins provide membrane identity. A selection of human Rab proteins linked to 
processes and organelles they regulate is depicted. The figure layout is based on Figure 1-1. 
Drawings are not to scale. 
1.2.6 Rabs modulate multiple steps in vesicular trafficking 
Rabs are involved in the regulation of multiple steps of vesicle trafficking. Their effectors 
exert various functions at these steps. In general, five distinct levels of trafficking have been 
shown to require Rabs (Segev, 2001). 
First, Rabs are involved at the step of vesicles formation and cargo or SNARE 
recruitment. The Rab1 effector p115 programs budding COPII vesicles by the incorporation 
of SNAREs necessary for their subsequent docking and fusion (Allan et al., 2000). Rab5 as 
another example is required for sequestration of activated receptors into CCPs prior to CCVs 
abscission (McLauchlan et al., 1998). 
Second, a role for Rabs in vesicle motility is suggested by several findings (Hammer 
and Wu, 2002). Rab6 interacts with the dynein/ dynactin complex and thus links vesicles to 
microtubules (Short et al., 2002). Melanosome localised Rab27 binds Melanophilin, which 
in turns binds myosin Va. This generates a tripartite protein complex that is required for 
melanosome motility along the actin skeleton (Fukuda et al., 2002). 
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Third, Rabs are proposed to be involved in active membrane remodelling processes. 
Rab5 and its effector EEA1 are proposed to interact with PI(3)-kinase, which generates 
PtdIns(3)P (Christoforidis et al., 1999b; Simonsen et al., 1998). The Rab5 effector 
Rabenosyn-5 binds to the Rab5 GEF Rabex-5 and is recruited by PtdIns(3)P as well (Nielsen 
et al., 2000). Thus a positive feedback loop is formed that generates more active Rab5 and a 
local increase of PtdIns(3)P. 
Fourth, Rabs are involved in long range docking of vesicles to their target by 
tethering. The tether p115 is recruited onto ER derived vesicles by Rab1 and interacts with 
the Golgi associated proteins GM130 and Giantin (Short et al., 2005). Furthermore, p115 is 
necessary for clustering of COPII vesicles to form the ERGIC (Alvarez et al., 1999). The 
Rab5 effector EEA1 is involved in homotypic early endosome docking and fusion 
(Christoforidis et al., 1999a; Mills et al., 1998; Simonsen et al., 1998). It is also required for 
the heterotypic fusion of early endosomes with CCVs (Rubino et al., 2000). 
Fifth, evidence is pointing to a role for Rabs in the event of membrane fusion by 
regulating the SNAREpin formation. Rabs themselves appear not to be directly involved in 
the regulation of SNARE function. However, in numerous cases, for example in the case of 
Rab1 (Allan et al., 2000) or Rab5 (McBride et al., 1999; Simonsen et al., 1999), their 
effectors interact with and modulate the activity of SNAREs. 
1.2.7 The classic Rab Cycle 
The regulation of Rabs is a process that involves multiple accessory and regulatory proteins. 
It is called the Rab cycle (Goody et al., 2005; Seabra and Wasmeier, 2004). 
Due to their highly hydrophobic geranyl-geranyl moieties, Rabs need a special 
chaperone called GDP dissociation inhibitor (GDI) (Sasaki et al., 1990) to be extracted from 
membranes and shuttle through the cytoplasm (Figure 1-7). GDI only associates with Rabs 
that are both prenylated and bound to GDP (Rak et al., 2003). This ensures that only inactive 
Rabs are extracted from membranes. GDI binds to the Rab and also provides a binding 
platform and a cavity to shield both prenyl groups from the cytoplasm (Pylypenko et al., 
2006). 
To release Rabs from GDI and insert them into membranes additional factors called 
GDI displacement factors (GDF) are required (Figure 1-7) (Wu et al., 2007). Only few of 
these are characterised so far, called either Ypt interacting proteins (YIP) (Sivars et al., 
2003) or prenylated Rab acceptors (PRA) (Hutt et al., 2000). These transmembrane proteins 
probably form a pore that facilitates the insertion of Rabs into the membrane. The kinetics of 
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the insertion and extraction of prenylated Rabs from membranes by GDI are 
thermodynamically similar (Pylypenko et al., 2006). To prevent recurrent membrane 
extraction the Rab must therefore become bound to GTP (Soldati et al., 1994). 
This exchange of GDP to GTP is mediated by GEFs (Figure 1-7). The substrate 
specificity of GEFs is crucial for the fidelity of membrane association of Rabs. GEFs are so 
far only poorly characterised. In contrast to other regulatory proteins GEFs do not share a 
common domain. Proteins with a VPS9 domain mediate nucleotide exchange in Rab5 related 
Rabs (Delprato et al., 2004). Sec2, which is the GEF for Sec4, catalyses the exchange 
reaction with a coiled coil (Dong et al., 2007). The transport protein particle complex I 
(TRAPPI) (Sacher et al., 1998) consists of multiple sub-units and has GEF activity towards 
YPT1. The addition of three further subunits changes both its localization and properties; the 
complex is then called TRAPPII and shows GEF activity towards YPT31 (Jones et al., 2000; 
Wang et al., 2000). 
The affinity of the Rab for its effector molecules rises by several orders of magnitude 
when it is in to the active conformation bound to GTP. The active Rab therefore recruits 
specific effector molecules to the membrane (Figure 1-7), which fulfil their downstream 
functions at the membrane specified by the Rab. The Rab-effector complex is dynamically 
regulated. When a vesicle fuses with its target membrane, the Rab has to be inactivated. As 
active Rabs define the identity of a membrane, this termination of their active state is 
mandatory to maintain the identity of the acceptor membrane after fusion with vesicles of 
different identity. 
To inactivate Rabs GAPs are needed (Figure 1-7). When the Rab is inactivated by the 
GAP, its affinity for its effectors is strongly reduced. The effectors relocate to the cytoplasm 
and recycle to the pool of GTP bound Rab. The inactive Rab is then extracted from the 
membrane by GDI. GDI shuttles the prenylated Rab through the cytoplasm and the Rab is 
reinserted in the donor membrane (Figure 1-7). 
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Figure 1-7 The classic Rab cycle. The small red sphere labelled GTP is active Rab bound to GTP, 
a small green square labelled GDP indicates inactive Rab bound to GDP. Rab interacting molecules 
are identified by common abbreviations. Sheets of grey spheres indicated lipid head groups. Drawing 
not to scale. 
1.3 RabGAPs regulate GTP hydrolysis by Rabs 
1.3.1 The TBC domain 
GAPs are key regulators of this classic Rab cycle. They regulate the lifetime of GTP bound 
Rab, and therefore regulate and maintain the identity of membranes conferred by Rabs. 
RabGAPs were first identified in S. cerevisiae (Strom et al., 1993), a decade after the first 
discovery of Rab GTPases (Gallwitz et al., 1983). A biochemical activity, which accelerated 
the GTP hydrolysis by Ypt6, was found in extracts generated by multi-copy plasmid based 
overexpression. Analysis of the plasmid revealed a gene named GAP for Ypt6 (GYP6) that 
encodes a 458 aa protein. After the identification of further Ypt GAPs (Albert and Gallwitz, 
1999; Vollmer and Gallwitz, 1995; Vollmer et al., 1999) it was noted that these proteins 
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share a common protein domain. Due to its sequence similarity with the human oncogene 
Tre2, with S.cerevisiae Bub2, and S.pombe Cdc16 (Neuwald, 1997) it was called a TBC 
domain. An arginine in the TBC domain is required to catalyse GTP hydrolysis similar to 
RasGAP (Albert et al., 1999). Human RabGAPs are TBC domain proteins as well (Cuif et 
al., 1999; Lanzetti et al., 2000). 
Bioinformatic analysis showed that the TBC domain is comprised of six sequence 
motifs termed A to F (Neuwald, 1997). Three of these motifs contain invariant so-called 
signature sequences: RxxxW in motif A; IxxDxxR in motif B; and YxQ in motif C. The 
sequence motifs A to F are part of the catalytically active region of the Ypt GAPs (Albert et 
al., 1999). The arginine required for hydrolysis is found in the signature sequence in motif B. 
The overall structure of the TBC domain is fully α-helical, and adopts the shape of the letter 
“V” (Rak et al., 2000). Invariant hydrophobic amino acids, which are contributed by 
multiple α-helices, form the core of the structure. The sequence motifs B and C are located 
in a rectangular groove inside the V. Co-crystallisation of yeast Gyp1 with human Rab33b 
showed that the Rab is bound in this rectangular groove (Pan et al., 2006). 
The TBC domain makes contact with the Rab via multiple α-helices. They mainly 
interact with both switch regions and the P-loop. This explains the nucleotide specificity and 
the substrate selectivity of RabGAPs. Mutations of residues contributing to this interaction 
decrease GAP activity. The specific recognition and interaction with target Rabs is therefore 
mandatory for specific acceleration of GTP hydrolysis. The interaction with the GAP is 
needed to position the Rab correctly relation to the GAP as the B and C motifs of the TBC 
domain form a loop that extends into the nucleotide-binding cleft of the Rab. 
1.3.2 The GTP hydrolysis reaction 
The GTP hydrolysis reaction cleaves the high-energy phosphoanhydride bond between the γ- 
and the β-phosphate. This leads to the conversion of GTP to GDP and inorganic phosphate 
(Pi) (Wittinghofer, 2006). After this reaction the two switch regions can no longer form 
hydrogen bonds to the γ-phosphate and thus change their conformation. 
The mechanism by which TBC domain proteins accelerate the GTP hydrolysis by 
Rabs was believed to be similar to the mechanism described for Ras. Here an arginine finger 
provided in trans by the GAP and a conserved glutamine provided by Ras in cis mediate 
GTP hydrolysis (Wittinghofer et al., 1997). However, recent co-crystallisation of a TBC 
domain with a Rab showed that a variation of this mechanism is used by RabGAPs (Pan et 
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al., 2006). Both the arginine and the glutamine are provided by the GAP in trans (Figure 
1-8). The conserved glutamine provided by the Rab mediates interaction with the backbone 
carbonyl of a tyrosine and the amino group of the glutamine provided by the TBC domain. 
This interaction is crucial to position the glutamine of the GAP properly. 
This trans glutamine of the TBC domain coordinates a water molecule for a 
nucleophilic attack on the γ- phosphate (Feuerstein et al., 1989). It is therefore is equivalent 
to the cis glutamine in other GTPases (Vetter and Wittinghofer, 2001). The nucleophilic 
attack leads to a shift of negative charge from the γ- to the β-phosphate (Figure 1-8). This 
charge distribution is closer to GDP than to GTP (Allin et al., 2001). The accumulating 
negative charge is compensated by the positively charged arginine provided by the GAP in 
trans (Figure 1-8). It was shown that this charge compensation by the arginine reduces the 
activation energy for the β - γ bond cleavage (Kotting et al., 2006). This arginine therefore 
helps to destabilise the bond between the γ- and the β-phosphate. It also promotes the 
formation of a dissociative transition state with a penta-coordinated phosphate group 
(Scheffzek et al., 1998). The Pi released during GTP hydrolysis can either fuse back to form 
GTP again or become the leaving group. Therefore the release of Pi is the rate-limiting step 
of the GTP hydrolysis reaction (Allin et al., 2001). Structures of Ras and its GAP show that 
the GAP covers the leaving group. The GAP is therefore thought to blocks Pi release 
(Scheffzek et al., 1997; Scheffzek et al., 1998). These structures suggest that the GAP acts as 
the rate-limiting factor in GAP activated GTP hydrolysis. 
 
 
Figure 1-8 Rab-GAP mediated GTP hydrolysis. This schematic depicts the probable transition 
state in TBC domain activated GTP hydrolysis. The amino acids involved directly or indirectly in 
catalysis are shown in orange. They are labelled with the common three letter abbreviations. The 
lavender sphere indicates the magnesium ion required for nucleotide coordination by the Rab. The 
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letter “G” indicates the guanine nucleotide. Attacking water molecule in red. Solid lines indicate 
bonds dashed lines indicate hydrogen bonds or ionic interactions. Drawing is not to scale. 
1.3.3 Open questions about Rab and their GAPs 
Many of the steps and factors involved in vesicle trafficking have been analysed in great 
detail. Both the vesicle formation by coats (Matsuoka et al., 1998) and SNARE mediated 
fusion (Weber et al., 1998) have been reconstituted in vitro. Much less is known about the 
other steps in vesicle trafficking. Rab GTPases and their effectors regulate most of these 
steps. The sheer amount of Rabs and their effectors has made the understanding of these 
steps so difficult. A better understanding of their regulation will help to gain further insight 
into this complex network. 
GAPs for Ras and Rho as prototypes for the Ras superfamily of monomeric GTPases 
have been studied in great detail (Bos et al., 2007). On the other hand, little is known about 
the GAPs of Rabs. Multiple GAPs for Rab GTPases have been identified by database 
research (Bernards, 2003). The attempt to match pairs of Rabs and their GAPs was only 
made in S. cerevisiae. In the human system so far only very few TBC domain proteins have 
been described or assigned to the Rabs they regulate. 
Work on RabGAPs in yeast led to the idea that these proteins are promiscuous in 
recognizing their substrate (Albert and Gallwitz, 1999). This is a very puzzling idea since 
GAPs bind the switch regions contributing to the specificity of effector binding (Pereira-Leal 
and Seabra, 2000). They furthermore regulate Rabs that regulate specific events in 
membrane trafficking. 
This work establishes the tools necessary to match pairs of human Rabs and GAPs and 
investigate the specificity of RabGAP substrate recognition. It also provides new insights 
into the trafficking processes they regulate. 
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2 Regulation of endocytosis by RabGAP-5 
2.1 Aim of this Work 
Endocytosis is a highly controlled process that involves many conserved families of proteins. 
One of the key players in this tightly orchestrated network of proteins is the family of Rab 
GTPases (Miaczynska and Zerial, 2002; Zerial and McBride, 2001). Rabs coordinate many 
steps of endocytic transport (Markgraf et al., 2007). One of the key Rabs regulating 
endocytosis and trafficking events at early endosomes is Rab5 (Zerial and McBride, 2001). 
GEFs and GAPs regulate the state of activity of Rabs. To find RabGAPs involved in 
the regulation of endocytosis, and for Rab5 in particular, the complete GAP family first had 
to be identified in the human genome. In a second step a system to identify the human GAP 
for Rab5 had to be established. Finally, this regulation had to be verified in cells by studying 
endocytic trafficking. 
2.2 Results 
2.2.1 Bioinformatic identification and characterisation of human RabGAPs 
It was known from work in yeast that RabGAPs contain a TBC domain (Albert et al., 1999; 
Strom et al., 1993; Vollmer et al., 1999). Human RabGAPs were known to contain TBC 
domains as well (Cuif et al., 1999; Lanzetti et al., 2004) but only very few members of this 
protein family were identified so far. The human genome was therefore searched for proteins 
containing a TBC domain using the online Basic Local Alignment Search Tool (BLAST) 
(http://www.ncbi.nlm.nih.gov/blast/). After eliminating splicing variants 40 proteins 
containing a TBC domain remained. The sequences of these proteins were aligned using the 
Vector NTI® software and further analysed (Figure 2-1). 
Even though these proteins showed enough similarity in their TBC domains for the 
algorithms to identify their relatedness, the TBC domain and the signature sequence 
IxxDxxR (T/S) in motif B are mutable. The arginine in the signature sequence that is 
involved in GTP hydrolysis is highly conserved, but not invariant. In some proteins, for 
example in USP6, part of the human tre oncogene, the arginine is shifted one position 
towards the N-terminus. Others like the TBC1D3 group showed no arginine in the catalytic 
motif. Some proteins like TBC1D7 have a TBC domain that lacks the signature sequence in 
motif B. 
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Figure 2-1 Sequence alignment of human TBC domain containing proteins. Only a part of the B 
motif with the signature sequence (IxxDxxR) containing the catalytic arginine is shown here. 
S.Cerevisiae BUB2 is added as a founding member of the TBC domain. In the consensus sequence 
the arginine involved in GTP hydrolysis is depicted in red. 
 
Most human TBC domain proteins are multi-domain proteins. The smallest proteins 
of this family only contain a TBC domain and have molecular weights between 30 and 40 
kDa like TBC1D20. The largest TBC domain proteins reach up to 160 kDa (e.g. USP6). The 
TBC domain can be situated at any position in the protein (Figure 2-2). Many different 
domains were found in RabGAPs, including phosphotyrosine-binding PTB domains; lipid 
binding PH domains; GRAM domains that are found in membrane associated phosphatases; 
ubiquitin ligase domains; SH3 domains involved in receptor tyrosine kinase signalling. Five 
examples of these diverse domain structures are shown in Figure 2-2. 
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Figure 2-2 Schematic representation of the domain structure of selected TBC domain 
proteins. Domains are indicated by the common abbreviations. Drawings are not to scale. 
2.2.2 Cloning of human RabGAPs 
After their bioinformatic identification, the RabGAPs were amplified from human cDNA 
libraries using PCR technology. The libraries used were either commercially available 
libraries generated from whole Foetus, Testis, Liver or Kidney, or were generated from 
mRNA purified from HeLa L cells. 
As a general strategy a mixture of these libraries was used as a source. PCR reactions 
were carried out using a nested PCR method described in (5.3.6). After excision of bands of 
the appropriate size from agarose gels, the DNA was integrated into a parental pCRIITOPO 
Vector. All inserts were verified by DNA sequencing and subsequently sub-cloned into 
mammalian and yeast expression vectors. 
2.2.3 Yeast two-hybrid screening to identify RabGAPs regulating endocytosis 
To identify a GAP for Rab5 the yeast two-hybrid technique was used. In a reverse screening 
system all TBC-domain proteins were tested against all human Rabs. All Rabs were sub-
cloned into the pGBT9 vector, which carries the GAL4 DNA binding domain. The TBC 
domain proteins were sub-cloned into the pACT2 vector, which contributes the GAL4 
activation domain to the synthetic transcription factor. Competent yeast cells were 
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transfected with both plasmids and plated onto selective media to select for co-transfection. 
After three days 5 independent colonies were transferred to quadruple dropout medium 
(QDO) to select for growth on medium lacking histidine and adenine as a readout of 
potential interactions. 
When the GAPs were tested against wild-type Rabs no specific signals were 
obtained. This was due to the fact that the interaction of a GAP and its target GTPase is 
transient (Allin et al., 2001) and is lost after GTP hydrolysis has occurred (Albert et al., 
1999). 
A conserved glutamine of all Rabs was therefore mutated to leucine to generate 
hydrolysis deficient Rabs that are restricted to their GTP bound conformation (Scheffzek et 
al., 1997). Each TBC domain protein was then tested against these Q-L Rabs. This approach 
identified several Rab- RabGAP interactions. Out of these only the RUN- and TBC-domain 
containing protein 3 interacted with Rab5Q79L. It also interacted with Rab22aQ64L and 
Rab31Q65L (Figure 2-3A) in this assay. The phylogenetic tree of Rabs (Figure 1-5) shows that 
these Rabs form a subfamily. This suggests that some, but not full specificity was gained 
using this approach. It led to the speculation that the introduction of the hydrophobic leucine 
in the Rabs prevented the correct insertion of the arginine finger of the GAP into the active 
site. This steric hindrance probably allowed the interaction of the GAP with several closely 
related Rabs. 
To overcome this steric hindrance, the arginine in the TBC domain was replaced by 
alanine. Each R-A mutant GAP was then tested against all Q-L Rabs. Again, several Rab-
RabGAP pairs were identified. Out of all RabGAPs tested, only the RUN- and TBC-domain 
containing protein 3R165A interacted with Rab5Q79L (Figure 2-3B). The interaction was 
stronger than in the previous experiments. In this assay the RUN- and TBC-domain 
containing protein 3 no longer showed an interaction with Rab22aQ64L and Rab31Q65L. 
Therefore it was referred to as RabGAP-5 to conform to the naming of the Rab5 exchange 
factor Rabex-5 (Horiuchi et al., 1997). 
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Figure 2-3 A system with two mutations is used for screening GAPs against Rabs. Five 
independent colonies were tested on SC-LW and QDO. Growth on QDO indicates an interaction 
between the two proteins. (A) Wild-type RabGAP-5 was tested against all human Rabs locked in 
their GTP bound state by introduction of Q-L point mutations. On selective QDO medium growth with 
Rab5Q79L, Rab22aQ64L and Rab31Q65L was observed. (B) RabGAP-5R165A was tested against a library 
of human Rabs locked in their GTP bound state. In this double mutant approach, RabGAP-5R165A 
only interacted with Rab5Q79L. 
 
Conformation specific Rab5 mutants were then used to confirm that the interaction 
between RabGAP-5 and Rab5 is dependent on the nucleotide state of Rab5 (Figure 2-4). 
When RabGAP-5 was tested against the Rab5 mutants the interaction was strongest 
with Rab5Q79L and RabGAP-5R165A. The interaction was weaker with Rab5WT and RabGAP-
5R165A. When both proteins where used as wild-type, no interaction was observed. Further 
demonstrating specificity, RabGAP-5 did not show any interaction with GDP-locked 
Rab5S20N. 
As a control for the nucleotide state of the mutant Rabs, the Rab5 exchange factor 
Rabex-5 (Horiuchi et al., 1997) and the Rab5 effector EEA1 (Simonsen et al., 1998) were 
used. Rabex-5 exclusively interacted with GDP-locked Rab5S20N whereas EEA1 only 
interacted with the GTP restricted Rab5Q79L. 
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Figure 2-4 Conformation specific mutants of Rab5 identify GEFs, effector molecules and 
GAPs. Directed two-hybrid tests of 3 different conformations of Rab5 against Rabex-5, EEA1, wild-
type RabGAP-5, and RabGAP-5R165A. Five independent colonies were tested on SC-LW and QDO. 
Growth on QDO indicates an interaction between the two proteins. 
 
Like most other TBC domain proteins, RabGAP-5 is a multi-domain protein (Figure 
2-2). The TBC domain is localised at its N-terminus. RabGAP-5 contains an Src-homology-
3 (SH3) domain C-terminal of the TBC domain. This domain recognizes proline-rich 
sequences (Mayer, 2001) and is mostly found in proteins involved in signal transduction. 
The third domain of RabGAP-5 is a RPIP8, UNC-14 and NESCA (RUN) domain (Callebaut 
et al., 2001) at its very C-terminus. The RUN domain is present in several proteins that are 
linked to GTPases of both the Rab and the Rap families. However, its molecular function is 
not known. 
2.2.4 RabGAP-5 specifically activates GTP hydrolysis by Rab5 
Next, the ability of RabGAP-5 to accelerate GTP-hydrolysis by Rab5 was tested using 
purified proteins. To address the question of specificity other Rabs related to Rab5 or 
reported to be involved in the regulation of endocytosis were tested as well. The Golgi 
associated Rab6 was used as a negative control. 
Rab proteins were generated as 6xHis and GST-tagged recombinant proteins in 
E.coli. They were purified using the 6xHis tag on Ni-NTA columns and dialysed into TBS 
containing 2mM DTT. RabGAP-5 was purified from E.coli tagged with maltose-binding 
protein (MBP) on the N-terminus. The C-terminus of the protein was tagged with a 6xHis 
tag. Recombinant RabGAP-5 was purified using the 6xHis tag on Ni-NTA agarose to ensure 
purification of full-length protein only. It was dialysed into TBS containing 2mM DTT.  
RabGAP-5 accelerated GTP-hydrolysis only by the three Rab5 isoforms Rab5a, 5b, 
and 5c (Figure 2-5A). None of the other Rabs tested showed significant increase of GTP 
hydrolysis upon addition of RabGAP-5 (Figure 2-5A). Also Rab22a and Rab31, which 
interacted with RabGAP-5 in the first yeast two-hybrid screen, were not stimulated by the 
addition of RabGAP-5. The N-terminal TBC-domain including aa 1-451 was purified in the 
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same way as the full-length protein. When tested under the same conditions, it activated 
GTP hydrolysis by Rab5 equivalent to the full-length protein (Figure 2-5B). This confirms 
the idea that the TBC domain acts as a RabGAP domain. The mutation of arginine165 in the 
catalytic site to alanine strongly reduced the ability of RabGAP-5 to stimulate GTP-
hydrolysis by Rab5 (Figure 2-5C). The constitutive active Rab5Q79L mutant did not 
hydrolyze GTP and was not stimulated upon addition of wild-type RabGAP-5 (Figure 2-5C). 
Taken together, these results indicate that RabGAP-5 is a GAP acting specifically on 
Rab5. They also support the data obtained by yeast two-hybrid screening using R-A mutant 
GAPs and Q-L Rabs. 
 
 
Figure 2-5 GTP- hydrolysis by Rab5 is accelerated by RabGAP-5. Gap assays were carried out 
using 100pmoles of the Rabs indicated. 10pmoles of RabGAP-5 indicated by filled bars or buffer as 
indicated by open bars were added. (A) Rabs were tested for their ability to hydrolyse GTP in the 
presence of buffer or RabGAP-5. (B) The TBC-domain of RabGAP-5 shows similar activity to the full-
length protein. (C) RabGAP-5R165A did not stimulate GTP hydrolysis by Rab5. Rab5Q79L is hydrolysis 
deficient. 
 
2.2.5 RN-tre is a specific Rab43 GAP 
Another TBC-domain protein called RN-tre (related to the N-terminus of tre) has previously 
been reported to have GAP activity towards Rab5 (Lanzetti et al., 2004; Lanzetti et al., 
2000). RN-tre was therefore analysed using the reverse yeast two-hybrid screening method. 
When wild-type RN-tre was tested against a library of GTP-restricted Rabs no 
growth of yeast on selective medium was observed. When RN-TreR150A was tested against a 
library of GTP-locked Rabs it interacted with Rab43Q77L and Rab30Q68L (Figure 2-6). These 
two Rabs form a group in the phylogenetic tree of human Rabs (Figure 1-5). While a weak 
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background signal was seen with Rab4Q72L, no interaction of RN-tre with Rab5Q79L was 
observed. 
Rab30 is known to associate with the Golgi apparatus (de Leeuw et al., 1998) but not 
with endosomal compartments. Rab43, formerly known as Rab41, was previously only 
described as a cDNA clone (Guo et al., 2003). 
 
 
Figure 2-6 RN-tre interacts with Rab30 and Rab43. A weak background signal was observed for 
Rab4. Five independent colonies were tested on SC-LW and QDO. Growth on QDO indicates an 
interaction between the two proteins. 
 
To further investigate the interaction of RN-tre with Rab43, recombinant RN-tre was 
produced as a MBP and 6xHis tagged protein as described for RabGAP-5. In an in vitro 
assay under the same conditions used for RabGAP-5, RN-Tre activated GTP-hydrolysis by 
Rab43 100-fold over the level observed in the absence of the GAP (Figure 2-7 A). RN-tre 
also weakly activated GTP-hydrolysis by Rab5, but to a much lesser extent. GTP Hydrolysis 
by Rab30 was stimulated by RN-tre to a minor extent. Based on the close relationship of 
Rab43 and Rab30 such a background activity in vitro is not surprising. When the catalytic 
arginine150 of RN-tre was mutated to alanine, the activity of RN-Tre towards Rab43 was lost 
(Figure 2-7B). It was therefore concluded that RN-tre acts as a GAP specific for Rab43 and 
not for Rab5. 
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Figure 2-7 RN-tre specifically activates GTP hydrolysis by Rab43. GAP assays were carried out 
using 100pmoles of the Rabs indicated. 10pmoles of RN-tre indicated by filled bars or buffer as 
indicated by open bars were added. (A) Rabs were tested for their ability to hydrolyse GTP in the 
presence of buffer or RN-tre. (B) RN-treR150A was not able to stimulate hydrolysis by Rab43. 
 
2.2.6 RabGAP-5 redistributes Rab5 effectors in vivo 
If RabGAP-5 acts as a GAP for Rab5 in vivo, then overexpression of the protein should 
redistribute Rab5 effectors such as EEA1 (Mu et al., 1995) to the cytosol. 
To localise to the early endosome, EEA1 requires both active Rab5 and PtdIns(3)P 
(Lawe et al., 2000; Simonsen et al., 1998). Neither factor in isolation is sufficient to localise 
EEA1 to early endosomes. If RabGAP-5 functions as a Rab5 specific GAP in vivo and 
inactivates Rab5, EEA1 would be lost from early endosomes. 
Consistent with this prediction, the expression of full-length myc–epitope tagged 
RabGAP-5 in HeLa cells resulted in the loss of EEA1 from punctate endosomal structures 
(Figure 2-8). The same was true for expression of the N-terminal TBC domain ranging from 
aa 1-451 (Figure 2-8). A faint staining of EEA1 throughout the cytoplasm was observed in 
both cases. Expression of the C-terminal SH3 and RUN domain containing part of RabGAP-
5 did not redistribute EEA1 (Figure 2-8). This indicates that EEA1 is lost from early 
endosomes as a result of the expression of the TBC domain of RabGAP-5. Expression of 
full-length inactive RabGAP-5R165A did not have an effect on the distribution of EEA1 
(Figure 2-8). This suggests that the redistribution of EEA1 depends on the catalytic 
inactivation of Rab5 by RabGAP-5. These data show that RabGAP-5 acts as a GAP for 
Rab5 in vivo. 
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Figure 2-8 RabGAP-5 redistributes EEA1. 24 hours after transfection with myc-epitope tagged full-
length wild-type RabGAP-5, truncation constructs or RabGAP-5R165A HeLa cells were fixed and 
stained with antibodies against the Myc epitope (red) and EEA1 (green). The bar indicates 10µm. 
 
If RabGAP-5 is a specific GAP for Rab5, then organelles independent of Rab5 for 
their formation and function will not be affected by expression of RabGAP-5. 
No effect of RabGAP-5 expression was observed on lysosomes (Figure 2-9A) stained 
with antibodies against the lysosomal protein LAMP1 (Rohrer et al., 1996). The Golgi 
apparatus stained with antibodies against the cis-Golgi marker GM130 (Nakamura et al., 
1995) was not affected by expression of RabGAP-5 as well (Figure 2-9B). 
This suggests that EEA1 is lost from early endosomes due to the specific inactivation 
of Rab5 by RabGAP-5. Non-specific side effects of RabGAP-5 expression on vesicle 
trafficking in general or inactivation of other Rab GTPases appear unlikely, as Rab5 
independent organelles like lysosomes and the Golgi remained unaffected. 
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Figure 2-9 RabGAP-5 expression does not affect Rab5 independent organelles. HeLa cells 
were transfected with myc-epitope tagged RabGAP-5 for 24h. The cells were then fixed and stained 
with for the Myc epitope (red) and (A) LAMP1 (green) or (B) GM130 (green) respectively. Bars 
indicate 10µm. 
 
2.2.7 RabGAP-5 causes redistribution of Rab5  
To investigate the inactivation of Rab5 by RabGAP-5, the fate of GFP-tagged Rab5 was 
followed. 
Wild-type Rab5 localized to early endosomes stained with EEA1 (Figure 2-10A). 
Expression of constitutive active Rab5Q79L caused the formation of enlarged endosomes 
(Figure 2-10A) as previously reported (Stenmark et al., 1994). Surprisingly, the GDP 
restricted Rab5S34N predominantly localized to the Golgi apparatus (Figure 2-10A). Co-
expression of myc-epitope tagged wild-type RabGAP-5 with GFP-tagged wild-type Rab5 
relocated Rab5 to the Golgi apparatus (Figure 2-10B) similar to the inactive Rab5S34N mutant 
(Figure 2-10A). This effect was due to the inactivation of Rab5 by RabGAP-5, as 
catalytically inactive RabGAP-5R165A did not redistribute wild-type Rab5 to the Golgi 
(Figure 2-10B). 
These findings indicate that Rab5 is inactivated by the catalytic activity of RabGAP-
5. RabGAP-5 therefore functions as a specific Rab5 GAP in vivo. 
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Figure 2-10 RabGAP-5 inactivates Rab5. (A) HeLa cells were transfected with GFP-tagged wild-
type and mutant Rab5 for 24h. The cells were then fixed and stained for EEA1 (red) or GM130 (red) 
respectively. (B) HeLa cells were co-transfected with myc-epitope tagged wild-type and inactive 
RabGAP-5R165A together with GFP-tagged wild-type Rab5 for 24h. The cells were then fixed with PFA 
and stained with for the myc-epitope tag (red). Bars indicate 10µm. 
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2.2.8 RN-tre does not function as a GAP for Rab5 in vivo 
Even though RN-tre was previously reported to act as a GAP for Rab5 it predominantly 
acted on Rab43 in vitro (Figure 2-7). 
To investigate the activity of RN-tre towards Rab5 in vivo, its influence on the 
distribution of EEA1 and Rab5 was analysed. In contrast to RabGAP-5, RN-Tre did not 
redistribute EEA1 (Figure 2-11A). The localisation of GFP-tagged wild-type Rab5 was also 
not affected by expression of RN-tre (Figure 2-11C). Rab43 localized to the Golgi (Figure 
2-11B) and is therefore unlikely to play a direct role in the regulation of endocytosis. 
These results suggest that RN-tre does not function as a specific Rab5 GAP in vivo. It 
rather appears to be involved in the regulation of Golgi associated trafficking. 
 
 
Figure 2-11 RN-tre does not function as a Rab5 GAP in vivo. (A) HeLa cells were transfected with 
myc-tagged RN-tre for 24 hours. The cells were then fixed and stained for the myc-epitope (red) and 
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EEA1 (green). (B) HeLa cells were transfected with GFP-tagged wild-type Rab43 for 24 hour. The 
cells were the fixed with PFA and stained for GM130 (red). (C) HeLa cells were co-transfected with 
myc-epitope tagged wild-type or inactive RN-treR150A together with GFP-tagged wild-type Rab5 24 
hours. The cells were then fixed with PFA and stained for the myc-epitope (red). Bars indicate 10µm. 
2.2.9 Expression of RabGAP-5 blocks the endocytosis of EGF 
Rab5 and its effector EEA1 are required on early endosomes for the regulation of several 
trafficking events (Christoforidis et al., 1999a; Rubino et al., 2000). Therefore, it was 
possible that RabGAP-5 overexpression might lead to a defect in early endosomal 
trafficking. To test this hypothesis, the endocytosis of the EGF receptor was investigated. 
After binding to its ligand the EGF receptor dimerises, auto-phosphorylates and 
signalling cascades are initiated (Carpenter, 2000). The EGF receptor is subsequently 
endocytosed into CCVs in a process that requires Rab5 (McLauchlan et al., 1998). CCVs 
fuse with each other and EEs in a Rab5 dependent process (Ceresa, 2006; Christoforidis et 
al., 1999a). Receptor signalling is propagated and amplified at EEs (Miaczynska et al., 
2004). After inactivation of Rab5 and activation of Rab7 (Feng et al., 1995; Rink et al., 
2005) the EGF receptor is sorted to MVBs and degraded (Stahl and Barbieri, 2002). 
When RabGAP-5 expression inactivates Rab5, trafficking of the EGF receptor from 
the cell surface through the early endocytic compartment should be blocked. This was 
analysed by following the fate of fluorescently labelled EGF. HeLa L cells were transfected 
with either wild-type or inactive RabGAP-5R165A 24 hours prior to the incubation with 
labelled EGF. Non-expressing neighbouring cells were used as control. The cells were 
incubated at 4°C in the presence of labelled EGF to allow binding to the receptor and then 
shifted to 37°C to initiate endocytosis of the activated receptor. 
Comparable amounts of EGF were bound to the surface of both RabGAP-5 
expressing and non-expressing cells (Figure 2-12A,B). After 10 minutes at 37°C EGF was 
found in small punctate structures, most likely clathrin coated vesicles, in non-expressing 
cells. In adjacent cells expressing RabGAP-5 EGF was still present at the plasma membrane 
(Figure 2-12A). After 30 minutes EGF was present in larger punctate structures resembling 
early endosomes in control cells. EGF was essentially lost from the PM of RabGAP-5 
expressing cells at this time point (Figure 2-12A). This loss was probably due to competition 
of excess unlabelled EGF in the growth medium. In cells expressing the inactive RabGAP-
5R165A EGF behaved exactly as in control cells was at any time point (Figure 2-12B).  
These data show that the expression of RabGAP-5 blocks the endocytosis of the 
EGF-receptor by the inactivation of Rab5. 
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Figure 2-12 Trafficking of EGF is blocked by RabGAP-5. HeLa cells were transfected with myc-
tagged (A) wild-type or (B) catalytically inactive RabGAP-5R165A for 24 hours. The cells were shifted 
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to 4°C and incubated with fluorescent EGF (green). Endocytosis of EGF was initiated by shifting of 
the cells to 37°C. The cells were fixed at the time points indicated, and stained for the myc-epitope 
tag (red). Bars indicate 10µm. 
2.2.10 RabGAP-5 blocks transferrin receptor trafficking 
After studying the fate of EGF receptor, a receptor undergoing degradation after endocytosis 
(Carpenter, 2000), a receptor recycling to the PM was analysed. 
The transferrin receptor recycles between endocytic compartments and the PM. EGF 
receptor and transferrin receptor are both endocytosed by the same pathway, but they are 
separated before EGF receptor is sorted into MVBs (Futter et al., 1996). The transferrin 
receptor is involved in iron homeostasis (Dautry-Varsat, 1986). Transferrin, a glycoprotein 
of the blood, transports iron. The iron-free form, apotransferrin, binds iron and forms 
ferrotransferrin. The transferrin receptor binds to ferrotransferrin and is endocytosed by a 
Rab5 dependent process into EEs. At the low pH of endosomes iron is released and 
apotransferrin is formed. Apotransferrin remains bound to the receptor. The receptor then 
recycles via REs in a Rab11 dependent process back to the PM (Sheff et al., 1999). At the 
neutral pH of the interstitial fluid apotransferrin is released from the transferrin receptor. 
To examine the effect of the expression of RabGAP-5 the fate of fluorescently 
labelled transferrin was followed. HeLa L cells were transfected with either wild-type or 
mutant RabGAP-5R165A 24 hours prior to the incubation with labelled transferrin. 
Neighbouring non-expressing cells were used as control. The cells were incubated with 
fluorescent transferrin at 4°C to allow binding to the receptor and subsequently shifted to 
37°C to initiate receptor endocytosis. 
Comparable amounts of transferrin were bound to the surface of both expressing and 
non-expressing cells (Figure 2-13A, B). After 5 minutes at 37°C, transferrin was internalised 
into small punctate structures in control cells. In adjacent RabGAP-5 expressing cells 
transferrin was still present as a diffuse haze characteristic of the plasma membrane (Figure 
2-13A). After 7.5 minutes transferrin was mainly seen in punctate structures in control cells. 
After this time point the fluorescence signal faded due to the recycling process. In cells 
expressing RabGAP-5 transferrin was still present at the plasma membrane at this time point 
(Figure 2-13A). When the catalytically inactive RabGAP-5R165A mutant was used, no 
difference in the trafficking of transferrin was observed between transfected and adjacent 
non-transfected control cells at any time-point (Figure 2-13B). 
These data show that endocytosis of the transferrin receptor is blocked in cells over-
expressing RabGAP-5 dependent on its ability to inactivate Rab5. 
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Figure 2-13 RabGAP-5 blocks endocytosis of the transferrin receptor. HeLa cells were 
transfected with myc-tagged (A) wild-type or (B) catalytically inactive RabGAP-5R165A for 24 hours. 
The cells were shifted to 4°C and incubated with fluorescent transferrin (green). Endocytosis of 
transferrin was initiated by shifting the cells to 37°C. The Cells were fixed at the time points indicated 
and stained for the myc-epitope tag (red). Bars indicate 10µm.  
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Next, the steady state distribution of the transferrin receptor was analysed in cells 
over-expressing RabGAP-5. The steady state distribution of this recycling receptor depends 
on various trafficking routes, at least one of which is dependent on the activity of Rab5. 
Various pools of the transferrin receptor can be observed in HeLa cells (Figure 2-14). 
One pool is on the cell surface to bind transferrin. This pool consists of recycled and newly 
synthesized receptors. The second pool is found in punctate structures inside the cell and 
corresponds to early endosomes. A third pool accumulates in the perinuclear region and 
corresponds to recycling endosomes. This normal distribution of the transferrin receptor was 
changed in cells expressing wild-type RabGAP-5 (Figure 2-14). The pool of transferrin 
receptor at the plasma membrane appeared unchanged, but the pools of transferrin receptor 
inside the cell were reduced. This effect was not observed in cells expressing RabGAP-
5R165A (Figure 2-14). 
Taken together, these findings show that RabGAP-5 interferes with trafficking of 
recycling proteins such as the transferrin receptor. The steady state of recycling proteins 
dependent on the activity of Rab5 is altered by RabGAP-5 expression as well. Therefore 
these data indicate that RabGAP-5 functions as a GAP for Rab5 in vivo. 
 
 
Figure 2-14 RabGAP-5 changes the steady state distribution of the transferrin receptor. HeLa 
cells were transfected with myc-tagged wild-type or catalytically inactive RabGAP-5R165A for 24 hours. 
The cells were then fixed and stained with antibodies against the myc-epitope (red) and transferrin 
receptor (green). The bar indicates 10µm. 
 
2.2.11 RabGAP-5 is an essential regulator of Rab5 
As RabGAP-5 is a GAP for Rab5 both in vitro and in vivo, the question arose of whether or 
not endogenous RabGAP-5 is essential for the regulation of Rab5. 
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To address this question small interfering RNA (siRNA) oligonucleotides were used. 
Antibodies against RabGAP-were generated to show the depletion of the endogenous 
protein. The antibodies were raised in rabbits against RabGAP-5 aa 1-451 tagged with MBP. 
MBP specific antibodies were removed by adsorption over an Affigel-15 column with 1mg 
MBP coupled per ml of gel. Subsequently, RabGAP-5 antibodies were affinity purified 
using a RabGAP-51-451 column. This purified antibody was used at 1 µg/ml for western blot 
and staining of cells. The antibody did not stain endogenous RabGAP-5 by 
immunofluorescence independent of the fixation method. However, the antibody recognized 
a band of the appropriate molecular weight on western blot. This binding was competed by 
pre-incubation of the purified antibody with recombinant RabGAP-5 (Figure 2-15). This 
shows that the antibody specifically binds to RabGAP-5. 
 
 
Figure 2-15 Antigen competition of the RabGAP-5 antibody. Western blot strips loaded with 
either 25 µg cell extracts (CE) or 1ng recombinant MBP-RabGAP-51-451 (RP) were probed with the α-
RabGAP-5 antibody. The Antibody was pre-incubated with 10µ/ml recombinant RabGAP-5 for 1 hour 
(+) or left untreated (-). 
 
HeLa cells were treated with RabGAP-5 specific siRNA duplexes for 72 hours. 
Western blots of extracts generated from these cells revealed that RabGAP-5 was efficiently 
depleted by specific siRNA oligonucleotides (Figure 2-16A, marked by an arrowhead). The 
levels of α-tubulin as a loading control as well as the levels of EEA1 and LAMP1 were not 
affected by depletion of RabGAP-5 (Figure 2-16A). 
In cells depleted of RabGAP-5 the staining of EEA1 was more intense and present on 
larger clustered structures than in control cells where EEA1 was found on smaller dispersed 
structures typical of early endosomes (Figure 2-16B). This distribution of EEA1 in RabGAP-
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5 depleted cells is similar to cells expressing GTP restricted Rab5Q79L (Lawe et al., 2002; 
Stenmark et al., 1994). The staining for the lysosomal marker LAMP1 was strongly reduced 
in cells depleted of RabGAP-5 (Figure 2-16C). When these cells were stained without 
detergent extraction of the plasma membrane, LAMP1 was found on the cell surface (Figure 
2-16C). This finding argues that endosomal trafficking is defective in cells depleted of 
RabGAP-5, since newly synthesized LAMP1 is transported from the TGN via early 
endosomes to lysosomes (Cook et al., 2004; Rohrer et al., 1996). 
 
 
Figure 2-16 RabGAP-5 depletion causes enlarged endosomes and sorting defects. HeLa cells 
treated with control Lamin A or RabGAP-5 siRNA duplexes for 72 hours were (A) analysed by 
western blot with antibodies against RabGAP-5 (marked by an arrowhead), α-tubulin, or EEA1 and 
LAMP1 (note that EEA1 runs at 175 kDa while LAMP1 is a smeared band in the 83 kDa region). (B) 
Cells treated equally were fixed and then stained for EEA1 (red), or (C) fixed and then stained for 
LAMP1 (red) either with (Internal) or without detergent extraction (Cell surface). Bars indicate 10 µm. 
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2.2.12 Elevated levels of Rab5 cause a phenotype resembling RabGAP-5 depletion 
If the enlarged endosomes caused by depletion of RabGAP-5 are due to elevated levels of 
endogenous active Rab5, then an elevation of the levels of GTP Rab5 by other means should 
cause the same phenotype. 
The size of endosomes was increased in cells expressing the GTP restricted mutant 
Rab5Q79L (Figure 2-17). Cells expressing Rabex-5 (Figure 2-17), the GEF for Rab5 
(Horiuchi et al., 1997), also showed enlarged endosomes. 
These results indicate that elevated levels of active Rab5 cause the phenotype 
observed after depletion of RabGAP-5. 
 
 
Figure 2-17 Elevated Rab5 GTP levels cause enlarged endosomes. HeLa cells were transfected 
with GFP-tagged Rab5Q79L or GFP-tagged Rabex-5 for 24h. The Cells were fixed and stained for 
EEA1 (red). The bar indicates 10µm. 
 
2.2.13 Depletion of RabGAP-5 blocks trafficking through early endosomes 
The depletion of RabGAP-5 probably led to miss-localisation of LAMP1 because of 
defective endosomal trafficking (Figure 2-16C). To further investigate this defect, the 
trafficking of EGF was analysed in cells depleted of RabGAP-5. Again, fluorescent EGF 
was followed as readout for receptor trafficking. HeLa L cells were treated with control or 
RabGAP-5 specific siRNA duplexes for 72 hours. Then they were incubated at 4°C in the 
presence of labelled EGF to allow binding to the EGF receptor. The cells were then shifted 
to 37°C to initiate endocytosis of the activated receptor and fixed at the indicated time 
points. 
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Both binding of EGF to the receptor at the PM and internalisation of EGF after 10 
minutes into EEA1 positive structures were not altered by depletion of RabGAP-5 in 
comparison to control siRNA (Figure 2-18). This indicates that the uptake of EGF into 
clathrin-coated vesicles and their trafficking to early endosomes is not affected by depletion 
of RabGAP-5. 
 
 
Figure 2-18 Depletion of RabGAP-5 doesn’t block the uptake of EGF. Uptake of EGF (green) 
was followed in HeLa cells treated with control Lamin A or RabGAP-5 specific siRNA 
oligonucleotides for 72 hours. After 0 and 10 minutes of uptake, cells were fixed and stained for 
EEA1 (red). Bars indicate 10 µm.  
 
EGF started to separate from EEA1 positive structures 30 minutes after 
internalisation in cells treated with control siRNA. After 60 minutes the EGF signal was lost 
from early endosomes in these cells (Figure 2-19). The reduction of the red EGF signal 
suggests that the EGF receptor was properly sorted into the degradative pathway. In cells 
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depleted of RabGAP-5 EGF accumulated in enlarged early endosomes after 30 minutes. It 
was still retained in these structures after 60 min (Figure 2-19) and did not enter the 
degradative pathway. This is clearly seen in the enlarged merged images where the yellow 
colour indicates an overlap of EGF and EEA1. 
Trafficking through early endosomes, which depends on Rab5, is therefore blocked 
in the absence of RabGAP-5 and endocytosed material is not sorted for lysosomal 
degradation. This shows that endogenous RabGAP-5 is an important regulator of Rab5 
dependent traffic. 
 
 
Figure 2-19 Depletion of RabGAP-5 blocks trafficking of EGF. Trafficking of EGF (green) was 
followed in HeLa cells treated with control Lamin A or RabGAP-5 specific siRNA oligonucleotides for 
72 hours. The cells were fixed after 30 and 60 minutes and stained for EEA1 (red). An enlargement 
of the merged images is shown in the rightmost panel. Bars indicate 10 µm. 
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2.3 Summary 
To identify GAPs regulating Rabs involved in endocytosis the human genome database was 
searched for proteins containing a TBC domain. These proteins are known from work in S. 
cerevisiae to function as RabGAPs. Forty proteins were identified, amplified by PCR from 
cDNA libraries and sub-cloned. 
To identify pairs of Rabs and their regulatory GAPs, a reverse yeast two-hybrid 
screening system was established. In this system all TBC domain proteins were tested 
against a all human Rabs for their ability to interact. To gain the required specificity, this 
system required the introduction of two mutations: a conserved glutamine of the Rabs was 
mutated to alanine to restrict them in the GTP bound form; a conserved arginine of the GAPs 
was replaced by alanine to ensure correct substrate recognition. Using this screening method, 
a GAP for Rab5 termed RabGAP-5 was identified. This novel RabGAP stimulated GTP 
hydrolysis by Rab5 in vitro dependent on its catalytic arginine165. The TBC domain was 
mapped to aa 1-451. Expression of RabGAP-5 in human cells redistributed the Rab5 effector 
EEA1 to the cytoplasm. Co-transfected Rab5 was relocated to the Golgi apparatus by the 
expression of RabGAP-5. Structures independent of Rab5 such as the Golgi apparatus were 
not affected. Expression of RabGAP-5 blocked the uptake of both EGF and transferrin. It 
also altered the steady state distribution of the endogenous transferrin receptor. 
When RabGAP-5 was depleted by siRNA the size of endosomes was increased. 
Similar phenotypes were observed in cells with elevated levels of GTP bound Rab5. In cells 
depleted of RabGAP-5 trafficking through endosomes was blocked. This was shown by 
distribution of lysosomal LAMP1 to the plasma membrane and the inability of endocytosed 
EGF to exit from endosome into the degradative pathway. 
Taken together, these data strongly suggest that RabGAP-5 is a novel and specific 
GAP for Rab5, and an essential regulator of endocytosis. 
RN-tre, which was previously reported to act as a Rab5 GAP interacted with the 
closely related Rab43 and Rab30 in the yeast two-hybrid screen but failed to interact with 
Rab5. When tested in vitro, RN-tre strongly stimulated GTP hydrolysis by Rab43. Rab43 
was found to localise to the Golgi apparatus. RN-tre furthermore failed to cause Rab5 
dependent phenotypes. This suggests that RN-tre does not act as a GAP for Rab5 in vivo, 
and that it is a novel Rab43 GAP. 
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3 Regulation of secretion by TBC1D20 
3.1 Aim of this Work 
Like endocytosis, secretion is a highly regulated process (Bonifacino and Glick, 2004). 
Many steps in the secretory pathway involve Rab GTPases (Zerial and McBride, 2001). The 
early secretory pathway from the ER to the Golgi apparatus (Duden, 2003) is regulated by 
the sequential activities of Rab1 (Allan et al., 2000; Segev, 1991) and Rab2 (Short et al., 
2001; Tisdale and Balch, 1996). 
Despite the fact that numerous Rabs are involved in the control of the secretory 
pathway, little is known about their regulation. It is also not known which Rabs are essential 
for these processes. To identify both GAPs and Rabs involved in the regulation of early 
secretory trafficking at the same time, a novel screening method had to be established. Using 
this method not only regulatory GAPs, but also the Rabs essential for secretion should be 
identified. 
3.2 Results 
3.2.1 Rab inactivation screening 
When a Rab is inactivated by its GAP it no longer recruits its effectors to the membrane. 
Trafficking processes dependent on these effectors are therefore blocked. The expression of 
RabGAP-5 redistributed the Rab5 effector EEA1 to the cytoplasm (Figure 2-8) but did not 
affect Rab5 independent organelles. RabGAP-5 also blocked the Rab5 dependent trafficking 
of EGF (Figure 2-12). All phenotypes caused by RabGAP-5 expression were dependent on 
its catalytic activity. 
Based on these initial studies on Rab5 it was proposed that the expression of a library 
of human RabGAPs and the analysis of the resulting phenotypes could be used to identify 
the GAPs involved in the regulation of a specific trafficking step. This screening technique 
uses three steps to define specificity: First, the catalytically inactive GAPs must not give rise 
to the same phenotype as the wild-type proteins. This ensures that the phenotypes observed 
are due to catalytic Rab inactivation. Second, the GAPs that cause activity dependent 
phenotypes have to be tested for their ability to promote hydrolysis against all Rabs. This 
ensures full specificity in the identification of the target Rab. Third, siRNA mediated 
depletion and expression of dominant negative putative target Rabs should recapitulate the 
phenotypes of GAP expression. 
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With this approach it is possible to identify GAPs and Rabs regulating specific 
trafficking steps at the same time. This screening method, as it does not postulate that any 
given Rab or GAP is involved, is a non-biased approach. 
3.2.2 A Rab inactivation screen for Golgi fragmentation  
The structure and integrity of the Golgi apparatus depends on multiple Rab effector proteins. 
To identify GAPs and Rabs involved in the regulation of the early secretory pathway a 
screen for Golgi fragmentation was performed. In this screen 38 human GFP-tagged TBC-
domain proteins were expressed in HeLa L cells. The cells were fixed after 24 hours and 
stained for the cis-Golgi marker GM130 (Nakamura et al., 1995) and the trans-Golgi protein 
TGN46 (Prescott et al., 1997). 
For each RabGAP, n=100 cells were examined for changes in their Golgi 
morphology in comparison to neighbouring non-expressing cells. Based on Golgi 
fragmentation in 10% of control cells, only a RabGAP causing a fragmentation in more than 
40 % of the cells was rated as positive to gain a signal to noise ratio of four to one. 
Out of 38 TBC domain proteins tested only seven (Figure 3-1A) showed significant 
effects on the Golgi morphology. These were TBC1D20, TBC1D22A, TBC1D22B, 
XM_37557, TBC1D14, RN-tre and PRC17, a protein involved in prostate cancer (Pei et al., 
2002) (Figure 3-1A, B). Five of these proteins caused Golgi fragmentation dependent on 
their catalytic activity (Figure 3-1B). This suggests that the phenotypes were due to 
inactivation of endogenous Rabs. TBC1D14 and PRC17 were classified as false positives 
since the expression of their inactive mutants showed equivalent or increased effects on 
Golgi morphology. The expression of both wild-type and inactive mutant PRC17 caused 
apoptosis. As Golgi fragmentation occurs in apoptosis (Lane et al., 2002) the phenotype 
caused by expression of PRC17 appears to be indirect. 
The closely related proteins TBC1D22A and B partially localised to the Golgi 
(Figure 3-1B). The S.cerevisiae homologue of TBC1D22B, GYP1, has GAP activity towards 
human Rab33b (Pan et al., 2006), which is involved in trafficking steps at the Golgi 
apparatus (Valsdottir et al., 2001; Zheng et al., 1998). RN-tre is a GAP for Rab43 (Figure 
2-7) and Rab43 localises to the Golgi (Figure 2-11). XM_37557 is a GAP specific for Rab8a 
(Yoshimura et al., 2007). Rab8a is required for the formation of primary cilia in quiescent 
cells and is localised at the Golgi in proliferating cells. TBC1D20, which has no known 
target Rab, caused the apparent loss of the Golgi apparatus and showed a distinct reticular 
localisation (Figure 3-1 B). 
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Figure 3-1 Golgi fragmentation in HeLa cells. HeLa cells were transfected with GFP-tagged TBC 
domain proteins for 24 hours. The cells were then fixed and stained with antibodies against GM130 
and TGN46. (A) n=100 cells for each TBC domain protein were analysed and their Golgi was rated 
as fragmented or not fragmented compared to neighbouring non-expressing control cells. (B) GFP 
tagged TBC domain proteins scoring Golgi fragmentation in more than 40% of the cells are depicted 
as both wild-type and inactive (RA) mutants. Bars indicate 10µm. 
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Next, the same screen was carried out in telomerase immortalized human retinal 
epithelial (hTERT-RPE1) cells to identify ubiquitously expressed essential Rabs and GAPs 
and to eliminate cell-type specific proteins. This second screen also helps to validate the 
screen in HeLa cells. 
In hTRET-RPE1 cells only three TBC domain-containing proteins caused significant 
alterations of the Golgi morphology: TBC1D20, RN-tre and TBC1D14 (Figure 3-2A). In the 
case of TBC1D14, the phenotype again did not depend on the catalytic activity (Figure 
3-2A) of the protein. 
 
 
Figure 3-2 Golgi fragmentation in hTERT-RPE1 cells. The cells were transfected with GFP-tagged 
TBC domain proteins for 24 hours. The cells were then fixed and stained with antibodies against 
GM130 and TGN46. (A) n=100 cells for each TBC domain protein were analysed and their Golgi 
morphology was rated as fragmented or not fragmented compared to non-expressing neighbouring 
cells. (B) GFP-tagged TBC domain proteins causing Golgi fragmentation in more than 40% of the 
cells are depicted both as wild-type and inactive (RA) mutants. Bars indicate 10µm. 
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The only GAPs positive in both screens were TBC1D20 and RN-tre (Figure 3-1A, 
Figure 3-2A). This indicates that these GAPs regulate ubiquitously expressed Rabs that are 
essential for structuring the Golgi apparatus in the cells tested. The GAPs that caused Golgi 
fragmentation in only one of the screens are unlikely to regulate ubiquitously essential Rabs. 
TBC1D20 again caused an apparent loss of the Golgi apparatus, affecting both the 
cis-Golgi stained by GM130 and the trans-Golgi stained by TGN-46 (Figure 3-2B, Figure 
3-3) equally. This indicates that the target Rab of TBC1D20 has an essential function for the 
integrity of the Golgi apparatus. 
RN-tre on the other hand showed a markedly stronger effect on TGN46 than on 
GM130 (Figure 3-2B, Figure 3-3) in hTERT-RPE1 cells. It was also the only GAP in both 
screens that showed a differential effect on the cis- and trans-Golgi compartments. This 
indicates that RN-tre may regulate a Rab involved in trafficking steps at the TGN. 
 
 
Figure 3-3 RN-tre shows more TGN fragmentation in hTERT-RPE1 cells. The cells were 
transfected with of GFP-tagged RN-tre and TBC1D20 for 24 hours. The cells were then fixed and 
stained with antibodies against GM130 and TGN46. n=100 transfected cells for each TBC domain 
protein were analysed by microscopy and scored as fragmented or not fragmented for both TGN46 
and GM130 independently. 
 
3.2.3 A Rab inactivation screen for changes in ERGIC morphology 
To further define which trafficking process the different GAPs regulate, the effect of their 
expression on the ER-Golgi intermediate compartment (ERGIC) was examined. A RabGAP 
that causes Golgi fragmentation and has an effect on the ERGIC is likely to be a regulator of 
the early secretory pathway. On the other hand, a TBC domain protein that gives rise to 
Golgi fragmentation, but has no effect on the ERGIC, most likely regulates trafficking 
between the Golgi cisternae or at the TGN. 
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ERGIC-53, a mannose-specific transmembrane lectin was used as a marker for this 
screen. This protein predominantly localises to the ERGIC, but a small fraction is found in 
the ER and on ERES (Hauri et al., 2000). It directly recycles between the ERGIC and the 
ER, and only little ERGIC-53 recycles from the Golgi to the ER (Klumperman et al., 1998). 
HeLa cells were transfected with 38 GFP-tagged TBC domain proteins 
independently and fixed after 24 hours. The cells were stained with an antibody against 
ERGIC-53. They were analysed and the morphology of their ERGIC was scored as either 
normal or altered in comparison to neighbouring non-expressing cells. Based on an altered 
ERGIC morphology in 10% of control cells, a cut-off of 40% was chosen. 
TBC1D20 fragmented the ERGIC (Figure 3-4A) dependent on its catalytic activity 
(Figure 3-4B). Interestingly, ERGIC-53 did not stain small punctate structures in the 
periphery of the cell, most likely ERES, in cells expressing TBC1D20 (Figure 3-4B). 
TBC1D22B, but not TBC1D22A, disrupted the ERGIC dependent on its catalytic activity 
(Figure 3-4A). The perinuclear pool of ERGIC-53 was distributed into fragments in cells 
expressing TBC1D22B, but in contrast to TBC1D20 expressing cells the small peripheral 
structures were still present (Figure 3-4B). RN-tre and XM_037557 only caused subtle 
changes to the ERGIC (Figure 3-4A, B). 
 
 
Figure 3-4 A screen for TBC domain proteins altering ERGIC structure. HeLa cells were 
transfected with GFP-tagged TBC domain proteins for 24 hours. The cells were then fixed and 
stained for ERGIC-53 (red). (A) n=100 cells for each TBC domain protein were analysed by 
microscopy and scored as fragmented or not fragmented. (B, see next page) GFP-tagged TBC 
domain proteins that caused ERGIC fragmentation in more than 40% of expressing cells are 
depicted both as wild-type (WT) and inactive (RA) mutants. Bars indicate 10µm. 
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3.2.4 A Rab inactivation screen for a block of VSV-G trafficking 
To further analyse which of the human GAPs regulates secretion, the trafficking of a protein 
from the ER through the secretory pathway to the plasma membrane was followed in cells 
expressing these GAPs. As a model cargo a temperature sensitive mutant of a type-I 
transmembrane glycoprotein of the vesicular stomatitis virus (VSV), ts-O45-G (VSV-G) was 
used. VSV-G misfolds and accumulates in the ER at the non-permissive temperature of 
39.5°C. It refolds at 4°C and is then transported to the cell surface at 31.5°C (Presley et al., 
1997; Scales et al., 1997). A GFP tag is fused to the C-terminus of VSV-G that faces the 
cytoplasm. A specific antibody detects the luminal domain of VSV-G. When used on cells 
without prior detergent extraction of the plasma membrane, this antibody only stains VSV-G 
at the cell surface and therefore provides readout for successful trafficking. 
Similar to the previous screens (see 3.2.2 and 3.2.3), 38 myc-epitope-tagged human 
TBC domain proteins were transfected in parallel into HeLa cells. A VSV-G encoding 
plasmid was co-transfected, and the cells were incubated for 2 hours at 37°C. Then the cells 
were incubated for 12 hours to 39.5°C to accumulate misfolded VSV-G in the ER. The cells 
were shifted to 4°C for 30 minutes to stop trafficking and promote proper folding of VSV-G. 
After these 30 minutes a sample, which corresponds to the t=0 time point, was immediately 
fixed. The cells were then incubated at 31.5°C to allow pulse secretion of VSV-G. After 60 
minutes the cells were fixed without detergent extraction of the plasma membrane to stain 
VSV-G at the plasma membrane. Afterwards the cells were permeabilised and stained for 
the myc-epitope-tag to identify GAP expressing cells. Co-transfected cells were identified by 
microscopy and dependent on the presence of VSV-G at the plasma membrane cells that 
block transport were identified. As in the previous screens for Golgi fragmentation or 
changes in the ERGIC morphology, a cut-off of 40% was chosen. 
Strikingly, out of all TBC domain proteins only TBC1D20 was able to prevent the 
appearance of the VSV-G at the cell surface after 60 minutes (Figure 3-5A). This block of 
transport was dependent on the catalytic arginine105 of TBC1D20 (Figure 3-5B). This 
indicates that this effect on VSV-G trafficking was due to specific inactivation of a Rab. The 
other RabGAPs that fragmented the Golgi or affected the morphology of the ERGIC did not 
block VSV-G transport (Figure 3-5A). They also didn’t show any significant difference in 
VSV-G trafficking between wild-type and catalytically inactive mutants (Figure 3-5B). This 
shows that out of all human RabGAPs only TBC1D20 inactivates a Rab that is essential for 
the secretion of VSV-G. 
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Figure 3-5 TBC1D20 is the only TBC domain protein that blocks VSV-G trafficking. VSV-G 
transport assays were performed for a total time of 15 hours in HeLa cells expressing myc-epitope-
tagged TBC domain proteins (A) HeLa cells co-transfected with VSV-G and wild-type TBC domain 
proteins were stained for surface VSV-G and the myc-epitope tag. n=100 cells were analysed by 
microscopy for each GAP and were scored as either block or no block of trafficking. (B) HeLa cells 
were co-transfected with VSV-G and wild-type (WT) or catalytically inactive (RA) mutant TBC domain 
proteins that fragment the Golgi. They were stained for surface VSV-G and the myc-epitope tag. 
n=100 cells were analysed for each GAP and were scored as either block or no block of trafficking.  
 
The over-expression of TBC1D20 caused a strong effect on Golgi morphology in all 
cell lines analysed. It also perturbed the organisation of the ERGIC in a unique way. Out of 
all TBC domain proteins it was the only one that blocked the secretion of VSV-G. TBC1D20 
is therefore the most likely candidate for a GAP that regulates an essential Rab involved in 
the regulation of the early secretory pathway. This TBC domain protein and the phenotypes 
caused by its over-expression were therefore studied in more detail. 
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3.2.5 TBC1D20 is a highly conserved TBC domain protein 
To investigate the evolutionary conservation of TBC1D20 the genomes of several 
vertebrates and yeast were searched. TBC1D20 homologues were identified using online 
database search engines at BLAST (http://www.ncbi.nlm.nih.gov/blast/).in macaque, mouse, 
rat, dog, cow, zebrafish, African clawed toad, and the three yeasts Saccharomyces 
cerevisiae, Schizosaccharomyces pombe, and Kluveromyces lactis. Partial sequences of 
homologue proteins were also found in other species but omitted for simplicity. The protein 
sequences of the homologue proteins were aligned to the human TBC1D20 protein sequence 
using the Vector NTI® software (Figure 3-6). 
This alignment showed that TBC1D20 is a highly conserved protein. It is almost 
identical in all mammals, and the similarity is very striking even to lower vertebrate 
sequences. The similarity to the yeast proteins appears less pronounced. But even in yeast, 
the consensus sequences that identify the TBC domain (1.3.1) and the catalytically relevant 
residues arginine105 and glutamine144 (Pan et al., 2006) are conserved. 
TBC1D20 is a rather small member of the family of TBC domain containing proteins 
with 403 aa for the human protein. In contrast to most other RabGAPs (Figure 2-2) it does 
not contain additional conserved protein domains. The only other component identified in 
the sequence of all homologue proteins is a hydrophobic stretch close to the C-terminus of 
TBC1D20 (Figure 3-6). Further analysis with the PSORTII prediction algorithms 
(http://psort.nibb.ac.jp/form2.html) suggested that this hydrophobic stretch might form a 
transmembrane domain (TMD) or membrane anchor. This indicates that TBC1D20 might be 
localised to membranes via its C-terminus. 
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Figure 3-6 Alignment of TBC1D20 sequences. Proteins were identified in human (hs), macaque 
(ma), mouse (mm), rat (rn), dog (cf), cow (bt), zebrafish (dr), African clawed toad (xl), 
Saccharomyces cerevisiae (scGyp8), Schizosaccharomyces pombe (spGyp10), and Kluveromyces 
lactis (klTBC1D20). Only full length sequences were included. Identical amino acids are coloured in 
red on a yellow background. Dark blue letters on a light blue background indicate a high degree of 
conservation. Dark blue letters on a green background show similar amino acids. Red arrowheads 
indicate the conserved arginine and glutamine residues required for GTP hydrolysis. 
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3.2.6 Over-expression of TBC1D20 causes a unique “loss of Golgi” phenotype 
TBC1D20 was unique amongst the GAPs that caused Golgi fragmentation since it triggered 
a complete loss of defined Golgi structures. To further investigate this “loss of Golgi” 
phenotype, markers for different Golgi sub-compartments were analysed in cells over-
expressing TBC1D20: the Rab1 effector p115 (Alvarez et al., 1999) that localises to the cis-
Golgi and ERGIC; the cis-Golgi transmembrane protein Golgin84 (Bascom et al., 1999; 
Diao et al., 2003); and Golgin97, which localises to the TGN via its ARF1 interacting GRIP 
domain (Barr, 1999; Griffith et al., 1997; Lu and Hong, 2003). 
The expression of TBC1D20 resulted in the loss of recognizable Golgi or punctate 
vesicular staining for all of these markers (Figure 3-7A). The specific staining was barely 
detectable by immunofluorescence and appeared as a haze distributed throughout the 
cytoplasm. On the other hand, the expression of TBC1D20 did not alter the staining of the 
endosomal Rab5 effector EEA1 (Figure 3-7A). The morphology of the Golgi apparatus was 
not affected by the expression of catalytically inactive TBC1D20R105A (Figure 3-7B) 
although a similar expression level and distribution was observed. 
These data show that TBC1D20 specifically perturbs all compartments of the Golgi, 
but doesn’t have an effect on other sub-cellular compartments like early endosomes. Taken 
together with the observation that catalytically inactive TBC1D20 did not have an effect on 
the morphology of the Golgi apparatus, these data suggest that the “loss of Golgi” phenotype 
is due to inactivation of a Rab involved in regulation of trafficking events at the Golgi. 
Results 
58 
 
 
Figure 3-7 TBC1D20 causes a “loss of Golgi” phenotype. HeLa cells were transfected with myc 
epitope-tagged (A) wild type or (B) catalytically inactive TBC1D20R105A for 24 hours. The cells were 
then fixed and stained with antibodies against the myc epitope tag (red), p115 (green), Golgin84 
(green), Golgin97 (green) or EEA1 (green). Bars indicate 10µm. 
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The “loss of Golgi” phenotype in cells expressing TBC1D20 raised the question of 
the fate of the Golgi proteins. Various fates are conceivable: integral membrane proteins 
such as Golgi enzymes might be redistributed to other membrane compartments or become 
degraded by missorting to lysosomes; peripheral membrane proteins such as GM130 or p115 
might be degraded by the proteasome or might be relocated to the cytosol; the Golgi proteins 
might also reside on or in membrane structures that are too small to be resolved by 
immunofluorescence. To test these possibilities a series of experiments was performed. 
First, the fate of a Golgi-enzyme was studied. N-acetylglucosaminyltransferase-I 
(NAGT-I) is a protein of the medial- and trans-Golgi (Nilsson et al., 1993). It is specifically 
retained in these Golgi cisternae by its transmembrane domain and stalk region (Nilsson et 
al., 1996) and initiates the conversion of N-linked oligosaccharides to the complex type 
(Dunphy et al., 1985). 
HeLa cells were transfected with GFP-tagged NAGT-I. The cells were then 
incubated for 10 hours to start the expression of NAGT-I and to localise it to the medial- and 
trans-Golgi. After 10 hours the cells were transfected with myc-epitope-tagged wild-type or 
catalytically inactive TBC1D20R105A. After a total time of 22 hours the cells were fixed and 
stained with the antibodies indicated. 
NAGT-I localised to the Golgi in cells that only expressed the GFP-tagged protein 
(Figure 3-8). In cells co-expressing wild-type TBC1D20 NAGT-I failed to co-localise with 
the Golgi marker GM130 (Figure 3-8), which was diffusely dispersed throughout the 
cytoplasm. Instead, it was found to localise to a reticular structure. When cells were stained 
for the ER marker calnexin, NAGT-I was found to co-localise with calnexin (Figure 3-8) in 
cells expressing wild-type TBC1D20. This shows that NAGT was redistributed to the ER. In 
cells expressing catalytically inactive TBC1D20R105A, NAGT-I was found in the Golgi and 
did not redistribute to the ER (Figure 3-8). The redistribution of NAGT-I was therefore due 
to the specific inactivation of a Rab GTPase by TBC1D20. 
These data show that Golgi enzymes such as NAGT-I are redistributed to the ER in 
cells over-expressing TBC1D20. 
Results 
60 
 
 
Figure 3-8 Expression of TBC1D20 redistributes Golgi enzymes to the ER. HeLa cells were 
transfected with GFP-tagged NAGT-I (green) for 10 hours. Then they were transfected with Myc-
tagged wild-type or catalytically inactive TBC1D20R105A for further 12 hours. The cells were then fixed 
and stained for GM130 (red) or Calnexin (red) and the myc-epitope tag (blue). The bar indicates 
10µm. 
 
To test whether or not peripheral Golgi proteins are degraded in cells over-expressing 
TBC1D20 several western blot experiments were carried out. HeLa cells grown on 10 cm 
cell culture dishes were transfected for 24 hours with myc-epitope-tagged wild-type or 
catalytically inactive TBC1D20R105A. The cells were then harvested, lysed in mammalian 
lysis buffer, and the lysate was cleared by centrifugation, and 20µg of these extracts were 
western blotted. The blots were probed with antibodies against the myc-epitope-tag, p115, 
GM130, and to tubulin as a loading control. Noticeably, the expression of wild-type and 
catalytically inactive TBC1D20R105A reached similar levels (Figure 3-9A). Despite the high 
transfection efficiency, over 50% estimated by immunofluorescence, no change was 
observed in the levels of either GM130 or p115 in cells expressing TBC1D20 (Figure 3-9A). 
This finding shows that these Golgi proteins were not degraded in cells over-expressing 
wild-type TBC1D20. 
To analyse whether or not the Golgi proteins were still membrane bound, a set of 
membrane fractionation experiments were carried out. For these experiments a 10 cm dish of 
HeLa cells was transfected with myc-epitope-tagged wild-type TBC1D20 for 24 hours. To 
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compare the TBC1D20 phenotype to other factors that cause Golgi fragmentation, another 
dish of HeLa cells was transfected with constitutive active Sar1H79G. Expression of Sar1H79G 
prevents un-coating of COPII and causes a phenotype similar to TBC1D20. (Ward et al., 
2001; Yoshimura et al., 2004). Another dish of cells was not transfected but incubated with 
Brefeldin A (BFA) for 30 minutes prior to harvesting. BFA treatment also fragments the 
Golgi and blocks secretion (Lippincott-Schwartz et al., 1989). As a control a dish of non-
transfected and non-treated cells was used. 
The cells were harvested and broken open by passing them 40 times through a 27G 
needle. Nuclei and cell debris were removed by centrifugation for 5 min at 1000x g and 4°C. 
This post-nuclear supernatant was split into two equal halves. One of them was kept on ice 
and represents the total material. The other half was spun for 30 min at 100,000x g. The 
supernatant of this centrifugation contains all the cytosolic proteins. Membranes and 
membrane bound proteins are found in the pellet fraction. The distribution of proteins 
between membranes and the cytoplasm can be analysed by western blotting these fractions. 
The peripheral membrane protein GM130 and the integral membrane protein 
Golgin84 remained associated with the membranes to the same extent in control cells and in 
cells expressing wild type TBC1D20 (Figure 3-9B). The same was true in cells expressing 
Sar1H79G or treated with BFA (Figure 3-9B). Under the same conditions, the membrane-
associated pool of the Rab1 effector p115 was lost in cells expressing TBC1D20 (Figure 
3-9B). This loss was not due to Golgi fragmentation, as BFA treatment and Sar1H79G 
expression did not have an effect on the distribution of p115 (Figure 3-9B). The fractionation 
experiments also showed that TBC1D20 is associated with membranes (Figure 3-9B) 
Taken together, these results show that Golgi proteins have different fates in cells 
expressing TBC1D20. Golgi enzymes are redistributed to the ER. Golgi matrix proteins such 
as GM130 of Golgin84 remain associated with membranes. They appear as a haze in 
immunofluorescence and are therefore likely to be associated with vesicles that are too small 
to be resolved by the light microscope. This suggests that the Golgi apparatus is vesiculated 
in the “loss of Golgi” phenotype. The Rab1 effector p115 was lost from the membrane 
fraction in TBC1D20 expressing cells. This indicates that the phenotypes observed in cells 
over-expressing TBC1D20 might be due to defects in the Rab1-p115 dependent COPII 
vesicle-tethering pathway. It also suggests that TBC1D20 may act as a GAP for Rab1, as 
p115 requires active Rab1 for its membrane association (Allan et al., 2000). 
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Figure 3-9 TBC1D20 displaces p115 from membranes. (A) HeLa cells were transfected with either 
wild-type (WT) or catalytically inactive TBC1D20R105A (RA) for 24 hours. 20µg of cell extracts were 
western blotted and probed for GM130 and p115. The myc-epitope shows the expression of 
TBC1D20, and α-tubulin acts as a loading control. The asterisk indicates a GM130 breakdown 
product. (B) HeLa cells left untreated, expressing myc-tagged TBC1D20 or Sar1H79G for 24 hours, or 
treated with BFA for 30 minutes were harvested and fractionated. Equivalent amounts of the total 
lysate (T), the membrane pellet (P), or the soluble cytosolic fraction (S) were western blotted and 
probed for p115, GM130, Golgin84 and the myc-epitope-tag, respectively. 
 
3.2.7 TBC1D20 blocks exit of VSV-G from the ER 
Next, the block of VSV-G trafficking in cells over-expressing TBC1D20 was studied in 
more detail. Wild-type or catalytically inactive TBC1D20R105A were co-transfected with a 
plasmid encoding VSV-G into HeLa cells. The experimental setup was as described in 3.2.4. 
COPII positive structures were stained with antibodies against Sec31 and the Golgi was 
stained for GM130. After 60 minutes cells were fixed without detergent extraction to stain 
VSV-G at the plasma membrane. 
At t=0 VSV-G accumulated in the ER (Figure 3-10) independent of TBC1D20. The 
amount of VSV-G was the same in cells transfected with either wild-type or catalytically 
inactive TBC1D20R105A as judged by immunofluorescence. This indicates that the absence of 
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VSV-G at the cell surface (Figure 3-5A, B) was not simply due to the lack of synthesised 
viral protein. VSV-G did not co-localise with COPII positive structures at this time point. 
After 10 minutes VSV-G started to leave the ER in cells expressing TBC1D20R105A 
as well as in cells expressing only VSV-G (Figure 3-10). The GFP-tagged VSV-G co-
localised with COPII positive structures at this time point. This shows that a wave of folded 
VSV-G started to exit the ER. In cells expressing wild type TBC1D20 however, the viral 
protein was retained in the ER (Figure 3-10). 
After 30 minutes of transport, the majority of VSV-G was found at the Golgi in cells 
expressing only VSV-G or both VSV-G and TBC1D20R105A (Figure 3-10). In cells 
expressing wild-type TBC1D20 it was still retained in the ER (Figure 3-10). 
At t=60 VSV-G reached the cell surface in cells expressing TBC1D20R105A (Figure 
3-10). The same was true for cells only expressing VSV-G. Even after 60 minutes VSV-G 
did not exit the ER in wild-type TBC1D20 expressing cells (Figure 3-10). VSV-G did not 
accumulate at any structures at the ER. This shows that VSV-G was not recruited to ERES in 
cells expressing wild-type TBC1D20. 
These data show that TBC1D20 blocks trafficking of VSV-G dependent on its 
catalytic activity. Importantly, VSV-G is retained in the ER and does not accumulate in 
COPII positive structures or at ERES. These data suggest a role for TBC1D20 and the Rab it 
regulates at the level of the ER. 
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Figure 3-10 TBC1D20 blocks VSV-G trafficking at the ER. VSV-G transport assays were 
performed for a total time of 15 hours in HeLa cells expressing myc-epitope-tagged wild-type (WT) or 
catalytically inactive TBC1D20R105A (RA). The cells were fixed at the time points indicated and 
stained for the myc-epitope-tag (blue), Sec31 (red at t=0, t=10), GM130 (red at t=30) or surface VSV-
G (red at t=60). GFP shows total VSV-G. The bars indicate 10 µm. 
 
3.2.8 TBC1D20 expression causes scattering of COPII 
Budding of vesicles from the ER and trafficking between the ER and the Golgi depends on 
the COPII coat. The block of ER to Golgi transport in cells expressing TBC1D20 might 
therefore be linked to defective COPII function. 
COPII vesicles are formed at ERES (Hammond and Glick, 2000). The activation of 
the small GTPase Sar1 leads to the consecutive stepwise recruitment of the heterodimeric 
COPII subunits Sec23/24 and Sec13/31 (Barlowe et al., 1994). The curvature of the sub-
complexes deforms the membrane and leads to abscission of the vesicles (Bonifacino and 
Glick, 2004). COPII vesicles form clusters, and consequently the ERGIC, dependent on the 
Rab1-p115 tethering pathway (Allan et al., 2000). 
HeLa cells were transfected with myc-epitope-tagged wild-type or inactive 
TBC1D20R105A for 24 hours to study COPII in more detail. The cells were then fixed and 
stained for Sec31 or Sec24C, respectively. In control cells COPII positive structures 
accumulated in the perinuclear region (Figure 3-11 A). In cells expressing wild-type 
TBC1D20 no perinuclear accumulation of COPII positive structures was observed (Figure 
3-11 A) in cells were stained for Sec31 or Sec24 (Figure 3-11 B). The peripheral COPII 
structures on the other hand were not affected. This indicates that COPII clustering but not 
COPII vesicle formation is defective in cells over-expressing wild-type TBC1D20. In cells 
expressing catalytically inactive TBC1D20R105A no scattering of COPII positive structures 
was observed (Figure 3-11A, B). The COPII positive structures observed in these cells were 
comparable to non-expressing control cells. This shows that the phenotype is due to the 
specific inactivation of a target Rab. 
TBC1D20 therefore interferes with the clustering of COPII vesicles that depends on 
the Rab1 effector p115. This finding fits with the observation that p115 is lost from 
membranes in cells over-expressing wild-type TBC1D20. 
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Figure 3-11 TBC1D20 expression causes COPII scattering. HeLa cells were transfected with myc-
epitope-tagged wild-type (WT) or catalytically inactive TBC1D20R105A (R105A) for 24 hours before 
fixation. (A) The cells were stained for the myc-epitope (green) and Sec31 (red). Bar corresponds to 
10 µm. (B) n=100 cells stained for Sec31 or Sec24C were analysed and the COPII staining was 
scored as either scattered or perinuclear as compared to neighbouring non-expressing cells. 
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3.2.9 TBC1D20 expression does not interfere with COPII dynamics 
To analyse if over-expression of TBC1D20 blocks transport of cargo in the ER by 
interfering with the assembly of the COPII vesicle coat, the dynamics of COPII vesicle 
formation were analysed. 
Fluorescence recovery after photobleaching (FRAP) was used in collaboration with 
Dr. David Stephens in the University of Bristol to study the dynamics of COPII vesicle 
formation in cells over-expressing TBC1D20. FRAP is a widely used technique (Presley, 
2005; Reits and Neefjes, 2001) that exploits the fact that chromophores can be bleached in a 
defined area by a laser pulse of an appropriate wavelength. The fluorescence of the bleached 
area is then measured over time. By measuring the time needed to regain the fluorescence 
intensity after the laser pulse, the dynamics of a system can be studied. 
As the COPII coat component Sec23 has GAP activity towards the small GTPase 
Sar1 required for COPII coat formation, it causes destabilisation and dissociation of the coat 
(Bickford et al., 2004). Therefore the COPII coat undergoes a cycle of disassembly and 
reassembly until the vesicle buds of the ERES. If TBC1D20 blocks ER exit by interfering 
with COPII dynamics, the FRAP kinetics of COPII should be different in cells over-
expressing TBC1D20. The fluorescence of the COPII component Sec16 (Connerly et al., 
2005; Watson et al., 2006) in cells expressing TBC1D20 was regained 50 seconds after 
bleaching (Figure 3-12A). Compared to the turnover of COPII components in control cells 
no change in the fluorescence recovery kinetics was observed (Figure 3-12B, C). This shows 
that TBC1D20 does not interfere with the dynamics of COPII vesicle formation. 
This finding indicates that the block of ER exit and the altered distribution of COPII 
positive structures in cells expressing TBC1D20 cannot be explained by alteration in the 
dynamics of COPII coat assembly. These effects are therefore likely to be caused by the 
inactivation of a Rab required for both COPII vesicle clustering or cargo exit from the ER. 
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Figure 3-12 COPII dynamics are not affected by TBC1D20 expression. FRAP was performed on 
cells expressing (A) myc-epitope-tagged TBC1D20 and Venus- Sec16 or (B) in control cells only 
expressing Venus- Sec16. A Leica TCS SP3 AOBS scanning confocal microscope with a pinhole 
size of 2 Airy units, eightfold line averaging, was used at 1 frame per second, and region-of-interest 
bleaching with 10 iterations of the 514 nm laser at 100% AOTF power. Cells used for photobleaching 
were confirmed to express myc-epitope-tagged TBC1D20 by subsequent immunofluorescence; 95% 
of all cell transfected with Venus-Sec16 were found to be transfected with myc-epitope tagged 
TBC1D20. Plots are of the average intensity of individual structures over time; error bars indicate the 
standard deviation (five cells per experiment, n=3). 
 
3.2.10 The cargo receptor p24 reveals a sorting defect caused by TBC1D20 
As the expression of TBC1D20 did not alter COPII dynamics, defective cargo selection as a 
reason for the block of ER exit was investigated. 
Both ERGIC-53, which recycles between the ERGIC and the ER, and p24, which 
recycles between the ER, the ERGIC and the Golgi were analysed. p24, a protein of a family 
of type-I membrane proteins, binds both COPI (Sohn et al., 1996) and COPII (Dominguez et 
al., 1998) to mediate its cycling. p24 proteins form oligomeric complexes (Denzel et al., 
2000) and function as receptors for various cargo molecules (Fiedler et al., 1996), which are 
proposed to be enriched in budding vesicles by p24 (Schimmoller et al., 1995). 
To analyse the effect of TBC1D20 over-expression on these molecules, HeLa cells 
were transfected with GFP-tagged p24 for 6 hours. Then the cells were transfected with 
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myc-epitope-tagged wild-type or catalytically inactive TBC1D20R105A for a further 12 hours. 
The cells were then fixed and stained for ERGIC-53 or Sec31, respectively. 
GFP-p24 localised to the ER, to ERES, the ERGIC and the Golgi apparatus in 
control cells. GFP-tagged p24 largely co-localised with ERGIC-53 (Figure 3-13B) and did 
not alter the distribution of ERGIC-53 positive structures. Their co-localisation on small 
punctate structures, most likely ERES, is shown more clearly in the enlargement. In cells 
expressing wild-type TBC1D20 GFP-p24 localised to large punctate structures (Figure 
3-13A). When cells expressing both wild-type TBC1D20 and GFP-tagged p24 were stained 
for ERGIC-53, both p24 and ERGIC-53 localised to the same large punctate structures 
(Figure 3-13B). Notably, the small punctate structures resembling ERES were no longer 
observed under these conditions. This can be seen more clearly in the enlargements. 
When cells expressing GFP-tagged p24 were stained for Sec31 as a COPII marker, a 
large extent of co-localisation was observed, especially on small punctate ERES (Figure 
3-13C). This is seen more clearly in the enlargement. In cells over-expressing wild-type 
TBC1D20 (Figure 3-13C), GFP-p24 localised to large structures whereas Sec31 was 
scattered throughout the cell as previously observed (Figure 3-11). Sec31 was also found on 
small punctate structures resembling ERES under these conditions. GFP-p24 did not co-
localise with Sec31 in these structures in cells expressing wild-type TBC1D20. This is more 
clearly seen in the enlargement that shows red punctate structures stained for Sec31, which 
lack green GFP-p24 signal (Figure 3-13C). The expression of TBC1D20R105A did not result 
in changes in the distribution of p24, ERGIC-53 or Sec31 in comparison to control cells 
(Figure 3-13A, B, C). This shows that the phenotypes observed are due to the catalytic 
activity of TBC1D20. 
These data show that cargo receptors such as ERGIC-53 and p24 are absent from 
ERES in cells over-expressing TBC1D20. This finding might provide an explanation for the 
defect in trafficking of cargo from the ER under these conditions. These findings also show 
that the ERGIC is a functionally separate compartment that reacts distinct from the Golgi 
and COPII positive structures to the over-expression of TBC1D20. 
 
Figure 3-13 Recycling ERGIC markers are lost from ERES in TBC1D20 expressing cells. See 
next page. HeLa cells were transfected with GFP-tagged p24 for 6 hours. Then they were 
transfected with wild-type (WT) or catalytically inactive (RA) myc-epitope-tagged TBC1D20 (blue). 
The cells were fixed after further 18 hours and stained for (A) the myc-epitope-tag (red), (B) ERGIC-
53 (Red) and the myc-epitope-tag (blue) or (C) Sec31 (red) and the myc-epitope-tag (blue). GFP was 
visualized (A, B, C) directly (green). The enlargements correspond to 10x10 µm and only show red 
and green colour. The bars indicate 10µm. 
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3.2.11 TBC1D20 is a GAP for Rab1 and Rab2 in vitro 
To identify the target Rab of TBC1D20, a series of in vitro GTP-hydrolysis assays similar to 
the ones used to identify Rab5 as the target of RabGAP-5 was performed. 
TBC1D20 could not be produced as a full-length recombinant protein in the same 
vector used for the production of RabGAP-5, probably due to the hydrophobic stretch 
(Figure 3-6). Without this stretch TBC1D20 was successfully produced in E. coli as a 
recombinant protein with a N-terminal MBP-tag and a C-terminal 6x His tag. Recombinant 
TBC1D20 was then tested for its ability to stimulate GTP hydrolysis by all human Rabs. For 
simplicity some Rab isoforms were omitted. The basal GTPase activity of the Rabs was 
subtracted from the activity stimulated by TBC1D20, so that only GAP mediated hydrolysis 
is shown. 
TBC1D20 strongly stimulated GTP hydrolysis by Rab1 and Rab2 (Figure 3-14A). 
Some additional activity of TBC1D20 was observed towards Rab8A, Rab13, Rab18, and 
Rab35 (Figure 3-14A). All these Rabs are closely related members of the Rab1/Sec4 group 
(Figure 1-5). This might explain why TBC1D20 can activate them in vitro. TBC1D20 did 
not display GAP activity towards Sar1 and ARF1 (Figure 3-14 A). Both these non-Rab 
GTPases also belong to the Ras superfamily and are required for protein trafficking and the 
maintenance of normal Golgi structure (Bonifacino and Glick, 2004). 
The minimal predicted TBC domain TBC1D20 aa 1-317 stimulated GTP hydrolysis 
by Rab1 to a similar extent as TBC1D20 aa 1-364 (Figure 3-14B). The catalytic activity of 
both the longer version of the protein and the minimal TBC domain was abolished when the 
catalytic arginine 105 of the TBC-domain was mutated to alanine (Figure 3-14B). When the 
glutamine 67 of Rab1 was mutated to leucine to restrict it in the GTP bound state the basal 
hydrolysis rate was strongly reduced (Figure 3-14B). TBC1D20 did not stimulate GTP 
hydrolysis by Rab1Q67L (Figure 3-14B).  
To investigate if TBC1D20 is the only GAP for Rab1 or Rab2, the five TBC domain 
proteins, which were able to disrupt the Golgi (see Figure 3-1 and Figure 3-2) or alter the 
structure of the ERGIC (see Figure 3-4), were produced in the same way as TBC1D20 and 
tested for their ability to stimulate GTP hydrolysis by Rab1 or Rab2. These assays showed 
that only TBC1D20, but none of the other GAPs was able to stimulate GTP-hydrolysis by 
Rab1 or Rab2 to a significant extent (Figure 3-14C). This finding is consistent with 
publications showing that the TBC1D22 family acts on Rab33 (Pan et al., 2006), and that 
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XM_037557 is a GAP for Rab8a (Yoshimura et al., 2007). RN-tre was already shown to be a 
GAP for Rab43 (Figure 2-11). 
These experiments show that TBC1D20 is a GAP for Rab1 and Rab2 in vitro. They 
also show that TBC1D20 is the only GAP that causes Golgi fragmentation or changes in the 
ERGIC morphology that acts on Rab1 or Rab2. 
 
 
Figure 3-14 TBC1D20 is a GAP for Rab1 and Rab2 in vitro. All reactions were carried out for 60 
minutes. (A) To determine the specific activity towards a wide range of GTPases, 0.5 pmoles 
TBC1D20 aa1-364 were tested against 100 pmoles of the GTPases indicated. The basal GTP 
hydrolysis with a buffer control was subtracted from TBC1D20 stimulated hydrolysis in each case. (B) 
5 pmoles of wild-type and TBC1D20R105A aa1-364 or the minimal TBC-domain aa 1-317 were tested 
against 100 pmoles of either wild-type Rab1 or Rab1Q67L. Basal GTP hydrolysis with buffer is plotted 
as open bars and GAP-stimulated GTP hydrolysis as grey bars. (C) Buffer (control) or 0.5 pmoles of 
the GAP indicated were tested against 100 pmoles of Rab1 or Rab2. Basal GTP hydrolysis with 
buffer is plotted as open bars and GAP-stimulated GTP hydrolysis as grey bars. 
 
3.2.12 Dominant negative Rab1N121I mimics the TBC1D20 phenotype 
To narrow down the target of TBC1D20 in vivo, the phenotypes caused by expression of 
dominant-negative Rabs were compared to the phenotypes caused by the over-expression of 
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TBC1D20. Dominant negative Rabs are generated by mutations that either keep the Rab in a 
nucleotide free state or prevent GEFs from reloading them with GTP. HeLa cells were 
transfected with dominant negative GFP-tagged Rabs for 24 hours. The cells were then 
fixed, and stained for the Golgi marker GM130 or the COPII marker Sec31, respectively. 
Dominant-negative Rab43T32N was used as a positive control (Fuchs et al., 2007). 
When n=100 cells were analysed only Rab43T32N and Rab1N121I fragmented the Golgi 
and scattered COPII positive structures (Figure 3-15A). None of the other Rabs that were 
activated by TBC1D20 in vitro caused significant changes to either structure. 
In cells expressing Rab43T32N small COPII clusters were observed that probably 
localised to the Golgi fragments that were observed under these conditions (Figure 3-15B). 
Dominant negative Rab1N121I on the other hand caused a “loss of Golgi” phenotype and 
scattered COPII into evenly sized structures throughout the cell (Figure 3-15B). These 
phenotypes mimic the phenotypes observed in cells over-expressing wild-type TBC1D20 
(Figure 3-7, Figure 3-11). The expression of neither wild-type nor constitutive active 
Rab1Q67L had an effect on the Golgi morphology or the distribution of COPII (Figure 3-15A, 
B). This shows that the phenotypes observed were not simply due to elevated Rab1 levels. 
These findings indicate that TBC1D20 acts as a specific Rab1 GAP in vivo. 
 
 
Figure 3-15 Dominant negative Rab1 causes a “loss of Golgi” phenotype. HeLa cells were 
transfected with GFP-tagged Rabs for 24 hours. The cells were then fixed and (B, see next page) 
stained for GM130 (red) or Sec31 (red), respectively. (A) In n=100 cells the Golgi morphology was 
scored as either normal or fragmented in comparison to non-expressing neighbouring cells. The 
COPII distribution was scored as either perinuclear or scattered in comparison to neighbouring non-
expressing cells. The bar indicates 10µm. 
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3.2.13 Depletion of Rab1 causes Golgi fragmentation 
To further narrow down the in vivo target of TBC1D20, both Rab1 and Rab2 were depleted 
by siRNA. The expression of a dominant negative Rab or the specific GAP diminishes the 
amount of active Rab and thus inhibits processes dependent on active Rab. The same should 
be achievable by diminishing the endogenous Rab by siRNA.  
To deplete HeLa cells of endogenous Rab1 or Rab2, respectively, cells were treated 
with specific siRNA duplexes or control siRNA for 72 hours. To check mRNA degradation, 
the cells were transfected with GFP-tagged wild-type Rabs for the last 24 hours. The cells 
were then fixed and stained for the Golgi marker GM130. Cell extracts were generated and 
10µg were analysed by western blot and probed for the GFP tag. This method is proven to be 
an effective readout for mRNA depletion in the case of other Rabs (Fuchs et al., 2007). 
Western blotting showed the depletion of the messages for Rab1 and Rab2 (Figure 
3-16A). No GFP signal was observed by immunofluorescence for Rab1 and Rab2 as 
compared to control siRNA (Figure 3-16B,C). 
Depletion of Rab2 caused scattering of the Golgi apparatus (Figure 3-16B). 
Remarkably, these Golgi fragments remained clustered in the perinuclear region. On the 
other hand, in cells depleted of Rab1 the Golgi apparatus was massively fragmented and 
vesiculated (Figure 3-16C). These fragments, in contrast to cells depleted of Rab2, were 
evenly distributed throughout the cytoplasm. 
In contrast to expression of dominant negative Rab1N121I or TBC1D20, in cells 
depleted of Rab1 the Golgi was only fragmented and no “loss of Golgi” phenotype was 
observed. The phenotype of Rab1 depletion, however, still resembles the TBC1D20 
phenotype better than depletion of Rab2. This again suggests that Rab1 is the primary target 
of TBC1D20 in vivo. 
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Figure 3-16 Rab1 depletion causes Golgi fragmentation. HeLa cells were treated with control, 
Rab1 or Rab2 siRNA duplexes for 72 hours were transfected for 24 hours with GFP-tagged Rab1 or 
Rab2, respectively. The cells were lysed and (A) analysed by western blot with antibodies against the 
GFP-tag to show mRNA depletion and α-tubulin as a loading control. (B) Cells treated equally with 
Rab2 specific or control siRNA duplexes were fixed and stained for GM130 (red). (c) Cells treated 
equally with Rab1 specific or control siRNA duplexes were fixed and stained for GM130 (red). The 
bars indicate 10 µm. 
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3.2.14 Depletion of Rab1 but not Rab2 blocks VSV-G transport 
To further narrow down the in vivo target Rab of TBC1D20, the trafficking of VSV-G was 
analysed in cells depleted of Rab1 or Rab2. The effects of depleting the Rab1 key effector 
p115 and the Rab1 and p115 interacting golgin GM130 on VSV-G trafficking were 
investigated as well. After 60 hours of depletion, HeLa cells were transfected with VSV-G 
and treated as previously described (see 3.2.7). 
The depletion of Rab1 resulted in a block of VSV-G trafficking at the level of the ER 
(Figure 3-17B). The phenotype observed was similar to expression of TBC1D20 (Figure 
3-10). Depletion of Rab2 on the other hand did not block anterograde transport of VSV-G 
from the ER to the cell surface, even though the Golgi was fragmented (Figure 3-17B). This 
shows that Rab1 but not Rab2 is essential for VSV-G trafficking. 
The effects of depleting the Rab1 effector p115 and GM130 on VSV-G transport 
were then analysed. Western blotting showed that these proteins were specifically depleted 
by siRNA (Figure 3-17A). In cells depleted of p115 VSV-G left the ER and accumulated in 
a collapsed punctate structure. VSV-G didn’t reach the cell surface after 60 minutes (Figure 
3-17B). This finding demonstrates the importance of p115 in the regulation of trafficking 
steps between the Golgi and the ER. Even though GM130 is required for normal Golgi-
ribbon and COPII vesicle organization (Puthenveedu et al., 2006), it was not required for 
VSV-G transport (Figure 3-17B). The Golgi was disrupted in cells depleted of GM130, but 
VSV-G was transported the plasma membrane after 60 minutes. 
These data show that the block of VSV-G trafficking observed in cells over-
expressing wild-type TBC1D20 is due to the inactivation of endogenous Rab1. They also 
show that Rab1 it the primary target of TBC1D20 in vivo. Although Rab1 binding proteins, 
such as its effector p115 and GM130 may contribute to the phenotypes caused by TBC1D20 
overexpression, they can’t explain why secretory cargo is blocked in the ER. This indicates 
that TBC1D20 and Rab1 have a function independent of these Rab1 binding proteins at the 
level of the ER. 
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Figure 3-17 Depletion of Rab1 blocks VSV-G trafficking at the ER. VSV-G transport assays were 
performed for a total time of 15 hours in HeLa cells depleted of Rab1, Rab2, p115 or GM130. (A) 
GM130 and p115 were specifically depleted as shown by western blot. (B) Cells were fixed after 60 
minutes and stained for surface VSV-G (red). GFP shows total VSV-G. The bar indicates 10 µm.  
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3.2.15 Dominant negative Rab1N121I blocks VSV-G transport 
To consolidate that the block of VSV-G trafficking seen in cells expressing TBC1D20 is due 
to inactivation of Rab1, the effect of various Rab1 mutants on the trafficking of VSV-G was 
investigated. 
HeLa cells were transfected with myc-epitope-tagged wild-type Rab1, constitutive 
active Rab1Q67L or dominant negative Rab1N121I and incubated at 37°C for 10 hours. 
Subsequently, the cells were transfected with a plasmid encoding VSV-G and treated as 
previously described (see 3.2.4). 
For each Rab1 variant n=100 cells were analysed and dependent on the presence of 
VSV-G at the plasma membrane after 60 minutes they were scored as either block or 
transport. Only the expression of Rab1N121 caused a block of VSV-G trafficking (Figure 
3-18A). It blocked the exit of VSV-G from the ER (Figure 3-18B), similar to the phenotype 
in cells depleted of Rab1 or over-expressing wild-type TBC1D20. Cells expressing wild-
type Rab1 did not show significant differences in transport when compared to non-
expressing control cells (Figure 3-18A, B). The hydrolysis deficient (Figure 3-14B) 
Rab1Q67L mutant did not cause a block of VSV-G transport to the plasma membrane (Figure 
3-18A,B). 
These findings support the idea that the ER exit of VSV-G depends on active Rab1. 
The depletion of endogenous Rab1 by siRNA or the over-expression of TBC1D20 showed 
the same phenotype as the expression of dominant negative Rab1N121I. Surprisingly, the 
hydrolysis deficient Rab1Q67L did not affect the transport of VSV-G as compared to control 
cells. According to the standard model, in which the GAP regulates the lifetime of active 
Rab, VSV-G should accumulate in COPII positive structures under these conditions, similar 
to EGF accumulating in early endosomes in Rab5Q79L expressing cells (Fuchs et al., 2007). 
This suggests that in the case of Rab1 another regulatory mechanism is used. 
Results 
80 
 
 
Figure 3-18 Dominant negative Rab1 blocks ER exit of VSV-G. VSV-G transport assays were 
performed for a total of 15 hours in HeLa cells expressing myc-epitope-tagged wild-type (WT) 
constitutive active (Q67L) or dominant negative (N121I) Rab1 (A) HeLa cells co-transfected with 
VSV-G and Rab1 were stained for surface VSV-G and the myc-epitope tag. n=100 cells were scored 
as either block or no block of trafficking. (B) Cells treated equally were fixed after 60 minutes and 
stained for surface VSV-G (red) and the myc-epitope-tag (blue). GFP indicates total VSV-G. The bar 
indicates 10 µm. 
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3.2.16 TBC1D20 depletion causes increased p115 clustering 
To test whether or not endogenous TBC1D20 is required to regulate Rab1 in HeLa and 
hTERT-RPE1 cells it was depleted using specific siRNA oligonucleotides. 
Various attempts with recombinant protein or synthetic peptides were made to 
generate an antibody against TBC1D20. None of these antibodies had high enough affinity 
to detect endogenous TBC1D20. To check the depletion of TBC1D20 therefore an approach 
similar to the one used for determining the depletion of Rabs (Figure 3-16) was used. HeLa 
cells were treated with specific siRNA duplexes to target TBC1D20 in parallel with control 
siRNA duplexes for 72 hours. For the last 24 hours, the cells were transfected with GFP-
tagged TBC1D20R105A. The inactive mutant was used to avoid the phenotype of TBC1D20 
over-expression to interfere with the analysis of the siRNA-mediated depletion. The cells 
were fixed and stained for various markers of the early secretory pathway. Cells treated 
equally were lysed and 10µg were analysed by western blot. 
Probing the western blot for with antibodies against GFP showed that TBC1D20 was 
efficiently silenced (Figure 3-19B). The intensity of the p115 staining was increased in cells 
depleted of TBC1D20 when compared to control cells (Figure 3-19A). The Golgi stained by 
p115 was also more compact. The staining pattern of GM130 was more compact in cells 
depleted of TBC1D20 as well, but it did not increase in its intensity (Figure 3-19A). COPII, 
stained with an antibody against Sec31, partially lost its perinuclear organization and was 
scattered in cells depleted of TBC1D20 (Figure 3-19A). More and smaller clusters compared 
to control cells were observed under these conditions. 
These data show that endogenous TBC1D20 contributes to the organization of COPII 
vesicles, the formation of VTCs and the morphology of the Golgi complex. They 
furthermore ague that TBC1D20 functions as a Rab1 GAP in vivo as the observed 
phenotypes can be explained by elevated levels of active Rab1. More active Rab1 recruits 
more of its effector p115 to membranes. Rab1 binds GM130 (Moyer et al., 2001) but does 
not recruit it to Golgi membranes. The compaction observed is consistent with the idea that 
p115 is required for the clustering of pre- Golgi compartments. The formation of COPII 
clusters also depends on p115; therefore an increase in active Rab1 might cause the 
formation of too many independent structures.  
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Figure 3-19 Depletion of TBC1D20 increases p115 staining and changes COPII distribution. 
HeLa cells treated with control (Control) or specific TBC1D20 siRNA duplexes (TBC1D20) for 72 
hours were transfected with GFP-tagged TBC1D20R105A for 24 hours and (B) analysed by western 
blotting with antibodies against the GFP-tag to show depletion and α-tubulin as a loading control. (A) 
Cells treated equally were fixed and stained for p115, GM130 or Sec31 (all red). Bars indicate 10 µm. 
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Next, TBC1D20 was depleted in hTERT-RPE1 cells in the same way as in HeLa 
cells. The cells were stained for COPII using Sec31 as a marker. 
In control hTERT-RPE1 cells the staining of COPII positive structures did not 
accumulate in the perinuclear region like in HeLa cells. Instead, the COPII positive 
structures were evenly distributed (Figure 3-20). In cells depleted of TBC1D20, an 
accumulation of these structures in the perinuclear region was observed (Figure 3-20). This 
clustering depends on the Rab1 effector p115. It indicates that there is more active Rab1 in 
cells depleted of TBC1D20, which recruits more p115 and thus causes increases clustering 
of COPII positive structures. 
The data obtained by depleting TBC1D20 in different cell lines strongly suggest that 
it acts as the GAP for Rab1 in vivo. Its depletion led to increased p115 staining and 
amplified p115 dependent COPII clustering. Both of these effects are most likely due to 
elevated levels of active endogenous Rab1. 
 
 
Figure 3-20 Depletion of TBC1D20 causes increased clustering of COPII. hTERT-RPE1 cells 
treated with control or specific TBC1D20 siRNA duplexes for 72 hours were fixed and stained with 
antibodies against Sec31 (red). The bar indicates 10 µm. 
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3.2.17 The depletion of TBC1D20 does not block VSV-G trafficking 
Surprisingly, the expression of Rab1Q67L did not block VSV-G transport. Therefore the effect 
of the depletion of TBC1D20 on VSV-G trafficking was analysed. Both expression of 
Rab1Q67L and depletion of TBC1D20 increase the amount of active Rab1 and should 
therefore cause the same phenotype. 
TBC1D20 was depleted for 72 hours as previously (see 3.2.16). 14 hours prior to the 
fixation the cells were transfected with a plasmid encoding VSV-G and treated as described 
previously (see 3.2.4). 
At the t=0 time point, equal amounts of VSV-G were found at the ER in both control 
and TBC1D20 depleted cells (Figure 3-21) as judged by microscopy. This shows that 
depletion of TBC1D20 did not affect the expression of VSV-G. After 5 minutes VSV-G was 
predominantly localised in COPII positive structures and after 30 minutes in the Golgi 
(Figure 3-21). Neither the disorganisation of COPII nor the compaction of the Golgi 
apparatus in cells depleted of TBC1D20 (see Figure 3-20) caused changes in VSV-G 
trafficking. In both the control and TBC1D20 depleted cells VSV-G was trafficking with 
similar kinetics. When the cell surface was stained for VSV-G after 60 minutes, in both 
control and TBC1D20 depleted cells VSV-G reached its destination. 
These data show that depletion of TBC1D20 does not cause a block of the trafficking 
of VSV-G. This observation fits with the finding that Rab1Q67L does not block VSV-G 
trafficking and is in contrast to the observations on EGF trafficking in the case of RabGAP-5 
depletion (Figure 2-19) and Rab5Q79L expression (Fuchs et al., 2007). Therefore, the 
regulation of Rab1 must differ from the regulation of Rab5 and does not fit the classical Rab 
cycle. 
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Figure 3-21 Depletion of TBC1D20 does not block VSV-G trafficking. HeLa cells were treated 
with TBC1D20 specific siRNA duplexes (TBC1D20) or control siRNA duplexes (Control) for 72 hours. 
VSV-G transport assays were performed for a total time of 15 hours. The cells were fixed at the time 
points indicated and stained for GM130 (blue, t=0,5,30) and Sec31 (red t=0,5,30) or surface VSV-G 
(red t=60). GFP indicates total VSV-G. The bars indicate 10 µm. 
 
3.2.18 TBC1D20 is a RabGAP localising to the ER 
The results presented so far show that TBC1D20 controls the activity of Rab1. Inactivation 
of Rab1 blocked the exit of cargo molecules from the ER, but the depletion of the Rab1 
effector p115 did not block ER exit. Therefore the question arose whether TBC1D20 and 
Rab1 have a function on the ER independent of p115. 
HeLa cells were transfected with wild-type or catalytically inactive TBC1D20R105A. 
After 24 hours the cells were fixed and stained for the ER marker Calnexin. TBC1D20 co-
localised with calnexin independent of its catalytic activity (Figure 3-22). It localised to the 
tubulated portions of the ER and also to the ring like structure characteristic of the nuclear 
envelope. Even though expression of TBC1D20 causes a “loss of Golgi” phenotype and 
blocks trafficking at the ER, no change of the ER morphology was observed. 
These data show that TBC1D20 is an ER localised RabGAP. As TBC1D20 regulates 
Rab1, they furthermore suggest the presence of Rab1 dependent processes on the ER. 
 
 
Figure 3-22 TBC1D20 localises to the ER. HeLa cells were transfected with myc-epitope-tagged 
wild-type (WT) or catalytically inactive TBC1D20R105A (RA) for 24 hours and then fixed with PFA. The 
cells were stained with antibodies against the myc-epitope-tag (red) and Calnexin (green). The bar 
indicates 10µm. 
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3.2.19 TBC1D20 localises to the ER via a C-terminal TMD 
Next, the ER localisation and the membrane association (Figure 3-9) of TBC1D20 were 
analysed in more detail. TBC1D20 has a hydrophobic stretch at its C-terminus (Figure 3-6). 
To analyse whether or not TBC1D20 is an integral membrane protein a series of 
carbonate extraction experiments was carried out (Fujiki et al., 1982). These experiments use 
Na2CO3 to break open membrane bound compartments. This releases their content and 
removes peripheral membrane proteins. Integral membrane proteins on the other hand 
remain associated with membranes. A 15 cm dish of HeLa cells was transfected with GFP-
tagged TBC1D20 for 24 hours. The cells were then harvested and broken open by passing 
them 40 times through a 27G needle. Nuclei and cell debris were removed by centrifugation 
for 5 min at 1000x g and 4°C to generate a post-nuclear supernatant (PNS). An aliquot of the 
PNS was split in two halves. One half was kept on ice as the total material (T), while the 
other was spun at 100,000-x g to generate a membrane pellet. The membrane pellet was 
resuspended in 100 mM Na2CO3 and incubated on ice for 30 min. To recover the 
membranes, the sample was spun at 100,000-x g again. The supernatant was precipitated 
with TCA and the pellet was resuspended in sample buffer. Equal amounts of the total (T), 
the carbonate extracted supernatant (SN) and the membrane pellet (P) were analysed by 
western blot. 
TBC1D20 was found in the in the membrane fraction, but was absent from the 
supernatant (Figure 3-23A). The type-II transmembrane protein Golgin-84 (Bascom et al., 
1999) behaved equally (Figure 3-23A). The peripheral membrane protein GM130 on the 
other hand was not found in the membrane fraction, but was precipitated from the 
supernatant (Figure 3-23A). These data show that TBC1D20 behaves like an integral 
membrane protein. 
To analyse the topology of TBC1D20 in the membrane a series of proteinase K 
digestion experiments (Tarone et al., 1982) was carried out. Proteinase K digests proteins, 
but cannot penetrate through intact membranes. Therefore portions of proteins inside the 
lumen of organelles are only accessible to proteinase K digestion after detergent treatment. 
A 15 cm dish of HeLa cells was transfected with N-terminally GFP-tagged TBC1D20 for 24 
hours. The cells were harvested and broken open. The cell suspension was cleared by 
centrifugation. The PNS was split into three equal aliquots: one was left untreated on ice; 
one was incubated in the presence of proteinase K on ice; the third was incubated in the 
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presence of both proteinase K and the detergent TritonX-100. All three aliquots were 
precipitated in TCA, and equal amounts were analysed by western blot. 
These experiments showed that TBC1D20 was degraded by proteinase K 
independent of the presence of detergent (Figure 3-23B). Therefore, the N-terminus of 
TBC1D20 tagged with GFP faces the cytoplasm. The type-II transmembrane protein Golgin-
84, which has a large cytosolic domain behaved like TBC1D20 (Figure 3-23B). TGN46 on 
the other hand, which has a large heavily glycosylated luminal domain, was only accessible 
to proteinase K digestion in the presence of detergent (Figure 3-23B). 
These findings show that TBC1D20 is an ER associated type-II transmembrane 
protein and that its N-terminal TBC domain is oriented towards the cytoplasm (Figure 
3-23C). 
 
 
Figure 3-23 TBC1D20 is a type-II-transmembrane protein. (A) Carbonate extraction experiments 
were performed to investigate the membrane association of GFP-tagged TBC1D20. Golgin84 and 
GM130 were taken as representative integral and peripheral membrane proteins, respectively. Total 
(T) refers to the input, Pellet (P) indicates the membrane bound fraction and the supernatant (SN) 
shows the membrane free fraction. (B) The topology of TBC1D20 was analysed by proteinase K (PK) 
digestion experiments in the presence (+) or absence (-) of Triton X-100 (TX). TGN46 and Golgin84 
were taken as representative proteins with large luminal or cytosolic domains, respectively. As 
TGN46 is glycosylated, a smear is observed. (C) A schematic shows the topology of TBC1D20. 
Lumen refers to ER lumen. 
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3.2.20 The TMD of TBC1D20 is required for its ER localisation 
To further analyse the targeting of TBC1D20, a series of truncations were generated. HeLa 
cells were transfected with these truncations for 24 hours. The cells were then fixed and 
stained for the Golgi marker GM130. 
Myc epitope tagged C-terminal truncations of wild-type TBC1D20 were used to 
determine the minimal TBC domain. Full length wild-type TBC1D20 localised to the ER 
and caused the “loss of Golgi” phenotype (Figure 3-24). TBC1D20 aa 1-337 and aa 1-317 
were catalytically active (Figure 3-24) but did not localise to the ER. The “loss of Golgi” 
phenotype was not observed in cells expressing TBC1D20 aa 1-300 (Figure 3-24). These 
data are consistent with the biochemical data (Figure 3-14B) and show that the ER 
localisation of TBC1D20 is dispensable for its activity. 
 
 
Figure 3-24 The activity of TBC1D20 is independent of its ER localisation. HeLa cells were 
transfected with wild-type myc-epitope-tagged TBC1D20 full length and truncation constructs. The 
cells were fixed after 24 hours and stained for the myc-epitope-tag (red) and GM130 (green). The 
enlargements to clarify TBC1D20 localisation correspond to 10x10 µm. The bar indicates 10µm. 
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To analyse the ER targeting of TBC1D20 GFP-tagged N-terminal deletion constructs 
were generated. Full-length TBC1D20R105A localised to the ER and nuclear envelope (Figure 
3-25). The N-terminal deletions aa 301-403 and aa 336-403 showed a similar localisation 
(Figure 3-25). The shortest localising sequence was encoded in aa 364-403 (Figure 3-25). 
This amino acid stretch, which only consists of the TMD and the luminal amino acids, 
showed a slightly altered distribution and localised more strongly to the nuclear envelope 
and less to the reticular ER. It localised to the Golgi as well. This is more obvious in cells 
expressing low levels of TBC1D20 aa 364-403. 
These findings show that the C-terminal TMD is required for the localisation of 
TBC1D20 to the ER. They furthermore indicate that a stretch of amino acids N-terminally 
adjacent to the TMD might be required to fine-tune the localisation of TBC1D20. 
 
 
Figure 3-25 TBC1D20 localises to the ER via its TMD. HeLa cells were transfected with 
catalytically inactive GFP-tagged TBC1D20R105A full length and truncation constructs. The cells were 
fixed after 24 hours and stained for GM130 (red). GFP was visualized directly (green). The bar 
indicates 10µm. 
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A schematic representation of these experiments is added (Figure 3-26) for clarity. 
The minimal TBC domain is encoded by aa 1-317, consistent with the data obtained by in 
vitro GAP assays. The localisation of TBC1D20 depends on the TMD on its C-terminus, and 
is encoded by the aa 364-403. 
 
 
Figure 3-26 Schematic representation of TBC1D20 mapping experiments. The red of the TBC 
domain represents myc-epitope-tagged constructs; GFP-tagged constructs are indicated by the 
green colour of the TMD. Drawings are not to scale. 
 
3.2.21 TBC1D20 interacts with Reticulon 1 variant 2 
The localisation of TBC1D20 to the ER raised the question of whether this targeting is 
mediated by the interaction of TBC1D20 with ER associated proteins. 
To identify interactors of TBC1D20 that could help its localisation to the ER, two 
yeast two-hybrid screens were performed. Full-length TBC1D20 and TBC1D20 aa 364-403 
was used as bait, respectively. A cDNA library generated from human testis was chosen as 
prey for these screens. The screen of TBC1D20 aa 364-403 covered 875,000 clones but 
failed to identify interactors. This indicates that this part of TBC1D20 might not be sufficient 
to interact with other proteins. The screen with full length TBC1D20 however, which 
covered 1,780,00 clones, revealed two interactors. 
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One of these interactors was a full-length clone of an ER resident protein called 
BAP31. This protein is involved in the regulation of ER exit and the quality control of MHC 
molecules (Ladasky et al., 2006) and IgD (Schamel et al., 2003). This protein is very 
interesting in the aspect of the role TBC1D20 plays in the regulation of ER exit. The second 
positive clone was the C-terminus of Reticulon 1 variant 2 (RTN-1). Reticulons are a group 
of 4 proteins, each of which has multiple isotypes (Yan et al., 2006). They are associated 
with the ER by four C-terminal hydrophobic regions (Iwahashi et al., 2007). RTNs were 
shown to be involved in ER-Golgi trafficking (Wakana et al., 2005), bind to SNAREs 
(Steiner et al., 2004) and shape sub-domains of the ER (Voeltz et al., 2006). A S. cerevisiae 
RTN homologue has been show to interact with Ypt1, the yeast Rab1 (Geng et al., 2005). As 
TBC1D20 functions as a GAP for Rab1, the interaction of RTN-1 and TBC1D20 was 
analysed in more detail. 
First, a series of directed yeast two-hybrid assays was performed. These showed that 
the TMD of TBC1D20 is necessary but not sufficient for the interaction with RTN-1 (Figure 
3-27A). The minimal RTN-1 interacting region included the TMD and an adjacent 
cytoplasmic stretch. This is the shortest fragment that showed the same localisation as full-
length TBC1D20 when expressed in cells (Figure 3-25). This suggests that the interaction 
with RTN-1 might be required for the proper localisation of TBC1D20. 
To confirm these results at the protein level, immunoprecipitation experiments were 
performed. The cells were lysed in digitonin as this mild detergent was previously shown to 
preserve RTN membrane complexes (Voeltz et al., 2006). 10 cm dishes of HeLa cells were 
co-transfected with one of the myc-epitope-tagged TBC1D20 constructs indicated and GFP-
tagged RTN-1 for 24 hours. The cells were then harvested, lysed and cleared by 
centrifugation. 1 µg of purified anti-GFP antibody and protein-G sepharose were added and 
the slurry was incubated for 2 hours. The slurry was then washed to remove non-bound 
proteins and boiled in SDS sample buffer. These experiments showed that RTN-1 interacts 
with full-length TBC1D20 irrespective of its catalytic activity (Figure 3-27B). The first 337 
amino acids of TBC1D20, which lack the ER-targeting region that interacted with RTN-1 in 
direct yeast two-hybrid, did not show any significant binding to RTN-1 under the same 
conditions (Figure 3-27B). These findings show that TBC1D20 forms a complex with 
RTN1. 
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Figure 3-27 TBC1D20 interacts with RTN-1. (A) A schematic of RTN-1 showing the two 
hydrophobic regions (HR). The minimal TBC1D20 binding fragment identified by yeast two-hybrid 
(Y2H) screening is shown in blue. Drawing is not to scale. Directed yeast two-hybrid assays were 
performed using RTN-1 as prey and the TBC1D20 truncations indicated. Growth on selective 
medium (QDO) indicates interaction. (B) GFP-immunoprecipitations were performed from HeLa cells 
co-transfected with myc-epitope-tagged RTN-1 and GFP-tagged TBC1D20 as indicated. The 
immunoprecipitates were probed with antibodies against GFP or Myc to detect TBC1D20 and RTN-1, 
respectively. Total (T) corresponds to the input, supernatant (S) to the non-bound and (IP) to 
precipitated material. (C) HeLa cells were transfected with GFP-tagged RTN-1 for 24 hours, fixed 
and stained for GM130 (red) or Calnexin (red). GFP was visualized directly (green). The bar 
indicates 10µm. 
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HeLa cells were then transfected with RTN-1 to analyse its localisation. The cells 
were fixed after 24 hours and stained for GM130 or calnexin, respectively. RTN-1 co-
localised with calnexin (Figure 3-27C) but not with GM130 (Figure 3-27C). Notably, the 
morphology of the Golgi apparatus was not affected by the over-expression of RTN-1. 
Taken together, these data show that TBC1D20 contains a specific ER-targeting 
motif that interacts with a member of a family of known ER proteins. This interaction 
appears to be required for the proper ER localisation of TBC1D20. The interaction requires 
the TMD of TBC1D20 together with an adjacent cytoplasmic stretch and the hydrophobic 
regions of RTN-1. This suggests that these proteins form a complex in the ER membrane. 
3.2.22 RTN-1 modulates the activity of TBC1D20 in vivo 
The interaction of TBC1D20 with RTN-1 suggests that RTN-1 might be important to control 
the activity of TBC1D20. As over-expression of TBC1D20 causes a “loss of Golgi”, this 
phenotype was used as readout of the activity of TBC1D20. HeLa cells were either 
transfected with myc-epitope-tagged TBC1D20 alone, or co-transfected with GFP-tagged 
RTN-1 for 24 hours. The cells were then fixed and stained for the Golgi marker GM130. 
The over-expression of wild-type TBC1D20 caused a loss of the Golgi (Figure 3-28). 
This effect was antagonized by the co-expression of RTN-1, as judged by the recovery of 
GM130 staining into a fragmented perinuclear ribbon structure in cells expressing both wild-
type TBC1D20 and RTN-1 (Figure 3-28). The “loss of Golgi” phenotype was therefore 
reduced in these cells to a Golgi fragmentation phenotype. The expression of TBC1D20R105A 
did not cause a “loss of Golgi” phenotype (Figure 3-28). When co-expressed, RTN-1 and 
TBC1D20R105A co-localised in the ER, and the Golgi appeared normal as compared to non-
expressing control cells (Figure 3-28). The expression of TBC1D20 aa 1-337 caused a “loss 
of Golgi” phenotype. If the antagonising effect of RTN-1 on TBC1D20 is specific, then it 
should require the RTN-1 interacting part of TBC1D20. As predicted, TBC1D20 aa 1-337, 
which does not interact with RTN-1 (Figure 3-27) caused the “loss of Golgi” phenotype 
independent of the presence of RTN-1 (Figure 3-28). 
These findings show that the interaction of RTN-1 with TBC1D20 not only serves to 
localise TBC1D20 to the ER, but also modulates its activity. This modulation might be 
linked to the properties of RTNs to define sub-compartments of the ER and thus restrict the 
distribution of TBC1D20 in the ER. 
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Figure 3-28 RTN-1 expression antagonises the “loss of Golgi” phenotype. HeLa cells were 
transfected with myc-epitope-tagged wild-type, catalytically inactive TBC1D20R105A, or TBC1D20 aa 
1-337 in the absence or presence of GFP-tagged RTN-1 (Reticulon) for 24 hours. The cells were 
fixed and stained for GM130 and the myc epitope. In single transfection panels DNA was stained 
with DAPI. The Bar indicates 10µm. 
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To show the distribution of these phenotypes the Golgi morphology in n=100 cells 
was analysed for each condition. The Golgi morphology was scored as intact, when it was 
comparable to neighbouring non-expressing cells. It was scored as fragmented, when 
GM130 stained a fragmented perinuclear ribbon structure. The cells were scored to have a 
“loss of Golgi” phenotype when these structures were not observed. 
This analysis showed that that the co-expression of RTN-1 with wild-type full length 
TBC1D20 strongly reduced the percentage of cells with a “loss of Golgi” phenotype while 
the percentage of cells with fragmented Golgi was equivalently increased (Figure 3-29). In 
the case of TBC1D20 aa 1-337, the co-expression of RTN-1 did not significantly alter the 
distribution of the phenotypes (Figure 3-29). Expression of TBC1D20R105A showed the same 
distribution of phenotypes as control cells independent of the presence of RTN-1 (Figure 
3-29). The over-expression of RTN-1 alone did not alter the distribution of phenotypes 
compared to non-expressing control cells (Figure 3-29). 
 
 
Figure 3-29 Distribution of phenotypes in cells expressing RTN-1 and TBC1D20. HeLa cells 
were transfected with myc-epitope-tagged wild-type, catalytically inactive TBC1D20R105A, or 
TBC1D20 aa 1-337 in the absence (-) or presence (+) of GFP-tagged RTN-1 (Reticulon) for 24 
hours. The cells were fixed and stained for GM130 and the myc-epitope tag. n=100 cells were 
analysed for each condition and the Golgi was scored as normal, fragmented or lost in comparison to 
non-expressing control cells. 
 
To exclude that the modulatory effect of RTN-1 on the activity of TBC1D20 is due 
to altered expression levels a series of western blots was performed. HeLa cells were 
transfected with myc-epitope-tagged TBC1D20 constructs alone or co-transfected with GFP-
tagged RTN-1 for 24 hours. The cells were then lysed and equal amounts were analysed by 
western blot. The blots were probed with antibodies against GFP and the myc-epitope-tag to 
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show RTN-1 and TBC1D20, respectively. These experiments showed that the co-expression 
of RTN-1 did not alter the expression levels of TBC1D20 (Figure 3-30), independent of their 
physical interaction. The modulatory effect of RTN-1 is therefore not due to decreased 
expression levels of TBC1D20. 
Taken together, these findings indicate that the interaction of RTN-1 with TBC1D20 
not only ensures the proper localisation of TBC1D20 to the ER, but also serves as a way to 
regulate the activity of TBC1D20. They furthermore suggest that RTN-1 helps to 
compartmentalize the ER not only by shaping ER sub-domains (Voeltz et al., 2006), but also 
by controlling the activity of TBC1D20, which is probably mediated by restricting 
TBC1D20 to specific ER sub-domains. 
 
 
Figure 3-30 Expression of RTN-1 does not alter TBC1D20 expression levels. HeLa cells were 
transfected with myc-epitope-tagged wild-type, catalytically inactive TBC1D20R105A, or TBC1D20 aa 
1-337 in the absence (-) or presence (+) of GFP-tagged RTN-1 (Reticulon) for 24 hours. The cells 
were harvested and lysed. Western blots were probed with antibodies against GFP to show RTN-1 
and against the myc-epitope-tag to show TBC1D20. The blots were probed with α-tubulin antibodies 
as a loading control. 
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3.3 Summary 
To identify GAPs and Rabs involved in the regulation of early secretory traffic a novel 
screening method was established. This method uses the over-expression of RabGAPs to 
inactivate endogenous target Rabs. This inactivation causes phenotypes that help to identify 
which Rabs and GAPs are involved in the regulation of the process of interest. Screening for 
changes in the morphology of both the Golgi apparatus and the ERGIC as well as the ability 
of RabGAPs to block secretion resulted in only one candidate among all 38 RabGAPs tested, 
the highly conserved protein TBC1D20. 
The over-expression of the ER localised TBC1D20 caused a unique “loss of Golgi” 
phenotype. When the fate of Golgi proteins was analysed by western blot, they were found 
to remain associated to membranes, with the exception of the Rab1 effector p115. Golgi 
enzymes redistributed to the ER. The exit of VSV-G from the ER was blocked in cells 
expressing TBC1D20. When TBC1D20 was tested in a biochemical assay against a broad 
selection of Rabs, it stimulated GTP hydrolysis by Rab1 and Rab2. Subsequent analysis of 
dominant negative mutant Rabs and specific siRNA showed that Rab1 is the primary in vivo 
target of TBC1D20. The expression of TBC1D20 scattered COPII positive structures, but 
did not interfere with the dynamics of the COPII coat. Under these circumstances cargo 
receptors such as p24 were absent from ERES, which possibly explains the block of 
secretion. Using truncations of TBC1D20 the minimal TBC domain was mapped to aa 1-
317, consistent with biochemical data. Truncations and biochemical analysis also showed 
that the ER localisation of TBC1D20 depends on the presence of a TMD on its C-terminus. 
These experiments showed that TBC1D20 a type-II transmembrane protein. 
The localisation of TBC1D20 depends on RTN-1, an interactor identified by a yeast 
two-hybrid screen. RTN-1 modulates the activity of TBC1D20 dependent on the physical 
interaction of both proteins. This suggests a model where TBC1D20 is localised to ER sub-
domains by RTN-1. 
These findings indicate a novel function of Rab1 at the level of the ER. They 
furthermore show that the activity of Rab1 is controlled at the level of the ER. Furthermore, 
the classical view of RabGAPs as the limiting factors of the lifetime of active Rab is 
challenged as both the depletion of TBC1D20 and the expression of constitutive active Rab1 
failed to block trafficking at the level of COPII vesicles. This suggests a novel mode of Rab 
regulation at least in the case of Rab1. 
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4 Discussion 
4.1 RabGAPs are a highly diverse protein family 
Work in yeast has shown that RabGAPs contain a TBC domain (Albert et al., 1999; Strom et 
al., 1993; Vollmer et al., 1999). However, only very few members of this protein family 
were identified in the human genome prior to this work. A search of the human genome 
identified 40 proteins containing a TBC domain, some of which also give rise to splicing 
variants. Sequence analysis revealed that the TBC domain and the catalytic site signature 
sequence IxxDxxR (T/S) in motif B are variable. The arginine in this signature sequence, 
which is involved in GTP hydrolysis, is highly conserved, but not invariant. In some of the 
TBC domain proteins the arginine is shifted, in others the arginine is replaced by other 
amino acids. These findings might reflect differences in the Rabs that these GAPs regulate. 
Rab20, Rab24 and Rab25 for example do not have a conserved glutamine in the DxxGQ 
motif in G3 (1.2.1), and are therefore unlikely to hydrolyse GTP in the same way as the rest 
of the Rab family (Pan et al., 2006). Variations in the catalytic mechanism to hydrolyse GTP 
are reported for other members of the Ras superfamily. For example, RanGAP has an 
asparagine instead of an arginine, and the small GTPases Sar1 contributes as histidine 
instead of a glutamine to the reaction (Bos et al., 2007; Daumke et al., 2004; Seewald et al., 
2002). It is therefore possible that in the largest group of the Ras super-family not only one 
catalytic mechanism is used to hydrolyse GTP. 
Most human TBC domain proteins are multi-domain proteins. Many different domains 
are found in these proteins, for example: PTB domains, PH domains, GRAM domains, 
ubiquitin ligase domains and SH3 domains to name only a few. The GAPs of other small 
GTPases of the Ras super-family are also multi-domain proteins (Bos et al., 2007). All these 
GAPs function as integrators of signals onto the activity of a GTPase. Their composition of 
multiple domains therefore appears to be critical for their function. 
4.2 Novel methods to study the interactions of Rabs and their GAPs 
4.2.1 A novel yeast two-hybrid system to identify Rab-GAP pairs 
To match the GAPs identified using a bioinformatic approach to the Rabs they regulate, a 
series of novel methods had to be established. First, a yeast two-hybrid based screen was 
established. Initial tests showed that wild-type GAPs do not interact with wild-type Rabs. 
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This finding is consistent with data that show that the interaction of a GAP and its target 
GTPase is only transient (Allin et al., 2001). After GTP hydrolysis has occurred, the GAP no 
longer interacts with its target and is released. It is also consistent with previous studies of 
yeast showing that the affinity of TBC domain proteins for their substrates is very low 
(Albert et al., 1999). To strengthen the interaction between the GAP and its target Rab a 
conserved glutamine of the Rabs was mutated to leucine to restrict them in their GTP bound 
active conformation. When wild-type GAPs were tested against these mutant Rabs 
interactions were observed but only partial specificity was achieved. It is likely that the 
introduction of the bulky hydrophobic leucine into the nucleotide-binding cleft of the Rab 
prevents the insertion of the arginine of the GAP into this cleft. This steric hindrance might 
explain why the GAPs showed reduced substrate specificity and interacted with groups of 
related Rabs under these circumstances. The arginine of the B motif of the GAPs was 
therefore replaced by alanine. When the mutant GAPs were tested against the constitutive 
active Rabs, specific interactions were observed. As shown for RabGAP-5 and RN-tre, the 
Rabs that interacted with the GAPs in this double mutant screen are their biochemical target. 
When RN-tre and RabGAP-5 were later tested against all human Rab GTPases, it was shown 
that these GAPs only activated GTP hydrolysis by the Rabs that they interacted with in the 
double mutant screen (Fuchs et al., 2007). These observations therefore validate the double 
mutant yeast two-hybrid approach. 
The yeast two-hybrid data are also consistent with the recently solved structure of a 
Rab bound to a GAP (Pan et al., 2006). The glutamine of the Rab forms hydrogen bonds to 
the polypeptide backbone of a loop of the GAP that is inserted into the nucleotide-binding 
cleft. It is likely that this loop of the GAP cannot be inserted into the cleft if the glutamine of 
the Rab is mutated to leucine. As the GAP also interacts with the switch regions of the Rab, 
some interaction is still maintained, but might not be sufficient to ensure full specificity. 
When the positively charged arginine of the GAP is replaced by alanine, the truncated loop 
might fit into the nucleotide-binding cleft and the GAP can bind to its specific target. 
Therefore, this double mutant screen turns the GAP into an effector of the Rab and generates 
a stable interaction. 
The data presented in this work also shed new light on the GTP restriction of 
constitutive active Rab mutants. The introduction of mutations in the conserved glutamine of 
Rabs was previously thought to prevent the glutamine from coordinating a water molecule 
for a nucleophilic attack at the γ-phosphate and thus keeps the Rabs GTP bound. According 
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to the recently solved structure discussed above (Pan et al., 2006) this glutamine interacts 
with a loop contributed by the GAP and is not directly involved in the catalysis of GTP 
hydrolysis. The findings that wild-type GAPs do not interact, or have reduced specificity for 
GTP restricted Rab mutants, suggests that the restriction is due to steric hindrance. This is 
illustrated by the finding that wild-type RN-tre does not interact with GTP restricted Rab43, 
and that RabGAP-5R165A interacts more strongly with Rab5Q79L than wild-type RabGAP-5 
does. It was shown in the case of Rab1 and Rab5 that the GTP restricted mutants indeed 
have a reduced basal GTP hydrolysis rate, but are not completely hydrolysis deficient. This 
reduced basal hydrolysis rate however was resistant to RabGAP-5 or TBC1D20 mediated 
stimulation of GTP hydrolysis. These findings suggest that constitutive active Rabs are kept 
in their active conformation because they fail to properly interact with their cognate GAPs. 
4.2.2 Rab inactivation screening as a novel method to analyse trafficking 
The yeast two-hybrid screening method established in this work is a potent tool to identify 
pairs of Rabs and their regulatory GAPs. This method however, has numerous limitations. 
First, this method might not work in all cases, due to the structural differences between the 
various GAPs and their target Rabs and thus generate false negative results. Second, and 
most important, the organelles and trafficking processes regulated by particular Rabs and 
their GAPs are largely unknown. To gain more information about both partners and the 
processes they regulate another novel screening approach was established. Based on the fact 
that an inactivated Rab does not recruit effector molecules onto the membrane it provides 
identity to, a novel method called Rab inactivation screening was established. It was 
proposed that the expression of all human GAPs and analysis of the resulting phenotypes 
should identify GAPs involved in the regulation of a specific trafficking step. 
To ensure that the phenotypes observed in the screen are due to the catalytic 
inactivation of a Rab, the catalytically inactive mutants of GAPs have to be examined in a 
next step. If a GAP causes a phenotype due to catalytic Rab inactivation, the inactive mutant 
GAP should not cause such an effect. RabGAP-5R165A and RN-treR150A interacted with their 
specific target in yeast two-hybrid, which shows that the secondary structure of these 
proteins was maintained. The R-A mutation however efficiently abolished their activity to 
stimulate GTP hydrolysis by their target Rabs in vitro. These findings show that the arginine 
to alanine mutation specifically inactivates the TBC domain proteins without effects on their 
secondary structure. Therefore these R-A mutant GAPs are valid controls to show the 
specificity of a phenotype that is caused by the inactivation of an endogenous Rab. 
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In a consequent step, the candidate GAPs have to be tested against all Rabs for their 
ability to promote hydrolysis to identify their target Rab. To consolidate that the Rab 
identified by in vitro experiments is the in vivo target of the GAP, the expression of the 
dominant negative mutant of the Rab and its depletion should mimic the phenotypes caused 
by the over-expression of the GAP. 
Proving the generality of this screening procedure, other researchers in the group 
used this method and successfully identified Rabs and their GAPs (Figure 4-1) involved in 
the formation of primary cilia and the regulation of clathrin independent endocytosis (Fuchs 
et al., 2007; Yoshimura et al., 2007). This technique was also used to prove that RabGAP-5 
is the only GAP that regulates clathrin dependent endocytosis of EGF (Fuchs et al., 2007). 
Not only Rabs, but also the other small GTPases of the Ras superfamily are 
controlled by GAPs and GEFs in their activity. The GAP mediated inactivation approach 
might therefore be useful to study the processes regulated by these GTPases as well. 
 
 
Figure 4-1 Rab inactivation screening results. Rab inactivation screening is a proven method to 
identify Rabs involved in a specific trafficking pathway and their regulatory GAPs. Figure layout is 
based on Figure 1-1. 
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4.3 RabGAP-5 is a specific Rab5 GAP 
Many evolutionary conserved proteins tightly control endocytosis. One of the key Rabs 
involved in the regulation of clathrin dependent endocytosis is Rab5 (Zerial and McBride, 
2001). In order to identify a Rab5 specific GAP out of forty human TBC domain proteins, 
the double mutant yeast two-hybrid screen was used. Only one out of all human TBC 
domain proteins was found to interact with Rab5, a protein later called RabGAP-5. 
Like many other TBC domain proteins, RabGAP-5 is a multi domain protein. 
According to own observations and data from a later publication (Lan et al., 2005), the 
minimal TBC domain of RabGAP-5 ranges from aa 13 to aa 411 and is followed by a short 
coiled- coil stretch. It in the case of the TBC domain protein GAPCenA, a coiled-coil C-
terminally of the TBC domain contributes to specific Rab binding (Fuchs et al., 2007). This 
coiled coil of RabGAP-5 might therefore contribute to specific substrate recognition as well. 
The TBC domain tested in the in vitro GAP assays and used in further experiments therefore 
contains this coiled-coil and ranges from aa 1 to aa 451. RabGAP-5 contains an Src-
homology-3 (SH3) domain C-terminal of the TBC domain. This domain recognizes proline-
rich sequences (Mayer, 2001) and is mostly found in proteins involved in signal 
transduction. This is an interesting finding for a regulator of Rab5 since this Rab is involved 
in the regulation of endocytosis of activated growth-factor receptors that follow the clathrin 
dependent pathway (Carpenter, 2000). The third domain of RabGAP-5 is a RUN domain at 
its C-terminus. The RUN domain was named after RPIP8, UNC-14 and NESCA (Callebaut 
et al., 2001). It is present in several proteins that are linked to GTPases of both the Rab and 
the Rap families. Its actual molecular function is not known. The C-terminus of RabGAP-5 
including the RUN domain has been previously shown to be required for the interaction of 
RabGAP-5 with other molecules, which will be discussed later in more detail (Ichioka et al., 
2005; Lee et al., 2004). 
When the ability of RabGAP-5 to stimulate GTP hydrolysis by Rabs was analysed in 
vitro, it was found to specifically activate GTP hydrolysis by the three Rab5 isoforms. It was 
shown later (Fuchs et al., 2007), when RabGAP-5 was tested against all human Rabs, that it 
only stimulates GTP hydrolysis by the same three Rab5 isoforms. 
To confirm that RabGAP-5 is a GAP for Rab5, the effects of over-expressing it in 
cells were analysed. RabGAP-5 over-expression redistributed the Rab5 effector EEA1 to the 
cytoplasm and inactivated co-expressed Rab5. Other sub-cellular organelles remained 
unaffected by the expression of RabGAP-5, which shows the specificity of these phenotypes. 
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These observations are consistent with previous publications that show that active Rab5 is 
required to recruit EEA1 to early endosomes (Christoforidis et al., 1999a; Lawe et al., 2000; 
McBride et al., 1999). EGF trafficking, which depends on Rab5 (Carpenter, 2000), was 
blocked by the over-expression of RabGAP-5. The recycling of the transferrin receptor was 
blocked under these circumstances as well. Remarkably, when all three isoforms of Rab5 
were depleted by siRNA (Fuchs et al., 2007), the phenotypes observed resembled the 
phenotypes observed in cells over-expressing RabGAP-5. This shows that diminishing the 
endogenous pool of active Rab5 caused these phenotypes. 
To analyse whether RabGAP-5 is an essential regulator of endocytic traffic, it was 
depleted by specific siRNA duplexes. The size of early endosomes was increased in cells 
depleted of RabGAP-5. This phenotype is also observed in cells that have elevated levels of 
active Rab5 (Stenmark et al., 1994). This shows that RabGAP-5 is required to control the 
activity of endogenous Rab5 and functions as a Rab5 specific GAP. When the trafficking of 
EGF was analysed in cells depleted of RabGAP-5, it was found that EGF is trapped in early 
endosomes and was not trafficked to lysosomes for degradation. This shows that RabGAP-5 
is required to inactivate Rab5 on early endosomes in order to allow the maturation events 
required for the late stages of the endocytic pathway. This observation is consistent with 
another study, which showed that Rab7 replaces Rab5 on early endosomes as they mature 
(Rink et al., 2005). It furthermore shows the essential role for RabGAP-5 in the control of 
trafficking through early endocytic compartments. 
Taken together, these data show that RabGAP-5 has all the characteristics expected 
of a GAP specific for Rab5. Evidence that RabGAP-5 in fact is the only human Rab5 GAP 
comes from a subsequent study (Fuchs et al., 2007), which showed that out of all human 
TBC domain proteins only RabGAP-5 blocks the Rab5 dependent endocytosis of EGF. 
4.3.1 RabGAP-5 links signalling to membrane traffic 
As RabGAP-5 is essential for sorting events at the early endosome and for the regulation of 
Rab5, the question raises of how RabGAP-5 might be controlled. 
RabGAP-5 has been shown to interact with the tumour-suppressor Merlin (Lee et al., 
2004) also known as Schwannomin, the gene product of NF2 (Okada et al., 2007). Merlin is 
an interaction partner of Hrs, which is an early endosome-associated adaptor molecule 
required for the sorting of growth-factor-receptors to late endosomes and lysosomes (Clague 
and Urbe, 2001). Hrs is recruited to the endosome by a complex of Eps15 (Komada and 
Kitamura, 2001) and the signal transducing adaptor molecule (STAM) (Row et al., 2005). 
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This complex is recruited to the endosome by activated growth factor receptors (Clague and 
Urbe, 2001). Therefore, RabGAP-5 may provide a link between growth-factor-receptor 
signalling and the regulation of endosomal trafficking by modulating the activity of Rab5. 
Based on these findings it can be proposed that activated growth-factor-receptors 
control their own degradation and the termination of their signalling in a feedback loop 
(Figure 4-2). Activated growth-factor-receptors are endocytosed and traffic to Rab5 positive 
early endosomes where they recruit adaptor molecules like Hrs. Hrs and its binding partner 
Merlin could the recruit RabGAP-5, which inactivates Rab5. Recent findings show that the 
inactivation of Rab5 is required to mature Rab5 positive endosomes into Rab7 positive late 
endosomes to enter the degradative pathway (Rink et al., 2005). It was also proposed that the 
probable Rab7 GEF C-VPS/HOPS or CORVET (Peplowska et al., 2007; Wurmser et al., 
2000) is a Rab5 effector. Rab5 might therefore indirectly activate Rab7. The inactivation of 
Rab5 by RabGAP-5 can thus promote the maturation of early endosomes into late 
endosomes and MVBs, and thus stimulate the degradation of signalling molecules. 
Interestingly, another RabGAP-5-interacting protein (Ichioka et al., 2005) called Alix is 
required for formation of the multivesicular body and endosome organization (Cabezas et 
al., 2005; Matsuo et al., 2004). 
Consistent with the proposed model, the depletion of RabGAP-5 did not have an 
effect on the Rab5 dependent uptake of EGF, but trapped EGF in early endosomes and 
prevented its degradation. RabGAP-5 therefore seems to be required to terminate the activity 
of Rab5 to allow the initiation of consecutive trafficking steps. On the other hand, Rab5 
activity is also required for CCV formation (McLauchlan et al., 1998). According to this role 
of Rab5, the expression of RabGAP-5 and the depletion of Rab5 (Fuchs et al., 2007) blocked 
EGF trafficking at this early stage. 
A recent publication shows that RabGAP-5 binds directly to TrkA and TrkB (Liu et 
al., 2007) and suggests a different model for the regulation of endosomal signalling. These 
authors propose that early recruitment of RabGAP-5 by TrkA/B prevents Rab5 from being 
activated and thereby results in long-lived signalling endosomes. Activation of Rab7 would 
therefore be prevented and the signalling molecules would therefore not enter the 
degradative pathway. 
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Figure 4-2 RabGAP-5 provides a link between signalling and Rab5 regulation. Activated growth 
factor receptors recruit protein complexes onto the early endosome that recruit RabGAP-5. RabGAP-
5 inactivates Rab5 and the early endosome matures into a Rab7 positive late endosome. The 
number 5 indicates Rab5, Rab7 is indicated by the number 7. Active, GTP bound Rab is symbolised 
by a red sphere, inactive Rab by a green square. 
 
4.3.2 RabGAP-5 and Merlin 
Of special interest for future research into RabGAP-5 function is its interaction with the 
tumor suppressor Merlin (Lee et al., 2004). Merlin switches between an active and an 
inactive conformation dependent on the phosphorylation of its C-terminus by the p21-
activated kinase (PAK). Merlin accumulates at adherence junctions (Lallemand et al., 2003) 
and is essential for cell-cell contact mediated cell cycle arrest (Lallemand et al., 2003; 
Morrison et al., 2001; Okada et al., 2005). The ability of PAK to release cells from contact 
inhibition is blocked by a form of Merlin that lacks the PAK phosphorylation site, which 
suggests that PAK promotes cell proliferation by phosphorylating and thus inactivating 
Merlin (Lallemand et al., 2003; Okada et al., 2005). 
Recent findings show that Merlin inhibits cell proliferation by stabilising adherence 
junctions and negatively regulates EGF receptor signalling and internalization (Curto et al., 
2007). The block of EGF endocytosis in cells over-expressing RabGAP-5 suggests an 
interesting link to these observations. Merlin might recruit RabGAP-5 to block Rab5 
dependent EGF uptake and thus stop cell proliferation. Further support for this idea comes 
from the finding that Connexin43, a component of gap junctions that interacts with cadherins 
(Giepmans, 2006), binds RabGAP-5 (Lan et al., 2005). RabGAP-5 might therefore be 
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recruited to cell-cell contacts by the combined action of Merlin and Connexin43 and block 
Rab5 dependent endocytosis at these sites.  
This model implies a role for RabGAP-5 not only in terminating Rab5 activity on the 
early endosome but also points to a role of RabGAP-5 in the regulation of cell proliferation 
and cell polarity. 
4.4 RN-tre is a GAP for Rab43 
The TBC domain protein RN-tre was reported to act as a GAP for Rab5 (Lanzetti et al., 
2004; Lanzetti et al., 2000). The data presented in this work show that RN-Tre acts as a 
weak Rab5 GAP in vitro, and that RN-tre is in fact a GAP for Rab43. The weak activity of 
RN-tre towards Rab5 is unlikely to be physiologically relevant for multiple reasons. 
RN-Tre was found to bind to Rab43 and Rab30 but not Rab5 in the yeast two-hybrid 
screen. These interactions were only observed when both the Rabs and RN-tre were mutated. 
This indicates that this interaction is due to a GAP-Rab interaction and not due to the fact 
that RN-tre as a Rab5 GAP is an effector for Rab43 or Rab30. 
RN-tre strongly activated GTP hydrolysis by Rab43 in vitro, and only weakly by 
Rab5. When RN-tre was later tested against all human Rab GTPases it was shown to have 
specific activity towards Rab43 (Fuchs et al., 2007). This indicates that the activation of 
Rab5 by RN-tre is most likely a consequence of using purified proteins at high 
concentrations in vitro. Remarkably, despite its high degree of similarity to Rab43, no 
significant activation of GTP hydrolysis by Rab30 was observed in the presence of RN-tre. 
This shows that the yeast two-hybrid system can identify interacting Rabs, but final 
specificity can only be provided by biochemical in vitro GAP assays with recombinant 
proteins. 
In contrast to RabGAP-5, the over-expression of RN-Tre failed to redistribute the 
Rab5 effector EEA1 or Rab5 in vivo. When tested in hTERT-RPE1 cells, the TGN marked 
by TGN46 was more affected by the expression of RN-tre than the cis-Golgi marked by 
GM130. Consistent with this, the target of RN-tre is present at the Golgi apparatus. This 
observation is consistent with the finding that RN-tre and Rab43 are regulators of retrograde 
transport from the PM to the TGN by a clathrin independent trafficking route exploited by 
Shiga toxin (Fuchs et al., 2007). 
The observation that RN-tre regulates an endocytic retrograde trafficking step helps to 
explain why it was previously found to interfere with EGF uptake (Lanzetti et al., 2000). 
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With low doses of EGF, the EGF receptor is almost entirely transported via the clathrin 
dependent pathway. At higher or saturating doses it spills over into the clathrin independent 
pathway (Sigismund et al., 2005). With saturating amounts of EGF, RN-tre would prevent 
transport of the pool of EGF receptor entering via the clathrin-independent pathway, and 
thus show a reduction in EGF uptake. It will therefore be interesting to investigate the role of 
the RN-tre and RabGAP-5 regulated pathways under true physiological conditions in tissues 
where EGF signalling is critical for normal growth and development. 
4.5 TBC1D20 regulates secretion by inactivating Rab1 
4.5.1 The Rab1 GAP TBC1D20 regulates Golgi morphology and ER exit  
Out of 38 human TBC domain proteins tested in a Rab inactivation screen only the GAPs 
TBC1D20, TBC1D22A, TBC1D22B, XM_037557 and RN-tre caused Golgi fragmentation 
in HeLa cells dependent on their catalytic activity. When the fragmentation of the Golgi 
apparatus was analysed in hTERT-RPE1 cells, only TBC1D20 and RN-tre caused a 
phenotype dependent on their catalytic activity. This finding suggests, that the GAPs that 
were not positive in both screens either do not regulate ubiquitously essential Rabs or that 
HeLa cells lack Rabs that can redundantly fulfil the role of the Rabs inactivated by these 
GAPs. 
TBC1D22A and TBC1D22B most likely regulate the Rab33 family (Pan et al., 2006) 
that regulates trafficking at the Golgi apparatus (Valsdottir et al., 2001; Zheng et al., 1998). 
RN-tre has GAP activity towards Rab43, which localises to the TGN and regulate a clathrin 
independent pathway from the PM to the TGN (Fuchs et al., 2007). XM_037557 is a GAP 
specific for Rab8a, which is required for the formation of primary cilia in serum-starved 
cells and localises to the Golgi in proliferating cells (Yoshimura et al., 2007). All these 
GAPs therefore regulate Rabs that are involved in trafficking associated to the Golgi. This 
validates the screening approach, and proves that in fact the GAPs associated with a 
trafficking step or organelle of interest are specifically identified by this method. 
When the ability of human GAPs to cause morphological changes to the ERGIC was 
analysed in a Rab inactivation screen, only TBC1D20 and TBC1D22B caused a phenotype. 
This indicates, that the Rabs regulated by these two GAPs are involved in the regulation of 
trafficking processes between the Golgi and the ER. However, out of all human GAPs only 
TBC1D20 blocked the trafficking of VSV-G. The role of the Rab regulated by TBC1D22B 
therefore appears less critical. 
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Based on the results of these screens, TBC1D20 was analysed in more detail. The 
expression of this highly conserved GAP resulted in the apparent loss of cis-, medial-, and 
trans-Golgi markers, a so-called “loss of Golgi” phenotype. Further investigation revealed 
that TBC1D20 blocked the exit of VSV-G from the ER. TBC1D20 is unique amongst the 
TBC-domain proteins in that it possesses a transmembrane domain. This domain is required 
to target TBC1D20 to the ER. When tested in a biochemical GAP assay against all human 
Rabs, TBC1D20 showed specific activity towards Rab1 and Rab2. The other GAPs that 
caused Golgi fragmentation failed to stimulate GTP hydrolysis by Rab1 or Rab2, consistent 
with their reported target Rabs. 
To narrow down the in vivo target of TBC1D20, the phenotypes of dominant 
negative Rabs were compared to phenotypes caused by over-expression of TBC1D20. These 
experiments showed that only dominant negative Rab1N121I recapitulates these phenotypes. 
When Rab1 and Rab were depleted by siRNA, both gave rise to Golgi fragmentation. The 
Golgi fragments in cells depleted of Rab2 were forming a cluster whereas the Golgi 
fragments in cells depleted of Rab1 appeared more vesiculated and spread throughout the 
cell. This is consistent with the idea that the Rab1 effector p115 is required for clustering of 
pre- Golgi structures (Alvarez et al., 1999). In the case of Rab2 depletion the fragments were 
possibly still connected by the Rab1 effector p115 interacting with the GM130/ GRASP65/ 
Giantin complex on the Golgi (Short et al., 2005). In contrast to the expression of dominant 
negative Rab1N121I or TBC1D20, in cells depleted of Rab1 the Golgi was only fragmented 
and no “loss of Golgi” phenotype was observed. This might be explained by the different 
kinetics of the Rab1 siRNA that takes 72 hours compared to 24 hours of expression. In 
contrast to the case of the depletion of Rab1, which removes both the active and the inactive 
pool of the Rab, expression of TBC1D20 or Rab1N121I increase the pool of GDP bound Rab. 
This GDP-bound Rab might sequester the Rab1 GEF, and thus strengthen the phenotype. 
The phenotype of Rab1 depletion, however, still resembles the TBC1D20 phenotype more 
closely than the phenotype obtained upon depletion of Rab2. The depletion of Rab1 and 
Rab2 by siRNA furthermore showed that only the depletion of Rab1 completely blocked the 
trafficking of VSV-G at the ER. Therefore it was concluded that the phenotypes observed in 
cells over-expressing TBC1D20 are mainly due to the inactivation of endogenous Rab1. As 
predicted, the block of VSV-G trafficking was also observed in cells expressing dominant-
negative Rab1N121I. Consistent with the role of TBC1D20 as the GAP for Rab1, the Rab1 
dependent clustering of COPII vesicles was strongly impaired in cells over-expressing 
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TBC1D20. Furthermore, p115, which is recruited by Rab1 to membranes, was lost from the 
membrane fraction in cells expressing TBC1D20. 
The finding that TBC1D20 acts as a GAP for Rab1 is consistent with previous 
studies on budding yeast Gyp8, the homologue of human TBC1D20. Gyp8p has GAP 
activity towards Ypt1p, the homologue of human Rab1 (De Antoni et al., 2002). The yeast 
GAP activity towards Ypt1p is found in a particulate membrane fraction (Jena et al., 1992), 
which suggests that Gyp8 might have the same ER localisation as TBC1D20. 
The finding that TBC1D20 blocks ER exit of cargo as a result of the inactivation of 
Rab1 is consistent with older observations that the membrane extraction of Rab1 by GDI 
prevents the ER exit of VSV-G (Peter et al., 1994) and that the ability to restore ER exit 
depends on the addition of recombinant Rab1. This argues that ER exit specifically depends 
on the presence of Rab1. In contrast to the inactivation of Rab1, the depletion of the Rab1 
effector p115 did not cause a block of ER exit. Secretory cargo was able to exit the ER under 
these conditions and accumulated in a punctate cluster adjacent to the nucleus, but did not 
reach the plasma membrane. This supports the role of p115 in regulating SNARE mediated 
fusion of ER derived vesicles with early Golgi compartments (Allan et al., 2000). In contrast 
to TBC1D20 expression, Rab1 depletion or the expression of dominant negative Rab1N121I, 
depletion of p115 does not alter the levels of active Rab1. These findings suggest that Rab1 
has a p115 independent function in controlling the exit of secretory cargo from the ER. 
To further consolidate that TBC1D20 acts as a GAP for Rab1 in vivo, it was depleted 
by siRNA. In cells depleted of TBC1D20 the intensity of the p115 staining and p115 
dependent COPII clustering was increased. Both these findings are consistent with elevated 
Rab1 levels caused by the depletion of a GAP for Rab1. 
Even though the data provided in this work strongly suggest that TBC1D20 acts 
predominantly on Rab1 in vivo, they cannot fully rule out the possibility that TBC1D20 is a 
GAP for Rab2 as well. Rab2 is only found in higher eukaryotic cells and does not have a 
counterpart in yeast. It is thought to act downstream of Rab1, and functions in tethering ER 
and ERGIC derived vesicle to the early Golgi (Tisdale and Balch, 1996). As TBC1D20 
mediated inactivation of Rab1 occurs before Rab2 comes to act, effects caused by Rab2 
inactivation will always be covered by phenotypes caused by Rab1 inactivation. 
4.5.2 RTN-1 is an ER associated regulator of TBC1D20 
To understand more about TBC1D20 function and ER, a yeast two-hybrid screen was 
carried out. This screen identified the Reticulon RTN-1 as an interaction partner of 
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TBC1D20, and this interaction was confirmed by immunoprecipitation. Reticulons are 
involved in the organisation and the shaping of the ER (De Craene et al., 2006; Voeltz et al., 
2006) and in the regulation of ER to Golgi transport (Wakana et al., 2005). All members of 
the Reticulon family are characterised by a C-terminal domain that forms two hairpin loops 
in the membrane of the ER. TBC1D20 interacts with this membrane bound portion of RTN-
1, which suggests that both proteins form a complex in the ER membrane. Four different 
Reticulons are known so far, all of which give rise to multiple splicing variants (Oertle and 
Schwab, 2003; Yan et al., 2006). The differences between the Reticulons are found in their 
variable N-termini, whereas their C-termini are very similar. TBC1D20 might therefore 
interact with multiple members of the Reticulon family. 
The physical interaction of TBC1D20 with RTN-1 had a modulatory effect on the 
ability of TBC1D20 to cause a “loss of Golgi” phenotype. One possible explanation may 
relate to the proposed function of Reticulons in the compartmentalisation of the ER (De 
Craene et al., 2006; Voeltz et al., 2006). The interaction of TBC1D20 with RTN-1 seems to 
be necessary for its proper ER localisation: the TMD of TBC1D20, which was not sufficient 
to interact with RTN-1, localised to both the Golgi apparatus and the ER. The minimal part 
of TBC1D20 interacting with RTN-1 however localised similar to the full-length protein. 
RTN-1 might therefore also restrict the localisation of TBC1D20 within the ER. It is 
conceivable that RTN-1 keeps TBC1D20 away from ERES, and that this restriction is 
important to define or confine these sites to sub-domains of the ER. The over-expression of 
TBC1D20 might override the spatial restriction by endogenous RTN-1 and thus inactivate 
Rab1 and cause the “loss of Golgi” phenotype. The co-expression of RTN-1 counteracts this 
effect and therefore weakens the phenotype. 
Work in budding yeast has shown that Rtn1p forms a complex with the GDF Yip3p 
(Geng et al., 2005). This complex precipitates Ypt1p, the yeast Rab1 homologue. This 
suggests that GDF mediated insertion of Rab1 into the ER is tightly controlled by the 
association of TBC1D20 with RTN-1 and the GDF. 
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4.5.3 Rab1 is the conserved key regulator of the early secretory pathway 
Surprisingly, out of all human GAPs only TBC1D20 was able to block trafficking of VSV-
G, which did not exit the ER in cells over-expressing wild-type TBC1D20. Both the 
depletion of Rab1 and the expression of dominant negative Rab1N121I caused the same 
phenotype, which shows that this block is due to the inactivation of Rab1. This raises the 
question of why the inactivation of none of the other Rab blocks secretion. 
First, simply analysing the appearance of VSV-G at the cell surface does not answer 
questions regarding changes in the kinetics of trafficking or in the route of transport. In the 
absence of one trafficking pathway it is possible that cargo might choose different, possibly 
redundant trafficking routes, which are regulated by other Rabs. Such routes are important 
for trafficking, for example in polarised apical and basolateral sorting. However, in a 
cultured non-polarised HeLa cell such different trafficking routes probably act redundantly. 
Second, and most importantly, the fact that TBC1D20 was the only positive in this 
screen suggests that it regulates an essential early trafficking step. All cargo has to pass 
through this step before it is sorted to its final destinations. Inactivation of other Rabs by 
GAP expression did not block transport of VSV-G, despite the fact that a number of these 
caused Golgi fragmentation. This indicates that the Rabs regulated by these GAPs are 
important for a normal Golgi morphology, but none of them regulates a essential step in 
secretory trafficking. 
These findings point to the fact that Rab1 is a key regulator of trafficking between 
the ER and the Golgi apparatus. In budding yeast although additional Rabs are needed for 
transport from the Golgi to the cell surface, the Rab1 homologue Ypt1 is the sole Rab 
required for ER to Golgi transport, and transport though the Golgi (Brennwald and Novick, 
1993). Surprisingly, the results shown in this work reveal a similar picture in mammalian 
cells. Despite its greater size and morphological complexity, the mammalian Golgi apparatus 
therefore appears more similar to its budding yeast counterpart in terms of Rab function. 
Interestingly, unlike other S.cerevisiae Ypt proteins whose homologue proteins usually form 
a group of Rabs in the human genome, Ypt1 has only one related human protein, Rab1. This 
shows that trafficking between the ER and the Golgi is an evolutionary conserved pathway, 
which was not subject to diversification during the evolutionary expansion of trafficking 
routes. The necessity to establish a tight regulation of this step in secretion might be a 
possible explanation for this finding. Therefore, Rab1/Ypt1 is the conserved key regulator of 
the early secretory pathway. 
Discussion 
113 
 
4.5.4 TBC1D20 and the Rab cascade 
The finding that trafficking of VSV-G is blocked at the level of the ER raises the question of 
why ER exit is defective in cells with inactive Rab1. 
One explanation is that it may be important to couple the sorting of cargo into COPII 
vesicles with the activation of Rab1. Interestingly, a similar role has already been proposed 
for Ypt1 in S.cerevisiae, where it was found that Ypt1p regulates and couples sorting of 
cargo molecules in the ER to subsequent vesicle targeting (Morsomme and Riezman, 2002). 
The same proposal has also been made for Rab5 (McLauchlan et al., 1998). Such a coupling 
ensures that the newly formed vesicles recruit the correct tethering factors and therefore 
dock to and fuse with the correct target membrane. Therefore, a vesicle without Rab1 should 
not recruit any cargo. Consistent with this prediction, cargo receptors such as ERGIC53 or 
p24 do not accumulate at ERES in cells over-expressing TBC1D20 despite normal COPII 
dynamics. This shows that the block of ER exit is based on defective cargo sorting rather 
than on defective vesicle formation. 
How such a coupling might occur is less clear, and will require investigation of 
further Rab1 effector molecules like the MICAL family of proteins, which also propose a 
link to the microtubule network (Fischer et al., 2005; Weide et al., 2003). The Rab1 GEF, 
TRAPPI (Wang et al., 2000), provides another possible explanation for this coupling. 
TRAPPI has recently been shown to directly bind to the Sec23 subunit of the COPII coat 
(Cai et al., 2007) At least one of the TRAPPI subunit is recruited to ERES (Yu et al., 2006). 
Thus, TRAPP provides a means to activate Rab1 at the forming vesicle when sufficient 
COPII components are recruited by cargo and cargo receptors. 
The finding that in cells lacking active Rab1 ER exit is blocked, gains further 
importance in the light of a model called Rab cascade (Haas and Barr, 2007; Markgraf et al., 
2007; Ortiz et al., 2002). This model is based on the finding that the Rab Ypt31/32 recruits 
Sec2, the GEF for the Rab Sec4, which acts downstream of Ypt31/32 (Ortiz et al., 2002). 
The Rab cascade model proposes that Rabs regulate the activity and recruitment of 
downstream Rabs by their effectors, which act as regulators of these Rabs. One question is 
how such a cascade is initiated. The observation that COPII recruits the Rab1 GEF TRAPPI 
shows that the vesicle coat itself can trigger the Rab cascade and provides a link between 
cargo recognition and the Rab cascade. Importantly, every cascade needs to be tightly 
controlled at the beginning. The ER associated Rab1 GAP TBC1D20 can provide a 
counterpart to the GEF activity of TRAPPI to ensure the specific initiation of this cascade. 
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4.5.5 Rab1 and Golgi biogenesis 
In contrast to any of the other 38 RabGAPs tested, over-expression of TBC1D20 caused the 
apparent loss of cis-, medial-, and trans-Golgi markers. This “loss of Golgi” phenotype 
cannot be simply due to a block of trafficking, as the expression of Sar1H79G (Yoshimura et 
al., 2004) or the treatment of cells with BFA (Lippincott-Schwartz et al., 1989) only cause a 
fragmentation of the Golgi apparatus despite their ability to block ER to Golgi trafficking . 
The difference of these to the over-expression of TBC1D20 is that they do not alter the level 
of active Rab1. Why does interfering with Rab1 function cause such an extreme phenotype? 
Although debated for many years (Mironov et al., 1997; Pelham, 2001), most recent 
findings indicate that the Golgi stack is not formed of static cisternae with cargo shuttling 
from one to the next via vesicle carriers. Instead, the Golgi is now widely believed to consist 
of highly dynamic and continuously maturing cisternae that modify their cargo as they 
progress from the cis- to the trans- face of the Golgi stack (Bonfanti et al., 1998; Losev et 
al., 2006). The residing enzymes in turns, which grant sequential biochemical activity, 
recycle in vesicles to equip the Golgi cisternae as they progress. The steady state structure of 
the Golgi stack is according to this cisternal maturation model a representation of the 
dynamic balance between anterograde and retrograde trafficking. The mode of Golgi 
biogenesis is also a matter of discussion (Glick, 2002; Lowe and Barr, 2007). According to 
the cisternal maturation model, the question of how the Golgi is formed might be answered 
by the ability of cisternae to be formed de novo from ER derived material. Even though 
under some conditions the division of pre-existing structures forms the Golgi (Shima et al., 
1998), there is good evidence that the Golgi can arise directly from the ER (Mironov et al., 
2003). It was shown that the organization of ERES and COPII vesicle trafficking are 
paramount for normal Golgi biogenesis and function (Connerly et al., 2005). Furthermore, 
the availability of cargo such as Golgi enzymes is a key factor in determining the size of the 
resulting Golgi cisternae (Guo and Linstedt, 2006). 
How do these findings correlate with the “loss of Golgi” phenotype? In the case of 
Rab1 inactivation, cargo and Golgi enzymes are trapped in the ER and thus prevent normal 
Golgi biogenesis, which depends on their availability. Inactivation of Rab1 also leads to the 
loss of p115 from membranes. This Rab1 effector is required for COPII clustering and the 
formation of Golgi precursors. Rab1 inactivation therefore combines defects in both cargo 
transport and vesicle tethering. This combination might cause a more severe defect in Golgi 
biogenesis than depletion of individual tethering factors or a block of cargo transport. 
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4.6 An additional model of GAP mediated Rab regulation 
Surprisingly, the depletion of TBC1D20 and the expression of constitutive active Rab1Q67L 
failed to cause a block of VSV-G trafficking. Consistent with these data, S.cerevisiae GYP8, 
which is the homologue of TBC1D20, is not essential for secretion (De Antoni et al., 2002). 
Furthermore, a yeast strain expressing constitutive active Ypt1Q67L does not exhibit growth 
defects, shows normal rates of secretion, and normal membrane morphology (Richardson et 
al., 1998). 
Since neither TBC1D20 in human cells nor GYP8 in yeast is essential for secretion, 
the regulation of GTP hydrolysis appears not to be critical for Rab1/Ypt1 function under 
laboratory conditions. On the other hand, the inactivation of Rab1 has a strong effect on 
Golgi morphology and secretion in both human and yeast (Bacon et al., 1989; Jedd et al., 
1995). How can these observations be consistent with the classical model of GAPs (Fig 1.6) 
as determinants of the lifetime of active Rab (Novick and Zerial, 1997)? According to the 
classic model, the GAP is also expected to localise to the target membrane but TBC1D20 
localises to the ER. Therefore an additional model of Rab control is proposed (Figure 4-3). 
In this model, GDI bound Rab is inserted into the membrane with the aid of a GDF 
and is then activated by its GEF. The GAP localises in the same membrane and inactivates 
the Rab again. The inactive Rab can be extracted by GDI or, more likely, become reactivated 
by the GEF. The Rab therefore cycles between the active and the inactive conformation, 
until the activity of the GEF can override the activity of the GAP. This could be mediated by 
either inactivation of the GAP or increased GEF activity. The GEF then keeps the Rab active 
and capable of recruiting effectors until the target is reached where the GEF activity 
decreases. The Rab is inactivated by its own basal GTP hydrolysis, and effectors recycle to 
the pool of active Rab. 
In support of this model, the Rab1 GEF TRAPPI is recruited by COPII coat 
components during vesicle formation at ERES (Cai et al., 2007; Yu et al., 2006). TRAPPI 
activates Rab1 on ERES when cargo accumulates and coat formation is initiated. The ER 
associated GAP TBC1D20 counteracts this activity. The GEF activity of TRAPPI might 
override TBC1D20 mediated Rab1 inactivation when COPII components recruit sufficient 
TRAPPI. Once sufficient COPII components are present on the vesicle to get Rab1 
activated, the vesicle buds from the ER as COPII components mediate budding and 
abscission. TRAPPI then keeps Rab1 active on the vesicle until the vesicle reaches the 
Golgi. At the cis-Golgi TRAPPI is converted to TRAPPII, and looses GEF activity towards 
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Rab1 (Morozova et al., 2006; Wang et al., 2000). On the cis- Golgi active Rab1 is required 
and binds to various molecules like GM130 or Golgin84. (Diao et al., 2003; Moyer et al., 
2001). In the absence of its GEF however, Rab1 inactivates itself by its basal GTP 
hydrolysis. 
According to this model, increased levels of active Rab1 in the absence of TBC1D20 
or in cells expressing Rab1Q67L do not prevent a vesicle to form and transport is therefore not 
blocked. This vesicle then fuses with the Golgi in a process that does not require the 
presence of a GAP and is thus not blocked under these circumstances. The cargo is then 
released and traffics on in a process independent of Rab1. The active Rab1 inactivates itself 
by its basal GTP hydrolysis in the absence of the GEF TRAPPI, and Rab1Q67L might just 
reside on the Golgi. 
Why is such a “regulator GAP” like TBC1D20 needed? One possibility is, that the 
regulation of the initiation vesicle transport is coupled to recognition of properly folded 
cargo as a proofreading mechanism before the commitment is made to form and traffic the 
vesicle. Such a proofreading mechanism might be important in ER stress conditions. Support 
for this idea comes from a recent study on the mechanism of α-synuclein mediated toxicity 
(Cooper et al., 2006). Misfolding of α-synuclein is associated with several 
neurodegenerative diseases like Parkinson's disease, even though the exact mechanism is 
unknown. This study shows that α-synuclein creates an ER-stress situation that results in a 
block of ER to Golgi trafficking. A genomic screen in yeast revealed that only YPT1 was 
able to suppress α-synuclein toxicity and recover ER to Golgi trafficking. GYP8 
significantly enhanced α-synuclein mediated toxicity presumably by inactivation of Ypt1. 
These findings suggest, that Ypt1/Rab1 activity is limiting for ER exit under stress 
conditions. The negative regulation of Ypt1/Rab1 by Gyp8/TBC1D20 might therefore 
function as a proofreading mechanism and prevent the exit of misfolded proteins from the 
ER. Interestingly, Reticulons are also involved in various neurodegenerative diseases, which 
points to a general role of the early secretory pathway for these diseases (Wildasin, 2004; 
Yan et al., 2006). 
Another explanation for the need of a “regulator GAP” comes from the observation 
that the NS5A protein of the Hepatitis C virus binds to TBC1D20 (Sklan et al., 2007a; Sklan 
et al., 2007b). TBC1D20 might be required in virus infected cells to block trafficking of 
membrane bound viral proteins to the cell surface to prevent spreading of the virus. The 
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interaction with the viral protein might inhibit TBC1D20 to ensure the transport of viral 
components to the PM. 
 
 
Figure 4-3 RabGAPs as regulatory factors of Rab cycle initiation. The small red sphere labelled 
“GTP” symbolises active Rab bound to GTP, a small green square labelled “GDP” indicates inactive 
Rab. Rab interacting molecules are identified by common abbreviations. A clock indicates the kinetic 
self-inactivation of Rabs. Drawing is not to scale. 
 
The idea that activation of Rabs by GEFs and their inactivation by GAPs are closely 
linked seems counterintuitive at the first glance. However, using such a mechanism, the 
amount of active Rab can be tightly controlled dependent on the activity of GAPs and GEFs. 
A tight cycle of activation and inactivation is commonly used to regulate of the activity of 
small GTPases. Sar1 for example, which is required for the COPII coat assembly is activated 
by Sec12 and inactivated by the coat subunit Sec23 it recruits. This allows the dynamic 
regulation of the coat assembly (Bonifacino and Glick, 2004). RhoA as another example is 
tightly regulated by its GAP and GEF at the same time during cytokinesis to generate a 
locally restricted pool of active RhoA (Yuce et al., 2005). Such a cycle of activation and 
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inactivation allows to respond to changes in conditions more precise and quickly and is a 
common feature amongst signalling molecules. Importantly, most GAPs are multi-domain 
proteins. This suggests that the activity of GAPs is regulated dependent on various signalling 
pathways. 
TBC1D20 is the prime example of a “regulator GAP” as it is localised to the ER, the 
donor membrane, by its TMD. RabGAP-5 on the other hand acts as a prototypic “terminator 
GAP” in the regulation of the Rab5 to Rab7 transition. The depletion of RabGAP-5 leads to 
an accumulation of EGF in early endosomes, which shows the critical role of RabGAP-5 in 
terminating Rab5 activity. However, if RabGAP-5 is in fact recruited by Merlin to adherence 
junctions to prevent EGF uptake, this would turn the “terminator GAP” into a “regulator 
GAP”. This suggests that interacting proteins and signalling processes can alter the 
regulatory properties of GAPs. 
Taken together, the observations made during the course of this work and data shown 
in recent publications indicate that RabGAP mediated inactivation of Rabs is a flexible and 
highly regulated process. This process requires further investigation to understand the basis 
and mechanics of the activity of these key regulators of Rab dependent membrane traffic. 
4.7 The specificity of Rab-GAP interactions 
The claim has been made based on findings in S.cerevisiae, that RabGAPs are promiscuous 
in the recognition of their substrates (Albert and Gallwitz, 1999). However, based on data 
presented in this work and in recent publications, this appears not to be the case. 
The claim was based on GTP hydrolysis assays with truncated yeast TBC domain 
proteins (Albert and Gallwitz, 1999; Will and Gallwitz, 2001). However, we have recently 
shown (Fuchs et al., 2007) that in the case of the Rab4 GAP GAPCenA (Cuif et al., 1999) 
truncations lose their substrate specificity and interact with a wide range of Rab GTPases. 
The full-length protein on the other hand specifically interacted with its target Rab4. This 
illustrates that in order to observe specific interactions and activity the use of full-length 
TBC domain proteins is mandatory. 
Another recent publication (Yoshimura et al., 2007) shows that the RabGAP 
XM_037557 stimulates GTP hydrolysis by Rab8a, but not by its isoforms Rab8b, reflecting 
the different properties of these very similar Rabs in the formation of the primary cilium. A 
promiscuous GAP certainly would not detect such small differences. Furthermore, if the 
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RabGAPs were in fact promiscuous in their substrate recognition, a Rab inactivation screen 
would not identify specific regulators of the organelles or trafficking processes of interest. 
Taken together, the results presented in this work and other recent publications point 
to the fact, that RabGAPs actually have high substrate specificity, which is expected as they 
regulate proteins that provide membrane identity. 
There are still much more GAPs not assigned to their target Rab than GAPs, which 
have been matched to their target. Furthermore, our knowledge about the mode of action and 
the regulation of the GAPs themselves is incomplete. With the tools and methods established 
in this work, further insights will certainly be provided. The RabGAP field therefore 
promises to generate many interesting findings in the coming years. 
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5 Material and Methods 
5.1 Materials 
5.1.1 Reagents 
Reagents were obtained from Sigma-Aldrich (Seelze, Germany), Carl Roth (Karlsruhe, 
Germany) or VWR (Darmstadt, Germany) unless stated in the text. 
5.1.2 Equipment 
A list of commonly used equipment and its suppliers is given in the table below. 
 
Equipment Description and manufacturer 
Benchtop centrifuge Eppendorf Centrifuge 5417C 
Benchtop refrigerated centrifuge Eppendorf Centrifuge 5417R 
Cell Culture Incubators Heraeus HeraCell 
Cell Culture Safety Hoods Heraeus HeraSafe 
Centrifuge Heraeus Multifuge 3 L-R 
Electroporation system BioRad MicroPulser 
Film Developer Kodak X-OMAT 2000 Processor 
Gel system BioRad Mini-PROTEAN 
Heating block/ mixer Eppendorf Thermomix Compact 
High pressure homogeniser Avestin Emulsiflex C5 
Incubators Heraeus Function Line 
Magnetic stirrer IKA RET basic IKAMAG 
PCR machines Perkin Elmer Gene Amp 2400 
Eppendorf Mastercycler Personal 
pH meter Beckman 340pH/Temp meter 
Power pack BioRad Power Pack 200 and 300 
Scintillation counter Packard Tri-carb 2900TR 
Semi- dry blotter BioRad Trans-blot SD 
Shakers Infors AG Multitron 
Grant Boekel BFR25 
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SW28 rotor Beckman 
SW40 rotor Beckman 
Transilluminators UVP 2UV Transilluminator 
UVP Gel Documentation System 
Fujifilm LAS3000 
Ultracentrifuge Beckman Optima LE-80K 
UV/Visible Spectrophotometer Amersham-Pharmacia Ultrospec 300pro  
Vortex shaker IKA MS3 basic 
Waterbath Haake DC10 
 
5.1.3 Solutions 
The composition of standard solutions not described in the respective methods chapter is 
given in the table below. Unless otherwise stated the solvent is water. 
 
Solution Composition 
Assay Buffer (10x) 500 mM HEPES-NaOH, pH 6.8, 10 mg/ml purified 
BSA, freeze at -20°C,  add DTT to 10 mM before using 
DNA loading dye (6x) 0.25% (w/v) bromophenol blue, 40% (w/v) sucrose in 
TE 
IMAC (5,20,200) 20 mM Tris-HCl pH8.0, 300 mM NaCl, (5, 20, 200) 
mM Imidazole 
LB (Agar) 10 g/l Bacto-tryptone, 5 g/l Bacto-yeast extract, 10 g/l 
NaCl, (plus 15 g/l Agar)  
LiPEG 100 mM LiOAc, 10 mM Tris-Cl, pH 8,0, 1mM EDTA, 
pH 8,0, 40 % PEG3350, sterile filtered, stored at 4°C 
LiSorb 100 mM LiOAc, 10 mM Tris-Cl, pH 8,0, 1mM EDTA, 
pH 8,0, 1M Sorbitol, sterile filtered, stored at 4°C 
Mammalian Lysis Buffer 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% (w/v) 
Triton-X 100 
Milk-PBS (blocking buffer) 4% milk powder in PBS , 0.2% (w/v) Tween-20 
Moviol + DAPI 2.4 g Moviol 4-88 added to 6 g analytical grade glycerol 
while stirring, 6 ml of ddH2O added and left for 2 hours 
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at room temperature, 12 ml of 0.2 M Tris-HCl pH 8.5 
added while stirring for 10 minutes at 50 °C , the 
solution was clarified by centrifugation at 3000 x g for 
15 minutes and stored at – 20 °C  
PBS 8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l Na2HPO4, 0.24 g/l 
KH2PO4 ,(pH 7.4) 
Ponceau 0.2% Ponceau red in 1% acetic acid 
SC (Agar) 6,7 g/l Yeast nitrogen base, 2 g/l appropriate “drop-out” 
mix, 20 g/l Glucose, 20 mM HEPES pH 6,5, (20 g/l 
Agarose) 
SDS-PAGE lower buffer (4x) 181.72 g/l Tris base, 4 g/l SDS 
SDS-PAGE running buffer 
(10x) 
30.2 g/l Tris base, 188 g/l glycine, 10 g/l SDS 
SDS-PAGE sample buffer (3x) For 100 ml: 2.3 g Tris base, 9.0 g SDS, 30 ml glycerol, 
Adjust pH to 6.8 with HCl, adjust volume to 90 ml with 
dH2O, 50 mg bromophenol blue, add 10% ß-
mercaptoethanol prior to use 
SDS-PAGE transfer buffer 1x SDS-PAGE running buffer, 10% methanol 
SDS-PAGE upper buffer (4x) 60.6 g/l Tris base, 4 g/l SDS 
TAE (50x) For 1 l: 242.4 g Tris base, 57.2 ml glacial acetic acid, 50 
mM EDTA pH 8.0 
TBS for dialysis 50 mM Tris, 150 mM NaCl, 2mM DTT 
TE 10 mM Tris-HCl pH 8.0, 1 mM EDTA 
Yeast lysis buffer 2,5% (w/v) SDS, 25 mM Tris-HCl pH 7,5 , 25 mM 
EDTA 
Yeast S-Buffer 10mM K2HPO4 , pH 7,2, 10mM EDTA, 50mM ß-
Mercaptoethanol, 50µg/ml Zymolyase 
 
5.1.4 PCR primer  
DNA primer to clone TBC domain proteins were designed according to 5.3.1, and obtained 
by Metabion (Martinsried, Germany). 
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Target Gene Forward and reverse primer including restriction site (in 
capital letters) 
EVI-5 GGGATCCCCatggccagtcaggtggcaagtc 
GCTCGAGtcagacagtggttgaatacgac 
RN-tre/USP6NL GAGATCTCCatgaattcagaccaggatgtagc 
GGTCGACtcacagcaacactgactcttgg 
RUTBC1 GAGATCTCCatgggcagcgcagaggacgcagtc 
CGTCGACtcacttgttctctatgagcatctg 
RUTBC2 GAGATCTCCatggaggaggctgtgacacgcaag 
CGTCGACtcacttgttctcaatcagagtctg 
RUTBC3/RabGAP-5 GGGATCCCCatgtcaggaagccatacacctgcctgtggccc 
GGTCGACtcacccgtccacatcccagctgaag 
TBC1D1 GAGATCTCCatggaaccaataacattcacagcaagg 
CGTCGACtcagtcgcccgtgggctcgggctgcg 
TBC1D2 GGGATCCCatggaagcttaccggacccag 
GGTCGACtcaggcttccccctccacctcg 
TBC1D3B/PRC17 GGGATCCCCatggacgtggtagaggtcgcg 
GGTCGACctagaagcctggaggg 
TBC1D4/AS160 GGGATCCCCatggagccgcccagctgcattcag 
GCTCGAGttatggcttatttcctatcttggc 
TBC1D5 GGGATCCCCatgtatcattccttatctgaaact 
GCTCGAGtcagatgtccaggggactcacaat 
TBC1D6 GGGATCCCCatgcagcccgccgagcgctcgcgg 
CGTCGACctatgcccactggtgcccgtcctg 
TBC1D7 GAGATCTCCatgactgaggactctcagagaaac 
GCTCGAGtcagcttgaatggaccggggtcccag 
TBC1D8 GGGATCCCCatgttcctgaacctggatgaggtg 
GCTCGAGctacaagttactcagcttaagttc 
TBC1D10A/EPI64 GGGATCCCCatggcgaagagcaacggagag 
GGTCGACttacaagtaggtgtcctcactctcttg 
TBC1D10B GTGATCACCatgtctgggaccttggagtccttg 
CGTCGACtcagaagtaagcgtcctgccgggc 
TBC1D10C GGGATCCCCatggcccaggccctgggggaggac 
GCTCGAGtcagaagcgggtgtccaggaagga 
TBC1D11/GAPCenA GGGATCCCCatggatgacaaggcttctgttggaaaaatc 
GCTCGAGtcagcaagtcctttcccttgaaccccgg 
TBC1D12 GGGATCCCCatggttcggggaatctccaggtcg 
CGTCGACctagcttttcaaagcaggactact 
TBC1D13 GAGATCTCCatgtcaagtctgcacaagag 
GGTCGACctactttgagtcttggagctccttg 
TBC1D14 GGGATCCCCatgactgatggaaaactctcc 
GGATCCtcagtgtcggagggatggacttcc 
TBC1D15 GGGATCCCCatggcggcggcgggtgttgtgagc 
GCTCGAGtcatgcaggtgttaatctgcagac 
TBC1D16 GAGATCTCCatgtctctgggccgcctccttcgc 
GCTCGAGctatctgcggaagccgaagccgtc 
TBC1D17 GAGATCTCCatggaaggagccggctacagggtg 
GCTCGAGttaggagtcggcgccctcgtcctc 
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TBC1D18 GTGATCACCatggaggtcagagcttcattacag 
GGTCGACctacaaatatacaaacttgtatctatcc 
TBC1D19 GGGATCCCCatgttgcaggaggagtcggacctc 
GCTCGAGtcaggtgacagtagcaaacagaaa 
TBC1D20 GAGATCCTCCatggccctccggagtgcg 
GGTCGACtcagggaaacagctgcagctgaacttag 
TBC1D21 GGGATCCCCatgaccaccctctctcctgaaaac 
GCTCGAGtcagaggaagaaatcctttaatgt 
TBC1D22A GGGATCCCCatggccagcgacggggccaggaag 
CGTCGACtcatttcttgtagtgattgggggc 
TBC1D22B GAGATCTCCatggccctccggagtgcg 
GGTCGACctatcggcggtagtgatttgg 
USP6 GGGATCCCCatggacatggtagagaatgcagat 
CGTCGACttactgtaacatagagtacttttc 
AK074305 GGGATCCCCatgtttcccctgaaggacgctgaa 
CGTCGACtcatatttgaggagatgggatggt 
KIAA1055 GAGATCTCCatgctcatggagaccatccaagcc 
CAGATCTtcaggtatcctcctcctcgtcact 
KIAA0676 GGGATCCCCatgtggctgagcccggaggaggtg 
GCTCGAGtcagccggaaactccaggctgctc 
KIAA0882 GGGATCCCCatgtgggtgaacccggaggaggtg 
CGTCGACtcagccggacatggccgagatttc 
NP_060222 GGGATCCCCatgtggctgaagcctgaggaagtg 
GCTCGAGttacatcttggttctagaccttaa 
NP_060779 GGGATCCCCatggcggaaggagaagatgtgccg 
GCTCGAGttaactttccaaagcatccaaaac 
EVI5-like GAGATCTCCatggcgagccccactctgagcccc 
GCTCGAGtcagttgtccagaccctggctgta 
XM_037557 CGGATCCCCatgcggcaggacaagctgaccggg 
GCTCGAGtcatcgttttttagtgccactgtttc 
KIAA1171 GGGATCCCCatggactctccaggatacaactgc 
GCTCGAGtcactgggtgtcagggtcctggaa 
Paris-1 GTGATCACCatggagggcgctggggagaacgccccgg 
GGTCGACtcaggcttccccctccacctcgtcctcgc 
 
5.1.5 siRNA oligonucleotides 
siRNA oligonucleotides for siRNA-mediated depletion of specific mRNAs were designed to 
a target sequence of NN(N19)dTdT using the siDESIGN Center on the Dharmacon 
homepage (www.dharmacon.com), or were obtained as preconfigured SMART- pools by 
Dharmacon. The siRNA oligonucleotides used in the course of this work are listed in the 
table below. 
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Target Gene Target Sequence 
GL2 (Control) CGUACGCGGAAUACUUCGAUU 
LaminA (Control) CTGGACTTCCAGAAGAACATC 
RabGAP-5 AACGGCCTGCGAGGCTGGTTT 
TBC1D20 (SMART-Pool) GGACUUGCCCUAUGAGACA 
 GGACCAACCGCUUUGUGAA 
 ACCCUCAGCUGCACUACUA 
 ACGCAUGGCUAUCAGUGAA 
p115 GCCGAGACGAUUCAAAAGCUU 
 GGCAGCAGGUUUCUACAUUUU 
GM130 CCCUGAGACAACCACUUCUUU 
 GGCUGGCAUGCAGCUUAACUU 
 CCCCACUGCACAGCAGAUCUU 
Rab1A (SMART-Pool) GAACAAUCACCUCCAGUUAUU 
 CAAUCAAGCUUCAAAUAUGUU 
 GGAAACCAGUGCUAAGAAUUU 
 CAGCAUGAAUCCCGAAUAUUU 
Rab1B (SMART-Pool) CCAGCGAGAACGUCAAUAAUU 
 GCGCCAAGAAUGCCACCAAUU 
 GACCAUGGCUGCUGAAAUCUU 
 CAGCCAAGGAGUUUGCAGAUU 
Rab2A (SMART-Pool) GAAGGAGUCUUUGACAUUAUU 
 GAUAUUACACGGAGAGAUAUU 
 CGAAUGAUAACUAUUGAUGUU 
 UGACCUUACUAUUGGUGUAUU 
Rab2B (SMART-Pool) GGACUUAUAUUCAUGGAAAUU 
 GCGCCAAGAAUGCCACCAAUU 
 GACCAUGGCUGCUGAAAUCUU 
 CAGCCAAGGAGUUUGCAGAUU 
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5.1.6 Antibodies 
The antibodies used in the course of this work are listed in the tables below, along with their 
typical dilutions used for western blotting (WB) and immunofluorescence (IF). The species 
indicated are M= Mouse, S= Sheep and R=Rabbit. 
5.1.6.1 Primary antibodies 
 
Name Antigen WB IF Source 
M α Myc c-myc, clone 9E10 1:1000 1:1000 Cancer Research  
R α Myc c-myc --- 1:1000 Santa Cruz 
M α VSV-G VSV-G luminal domain --- 1:20 Ira Mellman 
M α EEA1 Human EEA1 1:50 1:50 BD Biosciences 
S α GFP His-GFP 1:2000 ---- Barr laboratory 
M α GM130 Human GM130 --- 1:2000 BD Biosciences 
S α GM130 His-rat GM130 1:1000 1:1000 Barr laboratory 
M α Rab1b Human Rab1b, clone 1E7 1:5  Weide lab 
R α RabGAP-5 RabGAP-5 aa 1-451 1:250 ---- Barr laboratory 
M α Calnexin Human cell lysate 1:1000 1:1000 Chemicon 
S α Golgin-84 Human Golgin84 1:1000 1:2000 Martin Lowe 
S α Golgin-97 Human golgin-97 aa 589-
769 
1:500 1:500 Barr laboratory 
R α Golgin-160 Human golgin-160 1:1000 1:1000 Barr laboratory 
S α p115 Rat p115 aa 772-959 1:2000 1:2000 Barr laboratory 
R α sec24C Human Sec24C ---- 1:1000 David Stephens 
M α sec31 Human Sec31 ---- 1:1000 BD Biosciences 
M α ERGIC53 ERGIC53 ---- 1:1000 Alexis Biochemical
M α Lamp-1 Human Lamp1 1:1000 1:1000 BD Biosciences 
M α TFnR Human TFnR 1:1000 1:250 Chemicon 
S α TGN46 Human TGN46 1:2000 1:2000 Serotech 
M α Tubulin Tubulin, clone DM1A 1:1000 1:1000 Sigma-Aldrich 
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5.1.6.2 Secondary antibodies 
 
Name Species Antigen WB IF Source 
AMCA-α-M Donkey Mouse IgG ---- 1:250 Jackson Labs 
Cy2-α-M Donkey Mouse IgG ---- 1:1000 Jackson Labs 
Cy3-α-M Donkey Mouse IgG ---- 1:1000 Jackson Labs 
Cy2-α-R Donkey Rabbit IgG ---- 1:1000 Jackson Labs 
Cy3-α-R Donkey Rabbit IgG ---- 1:1000 Jackson Labs 
Cy2-α-S Donkey Sheep IgG ---- 1:1000 Jackson Labs 
Cy3-α-S Donkey Sheep IgG ---- 1:1000 Jackson Labs 
HRP-α-S Donkey Sheep IgG 1:10000 ---- Jackson Labs 
HRP-α-M Sheep Mouse IgG 1:2000 ---- Amersham 
HRP-α-R Donkey Rabbit IgG 1:2000 ---- Jackson Labs 
5.2 Bacterial methods 
5.2.1 Growth and maintenance of E. coli 
Bacteria were grown at 37 °C in LB medium containing an appropriate antibiotics for 
selection, either 100 µg/ml ampicillin, 50 µg/ml kanamycin, or 34 µg/ml chloramphenicol. 
Short-term storage was on LB-agar plates plus antibiotic at 4 °C. 
5.2.2 Bacterial strains 
The following E. coli strains were used in the course of this work. 
 
 
Strain Genotype Use 
XL1-blue F’::Tn10 proA+B+ lacIq ∆(lacZ)M15/ recA1 
endA1 gyrA96 (NaIr) thi hsdR17 (rK-mK+) 
glnV44 relA1 lac 
General cloning 
applications 
GM2163 F- ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 
galK2 galT22 mcrA dcm-6 hisG4 rfbD1 
rpsL136 dam13::Tn9 xylA5 mtl-1 thi-1 mcrB1 
hsdR2 
Non-methylated DNA 
for digestion with 
Dam/ Dcm- sensitive 
enzymes 
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BL21(DE3)* F- ompT gal [dcm] [lon] hsdSB rB- mB-; an E. 
coli B strain with DE3, a λ prophage carrying 
the T7 RNA polymerase gene 
Recombinant protein 
expression 
JM109* F’ traD36 proA+B+ lacIq ∆(lacZ)M15/ ∆(lac-
proAB) glnV44 e14- gyrA96 recA1 relA1 
endA1 thi hsdR17 
Recombinant protein 
expression 
TOP10 F- mcrA ∆(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 ∆lacX74 recA1 deoR araD139 
∆(ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG 
TA-cloning of PCR 
products 
 
*BL21(DE3) and JM109 strains carrying the pRIL plasmid (Stratagene) were used for 
recombinant protein expression. This plasmid encodes the tRNA genes for rare arginine, 
isoleucine, and leucine codons and conveys chloramphenicol resistance. 
5.2.3 Preparation and transformation of chemically competent bacteria 
To prepare chemically competent E. coli, a single colony was picked from a fresh plate and 
used to inoculate 50 ml of LB (with selection, if necessary) and grown overnight at 37 °C 
while shaking. 1 ml of overnight culture was then used to inoculate 100 ml of fresh LB and 
the cells were grown at 37 °C until an OD600 of 0.5. The culture was then chilled on ice for 
15 minutes before being transferred to a sterile centrifuge tube and centrifuged at 3000 x g 
for 10 minutes at 4 °C. The supernatant was discarded and the cell pellet resuspended in 0.4 
total culture volume of TfbI (30 mM KOAc, 100 mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 
15% (v/v) glycerol, pH adjusted to 5.8 with dilute acetic acid). The cells were incubated on 
ice for 15 minutes and then pelleted as before. The cell pellet was then resuspended in 0.04 
volumes TfbII (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15 % (v/v) glycerol, pH 
adjusted to 6.5 with dilute NaOH). After storing on ice for 15 minutes, the cells were 
aliquoted into 50 µl aliquots in sterile Eppendorf tubes, frozen in liquid nitrogen, and stored 
at – 80 °C until needed. 
For transformation, aliquots were thawed on ice before adding the DNA. In general, 
10 µl of a ligation reaction was used for transformation of 50 µl competent bacteria, or 1 µl 
of plasmid DNA (approx. 200 ng). Cells and DNA were mixed and left on ice for 20 minutes 
before being heat-shocked in a 42 °C water bath for 90 seconds. Cells were placed back on 
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ice for 2 minute before the addition of 250 µl LB lacking antibiotics. The cells were allowed 
to recover for 60 minutes at 37 °C with shaking before being plated on LB-agar plates 
containing an appropriate selection antibiotic. All 250 µl of a ligation transformation were 
plated while only 50 µl of a plasmid transformation was plated. Plates were then incubated 
overnight at 37 °C. 
5.2.4 Preparation and transformation of electrocompetent bacteria 
To prepare electrocompetent E. coli, a single colony was picked from a fresh plate and used 
to inoculate 5 ml of LB and grown overnight at 37 °C with shaking. 2.5 ml of the overnight 
culture was then used to inoculate 500 ml of fresh LB and grown at 37 °C until an OD600 of 
between 0.5 and 0.6. The culture was then chilled on ice for 15 minutes before being 
transferred to a sterile centrifuge tube and centrifuged at approximately 3000 x g for 10 
minutes at 4 °C. The supernatant was removed and the cells resuspended in 10 ml sterile, 
ice-cold water. Centrifuge tubes were then filled with 500 ml ice-cold water and spun as 
before. The supernatant was removed and the volume adjusted to 50 ml with ice-cold 10 % 
(v/v) glycerol before centrifuging as above. The cell pellet was resuspended in an equal 
volume of ice-cold 10 % (v/v) glycerol and the cells were aliquoted into 40 µl aliquots in 
sterile Eppendorf tubes, frozen in liquid nitrogen, and stored at – 80 °C until needed. 
For electroporation, sterile 2 mm electroporation cuvettes were placed on ice to chill 
during the cells thawed on ice. 2 µl of yeast miniprep DNA or 10ng plasmid DNA was 
added to the cuvette followed by 40 µl of electrocompetent cells. The cuvette was flicked to 
mix DNA and cells and left on ice for 15 minutes. The electroporator was set to 2.5 kV, 25 
µFarads. Cuvettes were dried with a tissue wipe and placed into the chamber. The cells were 
electroporated, ideally with a time constant of 4.7. 250 µl of LB medium was added to the 
cuvette immediately and the cells were transferred to a sterile Eppendorf tube and incubated 
shaking at 37 °C for 1 hour before being plated on LB-agar plates containing an appropriate 
selective antibiotic and grown at 37 °C over night. 
5.2.5 Plasmid DNA preparation from bacteria 
Plasmid DNA was prepared using either miniprep or maxiprep kits (Qiagen, Hilden, 
Germany) according to the manufacturers instructions. Minipreps were prepared from 1.5 
ml, maxipreps from 250 ml of overnight cultures grown in LB containing selective 
antibiotics at 37 °C. 
Materials and Methods 
130 
 
5.2.6 Purification of 6xHis-tagged proteins from bacteria 
A single colony was picked from a fresh plate of transformed E. coli and used to inoculate 
25 ml of LB plus selective antibiotics and grown overnight at 37 °C with shaking. 10 ml of 
the overnight culture was then used to inoculate 1 l of fresh LB plus antibiotics and grown at 
37 °C until an OD600 of 0.5 – 0.6 was reached. Depending upon the protein being expressed, 
cultures were shifted to 18 °C for 30 minutes before being induced with 0.5 mM Isopropyl 
β-D-thiogalactoside (IPTG) from a 1 M stock or induced immediately at 37 °C. Cultures 
were then left for either 3 hours (37 °C) or overnight (18 °C). Bacteria were then harvested 
by centrifugation at 3000x g for 15 minutes at 4 °C and cell pellets were frozen on dry ice 
for 20 minutes. 
For protein purification, cell pellets were thawed and resuspended by the addition of 
20 ml IMAC5 buffer containing protease inhibitor tablets and 0,1% TX100 per litre of 
original culture. The resuspended bacteria pellet was the homogenised using a chilled 
Emulsiflex C5 high-pressure homogeniser (Avestin Europe GmbH, Mannheim). The lysate 
was passed about 10 times through the homogeniser until the DNA was sheared and the 
lysate became much less viscous. The lysate was then centrifuged at 28000 rpm for 30 
minutes at 4 °C in an SW28 rotor in a Beckman Optima LE-80K Ultracentrifuge (Beckman, 
USA) to pellet the cell debris. The cleared lysate supernatant was transferred into a clean 
falcon tube. 0.5 ml of Ni-NTA agarose (Qiagen) per litre of original culture, washed in the 
same buffer, was added to the cleared lysate and the tube was rotated for 2 hours at 4 °C to 
allow protein binding to occur. The resin was then pelleted by centrifugation at 1000 x g for 
5 minutes at 4 °C and washed in 2 x 30 ml of IMAC20 containing 0.1 % TX100. The resin 
was then washed in a further 30 ml of IMAC20 without TX100 and bound protein was 
eluted by the addition of IMAC200. The eluate was collected in 1 ml fractions. After SDS-
PAGE analysis of 10 µl of these fractions, peak fractions containing recombinant protein 
were pooled and dialysed overnight at 4 °C TBS containing 2mM DTT. The recombinant 
protein was aliquoted, quickly frozen in liquid nitrogen and stored at -80°C. After quickly 
thawing the protein at 37°C with shaking the concentration was determined using a standard 
Bradford assay (5.4.3). 
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5.3 DNA methods 
Enzymes for DNA modification were obtained from New England Biolabs (Ipswich, MA, 
USA), Promega (Madison, WI, USA), or Invitrogen (Carlsbad, CA, USA) and used 
according to the supplier’s instructions. 
5.3.1 "Shortway" cloning strategy 
A standard cloning strategy, referred to as the “Shortway” system, was used when generating 
constructs, in order to make all inserts compatible with a wide range of different vectors. 
This involved generating inserts with a BamHI, BglII, or BclI site at the 5’ end and a SalI or 
XhoI site at the 3’ end.  The overhanging ATC of the BamHI/ BglII/ BclI site was designed 
to be in frame with the start codon of the insert.  
GGG ATC CCC ATG (BamHI) 
GAG ATC TCC ATG (BglII) 
GTG ATC ACC ATG (BclI) 
The restriction site is bold and the start codon is in italics. 
These restriction sites were added by PCR. The insert was TA-TOPO cloned into the vector 
pCRIITOPO (Invitrogen, Carlsbad, CA, USA). Constructs were sequenced in pCRIITOPO 
and then subcloned into the following vectors. 
5.3.2 Compatible vectors 
Yeast: 
DNA binding domain (n-term) pFBT9   BamHI-SalI 
Activation domain (N-term)   pACT2   BamHI-XhoI 
Bacterial expression: 
His-tagging (N-term)   pQE32   BamHI-SalI 
GST-tagging (N-term)   pFAT2   BamHI-XhoI 
MBP-tagging (N-term)    
with His-tag (C-term)   pMalTEV-His  BamHI-SalI 
Mammalian expression: 
GFP-tagging (N-term)   pEGFP-C2   BglII-SalI 
GFP-tagging (C-term)   pEGFP-N3   BglII-SalII 
Myc-tagging (N-term)   pcDNA3.1/MycA  BamHI-XhoI 
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If a DNA stretch of interest contained internal XhoI and SalI sites it was cloned using 
3´ BamHI / BglII / BclI sites, and inserted into singly cut vectors using the indicated 5´ end 
cutting enzyme. The vectors were treated with alkaline phosphatase for 15 min at 37° prior 
to loading on agarose gels. When all restriction sites required for “shortway –cloning” were 
found in the DNA stretch of interest, it was cloned, and one of the internal restriction sites 
was removed by a silent site directed mutagenesis.  
5.3.3 Restriction digests and agarose gel electrophoresis of DNA 
Analytical restriction digests were carried out in a total volume of 20µl using 0.5µl of each 
enzyme in the appropriate buffer to digest approximately 500 ng of DNA. Digests were 
carried out for 1.5 hour at the indicated temperature. The whole reaction was mixed with 4 
µl DNA loading buffer and loaded for electrophoresis onto an agarose gel of concentrations 
between 0.5% and 2% depending on the expected size of the DNA fragments. To pour gels 
agarose of the desired concentration was dissolved in 1 x TAE by heating. Ethidium bromide 
was added to a concentration of 0.8 µg/ml for visualisation. The gel was run in 1 x TAE at a 
constant voltage of 80 V for 45 minutes. DNA was visualized on a UV transilluminator. 
Preparative restriction digests were performed using 2.5 µg DNA. Vector DNA was 
treated with alkaline phosphatase at 37°C for 15 minutes by the addition of 1 µl enzyme to 
the digestion mix prior to loading on the gel. 
After electrophoresis, appropriate bands were excised using a scalpel blade and 
purified using a gel extraction kit (Qiagen) according to the manufacturer’s instructions. 
5.3.4 Cloning digested DNA fragments 
Ligations were performed in a total volume of 20µl using 1µl of T4 DNA ligase (NEB) in 1x 
ligase buffer (NEB). 100 ng of vector DNA was used along with enough insert DNA to 
make a 3:1 molar ratio of insert to vector DNA. Ligations were incubated for 2 hours at 
room temperature before transformation of bacteria with 10 µl ligation product. 
5.3.5 cDNA synthesis 
cDNA was generated by reverse transcription using the Advantage RT-for-PCR kit from BD 
Clontech (Franklin Lakes, NJ, USA). For this, 1 µg of total RNA was diluted to 12.5 µl in 
RNase-free water and, together with 1 µl of the oligo (dT)18 primer (20 pmol/µl), heated for 
2 minutes at 70 °C. After rapid cooling on ice the following components were added to the 
mixture: 4µl of 5x reaction buffer (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2), 
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1µl of dNTP mix (10 mM), 0.5µl of RNase inhibitor and 1µl of MMLV reverse 
transcriptase. The reaction was incubated for 1 hour at 42 °C, and then heated for 5 minutes 
at 94 °C to stop the reaction and to terminate DNase activity. The reaction was diluted with 
RNase-free water to 100µl total volume. 10 µl aliquots were frozen at -20°C. 
5.3.6 PCR and cloning of PCR products 
Oligonucleotides for PCR reactions were obtained from Metabion (Martinsried, Germany) 
pre-dissolved to 100 µM. 
For all PCR reactions a GeneAmp PCR System 2400 thermocycler (Perkin-Elmer, 
Waltham, MA, USA) or a Benchtop Cycler (Eppendorf) was used. Reactions were carried 
out in a total volume of 50 µl and contained 1 x polymerase reaction buffer, 1.25 µM 
forward and reverse primers, 0.25 mM dNTPs, and 1µl (2.5 U) Pfu turbo polymerase 
(Stratagene, La Jolla, CA, USA) or 1µl (1 U) KOD hot start polymerase (Novagen, Madison, 
WI, USA). As a template either 10ng plasmid DNA, 5µl marathon-ready cDNA library 
(Clontech, Palo Alto, CA, USA) or a HeLa cDNA library (see 5.3.5) was used.  
 
For Pfu polymerase the following scheme was used: 
- 2 min 95° C 
15sec 95°  
- 25 cycles of:   30 sec 55° 
2 min / kb of DNA to be amplified 68° 
 
- 2 min / kb of DNA to be amplified 68° 
- Cooling to 4°C 
 
For KOD polymerase normally the following scheme was used: 
- 2 min 95° C 
15sec 95°  
- 25 cycles of:   30 sec 60° 
30sec / kb of DNA to be amplified 72° 
 
- 30sec / kb of DNA to be amplified 72° 
- Cooling to 4°C 
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Dependent on the DNA stretch of interest elongation times and temperatures were altered. 
PCR products were then analysed by agarose gel electrophoresis.  
For cloning from cDNA libraries, a nested approach was used. A first round of PCR 
was performed as described using primers matching sequences in the 3` UTR and in the 
5`UTR. The product of this first round of PCR was purified using a PCR nucleotide removal 
kit (Qiagen, Hilden) according to the manufacturer’s instructions. 5 µl of the purified PCR 
product were used in a second round of PCR. This time primers matching to the 3` and the 5` 
end of the ORF were used. The product of this second round of PCR was then analysed and 
purified by agarose gel electrophoresis. 
Following gel extraction of PCR products using a Gel extraction kit (Qiagen, Hilden) 
according to the manufacturer’s instructions, Adenosine overhangs were added to the ends of 
the PCR product by incubation with 1 µl Taq polymerase (Promega, Madison, WI, USA) at 
72 °C for 30 minutes in the presence of 1x polymerase buffer and 0.25 mM dNTPs in a total 
volume of 50 µl. The product was inserted into the pCRIITOPO vector using the TA-TOPO 
cloning system (Invitrogen, Carlsbad, CA, USA). 
Two µl of TA- tailed PCR product was incubated with 0.5 µl TA-TOPO cloning mix 
for 5 minutes at room temperature. If the standard method wasn’t successful 0.5 µl of salt 
mix was added and the mix was incubated for 30 minutes at room temperature. The entire 
mix was then used for transformation of TOP10 bacteria. 
5.3.7 Site-directed mutagenesis 
Point mutagenesis was carried out using a Quickchange method. Forward and reverse 
mutagenic primers were designed to be 33 bases long with the codon to be altered in the 
middle, 15 unchanged bases on either side. The quickchange reaction was set up in a total 
volume of 50 µl like in 5.3.6. The cycling parameters used were the same as for 5.3.6. After 
cooling to 4 °C, 1 µl of the restriction enzyme DpnI was added to the reaction and incubated 
for 1 hour at 37 °C to digest methylated parental DNA. 10 µl of the reaction mix was used to 
transform XL1-blue bacteria. 
5.3.8 DNA sequencing 
All insert DNAs generated by PCR or mutagenesis were sequenced commercially by 
Medigenomix (Martinsried, Germany), or in house by the Core Facility of the Max-Planck-
Institute. 
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5.4 Protein methods 
5.4.1 SDS-PAGE and Coomassie staining 
Small (8 x 6.5 x 0.075 cm) SDS polyacrylamide gels were prepared. These consisted of a 
resolving, or upper gel and a stacking or upper gel. First the lower gel was cast in wide range 
of percentages dependent on the molecular size of the protein of interest. 
 
Gel (%)  4  5  6  7  7.5  10  12  12.5  15  
Lower buffer (4x) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
AMBA (37.5:1) 1.3 1.7 2.0 2.3 2.5 3.3 4.0 4.2 5.0 
Distilled water 6.2 5.8 5.5 5.2 5.0 4.2 3.5 3.3 2.5 
 
To polymerise the minigel 10 µl TEMED and 100µl of 10% (w/v) APS were added and the 
gel was carefully overlaid with water. After the lower gel was fully polymerized the 
overlaying water was sucked of and an upper gel was cast on top. 
 
Gel (%)  3  3.5  4  4.5  
Upper buffer (4x) 2.5 2.5 2.5 2.5 
AMBA (37.5:1) 1.0 1.2 1.3 1.5 
Distilled water 6.5 6.3 6.2 6.0 
 
To polymerise the minigel, 10µl TEMED and 100µl of 10% (w/v) APS were added. A comb 
was inserted immediately avoiding air bubbles. 
Samples were prepared in SDS-PAGE sample buffer and boiled for 5 minutes at 
95°C. Gels were run in a BioRad Mini-PROTEAN 3 gel chamber (BioRad, Germany) in 
SDS-PAGE running buffer at 180V, 30 mA per minigel. 
Protein gels were stained by immersion in 0.01 % Coomassie Brilliant Blue R-250 in 
50 % methanol, 10 % acetic acid for 20 minutes, while shaking. Gels were destained in 20 % 
isopropanol, 20 % acetic acid. 
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5.4.2 Western blotting 
Proteins run on SDS-gels were transferred to 45 µm Hybond-C Extra Nitrocellulose 
(Amersham-Pharmacia, UK) by semi-dry blotting in transfer buffer (1x SDS-PAGE running 
buffer plus 10 % methanol) using a Trans-Blot SD Transfer Cell (BioRad, Germany) at 15 
V, 300 mA, for 45 minutes. Blots were then blocked in milk-PBS for 1 hour before addition 
of the primary antibody. 
Blots were usually incubated with the primary antibody in milk-PBS for 1 hour at 
room temperature before being washed 3 x 5 minutes in milk-PBS. Secondary antibodies 
linked to horseradish peroxidase were subsequently incubated with the blot for 1 hour before 
the blots were washed for a further 3 x 5 minutes in milk. Bound antibodies were then 
detected by chemiluminescence using ECL Western blot detection reagents (Amersham-
Pharmacia, UK) according to the manufacturer’s instructions, exposed to Kodak X-Omat 
XAR-5 film for an appropriate length of time and developed in a Kodak X-OMAT 2000 
Processor. 
5.4.3 Determination of protein concentration 
Protein concentrations were determined using the BioRad Protein Assay kit (BioRad, 
Germany), a modified version of the Bradford Assay. The dye reagent was diluted 1:5 in 
water and 1 ml 1x reagent was used per assay point. Known concentrations of bovine serum 
albumin (BSA) were used to generate a standard curve. The samples were mixed well with 
the dye reagent, and transfered to disposable cuvettes for measurement of the OD595 in an 
Ultrospec 3000 Pro spectrophotometer (Amersham-Pharmacia). The Concentration of the 
protein samples was calculated according to the BSA standard curve. 
5.4.4 Protein precipitation with TCA 
From large volumes proteins were precipitated using trichloroacetic acid (TCA) for loading 
on SDS-PAGE gels. Sodium deoxycholate was added to a final concentration of 0.02 % and 
the sample vortexed. Next TCA was added to a final concentration of 12 %, the sample 
vortexed, and left on ice for 30 minutes. Precipitated proteins were then recovered by 
centrifugation at 20000 x g for 20 minutes at 4 °C. The supernatant was discarded and the 
pellet washed with ice-cold acetone before being centrifuged for a further 10 minutes. The 
supernatant was discarded and the pellet resuspended in an appropriate amount of 1.5x SDS-
PAGE sample buffer with addition of 1 M Tris-HCl pH 8.0, to adjust the pH of the sample if 
necessary. 
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5.4.5 Antibody generation and purification 
Polyclonal antibodies were generated by immunisation of rabbits with recombinant protein 
either in collaboration with Charles River Laboratories, L'Arbresle Cedex, France or the 
Max-Planck-Institute animal facility. Rabbits were immunised initially subcutaneously with 
250 µg antigen mixed with Freund’s complete adjuvant followed by four intramuscular 
boosts with 250 µg antigen mixed with Freund’s incomplete adjuvant. All test bleeds and the 
final bleed out samples were tested on Western Blot for their ability to recognise 
recombinant antigen and the endogenous protein in cell extracts. Specific antibodies were 
purified from the bleed out via affinity chromatography. 
In order to exclude antibodies against the tag- protein (MBP, GST, 6xHis) used to 
purify of original recombinant antigen, the tag- protein alone was coupled to Affigel-15 
(BioRad, Germany). 4 ml of Affigel-15 beads were washed once with water to remove the 
isopropanol storage solution and added to 4 ml protein solution of 1 mg/ml recombinant tag 
protein. After 2 hours of incubation with shaking at 4 °C, the gel was spun for 2 minutes at 
1000x g. Thereafter it was washed three times with 15 ml PBS, once with 15 ml of 0.2 M 
glycine pH 2.8 and again three times with 15 ml PBS to remove any uncoupled protein.  
For purification of the antibody 15 ml of serum was filtered and incubated with 1 ml of 
the affinity matrix coupled to about 1 mg tag- protein rolling for 90 minutes at 4 °C. After 
this, the slurry was pelleted by centrifugation for 2 minutes at 1000x g. The supernatant 
contained the antigen- specific antibodies. Tag protein- specific antibodies remained bound 
to the matrix. The supernatant was then incubated rolling for 90 minutes at 4 °C with another 
equally prepared affinity matrix coupled to approx. 1 mg antigen to purify the antigen-
specific antibodies.  After this, the slurry was pelleted by centrifugation for 2 minutes at 
1000x g. Following three washes with 15 ml PBS, bound antibodies were eluted using 0.2 M 
glycine pH 2.8 and collected as 1 ml fractions into Eppendorf tubes containing 200ml 1M 
Tris-HCl pH 8.0. Samples were immediately mixed to neutralise the acidic pH and stored on 
ice. After SDS-PAGE analysis antibody peak fractions were pooled, dialysed overnight 
against PBS, aliquoted and stored at – 80 °C or kept at 4 °C for immediate use. 
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5.5 Yeast methods 
5.5.1 Strains, media and growth 
The S.cerevisiae strain PJ69-4A was used for all two-hybrid experiments, the genotype of 
which is: 
MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4∆, gal80∆, LYS2::GAL1UAS-
GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2, MEL1 met2::GAL7-lacZ 
 
Yeast was grown in either YPDA or SC dropout media selecting for appropriate plasmids at 
30 °C. Short-term storage was on agar plates at 4 °C. 
YPDA medium consisted of 20g/l peptone (Difco/Becton-Dickinson), 10 g/l yeast 
extract (Difco), and 20g/l glucose (plus 20 g/l Bacto-agar for YPDA-agar). The medium was 
then sterilised in an autoclave and, after cooling to approximately 55 °C, 6 ml 0.2 % sterile 
filtered adenine hemisulphate was added. 
Synthetic complete (SC) dropout medium was prepared as follows: Amino acid base 
(-His/-Trp/-Leu/-Ura) was prepared by mixing 20 g alanine, arginine, asparagine, aspartic 
acid, cysteine, glutamine, glutamic acid, glycine, inositol, isoleucine, lysine, methionine, 
phenylalanine, proline, serine, threonine, tyrosine, and valine with 5 g adenine and 2 g para-
aminobenzoic acid. To prepare dropout mixes, 36.7 g of amino acid base was mixed with 
either 2 g histidine, 4 g leucine, 2 g tryptophan, or 2 g uracil, as appropriate to form the 
correct dropout mix. The SC dropout medium was autoclaved and after cooling to 
approximately 55 °C, 6 ml 0.2 % sterile filtered adenine hemisulphate was added, unless the 
dropout medium should be without adenine. 
5.5.2 Yeast transformation (frozen cell method) 
To prepare frozen competent yeast cells, several colonies were picked from a freshly grown 
plate and grown overnight in YPDA or in SC –Trp for bait strains at 30 °C with shaking. 
The overnight culture was diluted to an OD600 of 0.15 in fresh medium and grown at 30 °C 
to an OD600 of 0.5 – 0.6 (1.2 – 1.5 x 107 cells). The cells were then harvested at 3000 rpm for 
2 minutes at room temperature in a Heraeus centrifuge. The cells were washed in one half 
culture volume sterile water and spun as before. The cells were then resuspended in 1/8th 
culture volume of LiSorb and incubated for 5 minutes at room temperature before being 
spun as before. The cell pellet was resuspended in 600 µl LiSorb per 100 ml original culture. 
Materials and Methods 
139 
 
Single stranded carrier DNA was added (10µl /100µl yeast of 10 mg/ml Gibco salmon sperm 
DNA, heat-treated at 95 °C for 5 minutes). After aliquoting the cells were kept at -80°C. 
To transform frozen competent yeast, the cells were thawed at room temperature. Per 
transformation 10 µl of cells were used. About 100ng of plasmid DNA were added to the 
cells, followed by 150 µl LiPEG and 17,5 µl DMSO. The mixture was vortexed and 
incubated for 15 minutes at room temperature before heat-shocking for 15 minutes in a 42 
°C waterbath. The cells were then pelleted at 400xg in a microfuge, the supernatant was 
removed, and the cells were resuspended in 200 µl sterile water.  100 µl were the plated onto 
appropriate selective plates and grown at 30 °C. 
In the case of directed yeast two-hybrid experiments, transformed cells were 
originally grown on SC-Leu/-Trp plates to select for both the bait and prey plasmids. After 2 
–3 days growth, colonies were picked and restreaked onto SC-Leu/-Trp and SC-QDO (SC-
Leu/-Trp/-His/-Ade) plates to assess the two-hybrid interaction. 
5.5.3 Plasmid DNA minipreps from yeast cells 
To prepare plasmid DNA from yeast cells a matchhead-sized ball of cells scraped from a 
fresh plate into 1 ml water was pelleted at 400 g in a microfuge. The cell pellet was 
resuspended in 500 µl buffer S. The cells were then incubated at 37 °C for at least 1 hour. 
Afterwards 100 µl lysis buffer was added, vortexed, and the lysate incubated at 65 °C for at 
least 30 minutes until the mixture cleared. 166 µl 3 M KOAc pH 5.5 was then added to stop 
the lysis reaction. The tubes were inverted to mix, and incubated on ice for 10 minutes. After 
centrifugation at 20000x g in a microfuge at 4 °C for 15 minutes the supernatant was 
transferred to a clean Eppendorf tube. 800 µl cold ethanol was added and the tubes were 
inverted to mix. Following incubation on ice for 10 minutes the reaction was spun as before 
for a further 10 minutes. The supernatant was removed and the pellet washed in 1 ml 70% 
ethanol. The pellet was allowed to air dry before resuspending in 40 µl sterile water. 
5.5.4 Yeast two-hybrid screening 
To screen human a cDNA library for potential interactors of a protein of interest, the protein 
was cloned into the pFBT9 vector. Next a competent bait strain containing this construct was 
generated as described in (5.5.2) using SC –Trp media as selection.  
To determine the efficiency of transformation in the newly generated bait strain it 
was transformed using a cDNA library in pACT2 generated from human testis. It was then 
plated in different dilutions on SC -Leu/-Trp to select for co-transfected yeast. The 
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efficiency was calculated as [(number of colonies x volume of suspension (µl)]/plated 
volume (µl) x dilution x amount of library DNA (µg). With this information a defined 1 
million clones could be screened. 
After transformation of the bait strain with sufficient cDNA library to ensure 1 million 
screened clones, the yeast was plated on 15 cm dishes on SC QDO to select for interaction. 
Plates were left at 30°C for up to seven days, before DNA was purified from the yeast as 
described in 5.5.3. The DNA was then transformed for amplification in E. coli using 
electroporation as described in 5.2.4 and subsequently purified as in 5.2.5. These plasmids 
were then re- transformed into the bait strain as in PJ 694A together with an empty pFBT9 
plasmid. Using these two controls real positives could be distinguished from false positives 
and were then sequenced as in 5.3.8 and identified using the “Basic Local Alignment Search 
Tool” BLAST (http://www.ncbi.nlm.nih.gov/BLAST/). 
5.6 Mammalian cell culture 
5.6.1 Cell culture 
HeLa L and hTERT-RPE1 cells were cultured at 37 °C and 5 % CO2 atmosphere in 
Dulbeccos Modified Eagle Medium (DMEM) containing 10 % fetal calf serum, 100 U/ml 
penicillin and 100 µg/ml streptomycin (GIBCO, Invitrogen, Carlsbad, CA, USA) 
5.6.2 Transient transfection of mammalian cells 
HeLa cells were transiently transfected with plasmind DNA constructs using the lipid-based 
transfection reagent FuGENE6 (Roche, Germany) or the equivalent LT1 (MoBiTec, 
Germany). For a 24-hour transfection about 50.000 cells per well of a 6-well plate were 
seeded 24 hours prior to the transfection. Per single well of a 6-well plate 1 µg plasmid DNA 
was used with 3 µl FuGene6 or LT1 diluted in 100 µl OptiMEM medium (Invitrogen, 
Carlsbad, CA, USA). After gentle mixing and complex formation for 25 minutes at room 
temperature the mixture was added drop-wise to the cells. Usually the transfection was left 
for 24 hours. 
5.6.3 RNA interference 
In order to selectively knockdown the expression levels of particular proteins, small 
interfering RNA duplexes (siRNAs) were transfected into Hela cells. Either 21 nucleotide 
siRNA duplexes with a 3’ overhang of two nucleotides were designed or pre-designed 
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SMART Pools by Dharmacon Inc. were used. The lyophilised and pre-annealed siRNA 
duplexes were diluted to a stock solution of 100 µM and aliquots were stored at – 80 °C. 
HeLa cells were seeded 24 hours prior to transfection to a density of about 25.000 cells 
per well of a 6-well plate for a typical 72 hours siRNA time course. For transfection the 
lipid-based transfection reagent Oligofectamine (Invitrogen, Carlsbad, CA, USA) was used. 
For a single well of a 6-well plate 3 µl Oligofectamine and 3 µl of 20 µM siRNA duplex 
were added to 200 µl OptiMEM medium (Invitrogen, Carlsbad, CA, USA) in a RNAse-free 
Eppendorf tube. The mixture was mixed gently and left for 25 minutes at room temperature. 
The mixture was then added drop-wise to the cells. 
5.7 Mammalian cell methods 
5.7.1 Immunofluorescence 
For immunofluorescence cells were cultured on ethanol-flamed coverslips in 6-well plates.  
For paraformaldehyde fixation, 3 % paraformaldehyde was prepared by dissolving 3 g 
paraformaldehyde in 100 ml PBS at 80 °C in a fume hood. 10 µl 1 M CaCl2 and 10 µl 1 M 
MgCl2 were added while stirring before the solution was allowed to cool to room 
temperature and pH adjusted to 7.4. The solution was then vacuum-filtered through a 0.45 
µm filter and 15 ml aliquots were stored at – 20 °C. The coverslips were fixed in 3% 
paraformaldehyde for 15 minutes and were then washed once in 2 ml quench solution (50 
mM NH4Cl in PBS made freshly prior to use) before incubation in a further 2 ml quench 
solution for 10 minutes. The coverslips were then washed in 3 x 2ml PBS. If the cells were 
to be permeabilised, they were incubated for 5 minutes in permeabilisation solution (0.2% 
TX100 in PBS) before washing in 3 x 2ml PBS. 
For methanol fixation, the coverslips were washed twice in PBS. Per well 2ml of -
20°C methanol was added, and the 6-well was incubated at -20°C for 5 minutes. 
Subsequently the coverslips were washed in room temperature PBS twice. 
For antibody labelling, primary antibodies were diluted appropriately in PBS. A strip 
of parafilm was placed on a flat surface and 50 µl drops of the antibody solution were placed 
on the strip. Coverslips with fixed cells were then transferred, cell face down, onto the 
antibody drops. The coverslips were then covered with a moist, dark chamber and left for 1 
hour at room temperature. After this incubation the coverslips were returned to the wells and 
washed in 3 x 2ml PBS. The same procedure as before was followed for incubation with 
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secondary antibodies conjugated to appropriate fluorophores. After washing in PBS for the 
final time, coverslips were mounted onto clean microscope slides by placing them, cell face 
down, onto a 10 µl drop of Moviol mounting medium. The mounting medium used usually 
contained 1 µg/ml DAPI stain. The coverslips were then left overnight at room temperature 
to allow the Moviol to dry. 
Images were collected using an Axioskop-2 with a 63x Plan Apochromat oil 
immersion objective of NA 1.4, standard filter sets (Carl Zeiss, Göttingen, Germany), a 1300 
by 1030 pixel cooled-CCD camera (model #CCD-1300-Y, Princeton Instruments, Trenton, 
NY) and Metavue software (Visitron Systems, Puchheim, Germany). Images were cropped 
in Adobe Photoshop CS then sized and placed using Adobe Illustrator CS (Adobe, San Jose, 
CA). 
5.7.2 Cell extracts 
In order to detach cells from the cell culture dishes, HeLa cells were treated with PBS 
containing 1 mM EDTA for 15 minutes at 37 °C, then gently pipetted off from the cell 
culture dishes into clean plastic vials and centrifuged for 5 minutes at 400 g. Total cell 
extracts were prepared from cell pellets by addition of ice-cold mammalian lysis buffer 
containing 1 tablet of complete mini protease inhibitor (Roche, Mannheim, Germany) per 10 
ml solution and pipetting up and down several times. After 20 minutes incubation on ice the 
lysate was cleared by centrifugation at 20000 g at 4 °C for 15 minutes. The supernatant was 
transferred to a clean Eppendorf and the protein concentration of the extract was determined 
as described in 5.4.3. 
5.7.3 Immunoprecipitation 
For immunoprecipitation (IP) cell extracts were incubated with antibodies in an appropriate 
volume of mammalian lysis buffer. To detect proteins on Western blot IPs were usually 
performed with cell extracts from one 10 cm dish and 1 µg purified antibody in a total 
volume of 1 ml. After addition of 15 µl of protein- G sepharose (Amersham, UK) the slurry 
was incubated for 2 hours on a roller at 4 °C for the antibody-antigen complex to form and 
be extracted. The complex on the sepharose beads was collected by 400g centrifugation at 4 
°C for 5 minutes; the supernatant was kept to show depletion of the antigen. The beads were 
washed three times with 1 ml lysis buffer. After a final centrifugation at top speed for one 
minute, residual buffer was removed, and boiling in 1.5x SDS sample buffer eluted the 
bound complex. 
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To IP intact transmembrane complexes, a different buffer (50mM HEPES-NaOH pH 
7.5, 150 mM KCl, 1 mM EGTA, 1 mM EDTA, 5mM MgCl2, 5% [vol/vol], 1% Digitonin 
[wt/vol], heated to 95°C prior to use) had to be chosen.  
5.7.4 Cell fractionation 
For fractionation experiments HeLa cells were grown on 15 cm dishes to 70% confluence. 
Cells were either transfected using 15 µg of each plasmid DNA and left for 24 hours to 
express the protein of interest, or incubated for 30 min in growth medium containing 5 µg/ml 
Brefeldin A. The cells were then harvested and washed twice in ice cold PBS. The cell pellet 
was resuspended in 1 ml of 25 mM Tris HCl pH 7.4, 130 mM KCl, 5 mM MgCl2, containing 
protease inhibitor cocktail tablets (Roche, Germany). Cells were then broken open by 
passing them 40 times through a 27G needle using a 1 ml syringe. Nuclei and cell debris 
were removed by centrifugation for 5 min at 1000x g and 4°C. This post-nuclear supernatant 
was split into two equal aliquots. One was kept on ice and corresponds to the total material. 
The other half was centrifuged for 30 min at 100,000x g and 4 °C. The supernatant 
corresponding to the soluble cytosolic fraction was transferred to a fresh tube. The pellet, 
corresponding to the membrane fraction, was resuspended in 100µl 1.5x sample buffer. 
Aliquots of the supernatant and total of each sample were precipitated by adding 0.5 µl of 
10% 26 [wt/vol] sodium deoxycholate and 30 µl of 100% [wt/vol] TCA. After 30 min 
incubation on ice, precipitated protein was collected by centrifugation at 20,000x g and 4 °C. 
Pellets were washed with ice cold acetone, and then resuspended in 100 µl of 1.5x sample 
buffer. 
5.7.5 Carbonate extraction 
For carbonate extraction experiments, a 200µl aliquot of the post nuclear supernatant 
generated as in 5.7.4 was split in two identical halves. One was kept on ice as the total 
material, while the other was centrifuged at 100,000 x g for 30 min at 4°C to generate a 
membrane pellet. The pellet was then resuspended in 100 mM Na2CO3 and incubated on ice 
for 30 min. To recover the membrane the sample was centrifuged at 100,000 x g for 30 min 
at 4°C. The supernatant was precipitated using 25% [wt/vol] TCA, and equal amounts of the 
total, carbonate extracted supernatant and membrane pellet fractions were analysed by 
western blotting. 
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5.7.6 Proteinase K digestion 
For proteinase K digestion experiments, HeLa cells from two 70% confluent 15 cm dishes 
and one 10 cm dish transfected with GFP-tagged TBC1D20 constructs for 24 h were washed 
twice in cold PBS, then scraped of the dishes, and pooled. The cell pellets were resuspended 
using 6 passes through a 21G needle in 50 mM HEPES pH 7.5, 200 mM Sucrose, 1 mM 
MgCl2, and 1 mM EDTA to give a final volume of 1 ml. This cell suspension was passed 
though an EMBL cell cracker (European Molecular Biology Laboratories, Heidelberg, 
Germany) fitted with an 8.002 mm diameter ball. The broken cell suspension was 
centrifuged twice at 1000 x g and 4°C for 5 min to remove cell debris and leave a post 
nuclear supernatant. Proteinase K (New England Biolabs, Ipswich, MA) was incubated at 
37°C for 30 min prior to use to inactivate any contaminating lipase activity. The post nuclear 
supernatant was then adjusted to 10 mM CaCl2, and 100 µl aliquots treated with 2 µg 
proteinase K, 0.5 [vol/vol] % Triton-X 100, or both proteinase K and Triton-X 100 for 30 
min on ice. To stop the reaction, a half volume of 100 [wt/vol] % TCA was added, samples 
were then vortexed and incubated on ice for 30 min. Proteins were recovered by 
centrifugation at 20,000 x g for 15 min, the pellets washed in 1 ml of –20°C acetone, 
resuspended in 100 µl of sample buffer, and 20µl analysed by western blotting. 
5.8 Cellular and biochemical assays 
5.8.1 EGF uptake assay 
EGF coupled to Alexa Fluor 488 (40xstock, 200 µg/ml) and transferrin coupled to Texas 
Red (100xstock, 5 mg/ml) (Molecular Probes, Karlsruhe) were stored as stock solutions in 
PBS at –20 °C. For uptake assays, HeLa cells plated on glass cover slips at a density of 
50,000 cells/well of a six-well plate were washed three times with serum-free growth 
medium 36 h after plating, and then incubated in serum-free growth medium for 15–16 h at 
37 °C and 5% CO2. Cover slips were washed three times in ice-cold PBS, and placed on 40 
µl drops of uptake medium (DME, 2% [wt/vol] bovine serum albumin, 20mM HEPES-
NaOH (pH 7.5) and either 5 µg/ml EGF or 50 µg/ml transferrin on an ice-cold metal plate 
covered in Parafilm (Pechiney Plastic Packaging, Menasha, WI). After 1 h incubation, the 
coverslips were washed three times in ice-cold PBS to remove excess ligand. One cover slip 
was fixed to give the total bound ligand, and the remaining cover slips were transferred to a 
six-well plate containing pre-warmed growth medium and incubated at 37 °C and 5% CO2. 
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At the time points of interest, cover slips were fixed and processed for immune fluorescence 
microscopy (5.7.1). 
5.8.2 VSV-G transport assay 
HeLa cells plated on glass cover slips were transfected with a plasmid encoding green 
fluorescent protein (GFP) tagged VSV G ts045 protein for 2 h at 37°C then 12 h at 39.5°C. 
The cells were then incubated for 30 minutes at 4°C on ice to promote VSV G protein 
folding, and afterwards the growth medium was replaced with pre-warmed medium at 
31.5°C. Immediately before adding pre-warmed medium a t=0 time point was fixed with 3% 
[wt/vol] paraformaldehyde in PBS. After the required chase period, usually at 30 and 60 
minutes, cover slips were fixed and processed for fluorescence microscopy (5.7.1). Cell 
surface VSV G was detected with a monoclonal antibody against the VSV G luminal 
domain. To detect transfected cells or to stain endogenous markers, the cell membrane was 
permeabilised using 0.2 % TX100 [vol/vol] after staining for cell surface VSV G and cells 
were incubated with antibodies.  
5.8.3 GTP-hydrolysis assay 
For Rab loading reactions, 10 µl of assay buffer, 73 µl dH2O, 10 µl of 10 mM EDTA (pH 
8.0), 5 µl of 1 mM GTP, 2 µl of [γ32P] GTP (Amersham PB10244; 10 mCi/ml; 5000 
Ci/mmol) and 100 pmoles GST–Rab protein were mixed on ice. Initially GTP binding was 
measured using a nitrocellulose filter-binding assay to determine the optimal time for GTP- 
loading. To do this a 20µl aliquot of the loading mixture was taken and pipetted immediately 
onto a nitrocellulose filter on top of a vacuum flask. The filter was washed twice with assay 
buffer (without BSA) and then dried on Whatman paper, before being transferred to a 
scintillation vial containing 4 ml of Ultima Gold scintillation liquid (Perkin-Elmer) and was 
scintillation counted.  
After 15 min incubation at 30 °C, loaded Rabs were stored on ice. 5 µl aliquots were 
taken in duplicate and immediately added to 795 µl of ice cold 5% [wt/vol]-activated 
charcoal slurry in 50 mM NaH2PO4, and left on ice. This is the t=0 value. The Rab loading 
mix was then split into two equal halves. In one half (+GAP) GTPase- reactions were started 
by the addition of 0.5- 10 pmoles of GAP. The other half was used to calculate the basal 
hydrolysis by the Rab (-GAP), so only a corresponding amount of 1x assay buffer was 
added. Reactions were then incubated at 30 °C, taking 5 µl samples in duplicate at 60 min. 
The 5 µl aliquots were immediately added to 795 µl of ice cold 5% [wt/vol]-activated 
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charcoal slurry in 50 mM NaH2PO4, left for 1 h on ice and then centrifuged at 16000 g in a 
bench-top microfuge to pellet the charcoal. A 400µl aliquot of the supernatant was 
scintillation counted in 4ml of Ultima Gold scintillation liquid (Perkin-Elmer).  
At the end of the reaction a 2.5µl aliquot of the assay mix was scintillation counted to 
measure the specific activity of the reaction in cpm/pmole of GTP, so the amount of GTP 
hydrolised during the reaction could be calculated. The measured specific activity was then 
multiplied by 40 in order to get the specific activity for the full assay of 100 µl. This value 
was then divided by the total of 5000 pmol GTP in the reaction to obtain the specific activity 
in cpm/pmole of GTP.  
The measured values of the 5 µl aliquots taken from each reaction in duplicate at 
each time point were averaged and then multiplied by 2 as only 400 µl out of 800 µl charcoal 
mix were used. The values were then multiplied by 20 as only 5 µl out of 100 µl total 
reaction mix were measured. To calculate the amount of GTP hydrolysed in pmol, these 
values were then divided by the specific activity per pmole GTP cpm/pmole. The t=0 values 
were then subtracted to eliminate the background of the reaction. The amount of GTP 
hydrolysed by the Rabs alone (-GAP) was then subtracted from the stimulated reactions 
(+GAP). By this calculation the stimulation of GTP hydrolysis by all Rabs upon addition of 
the same GAP can be compared. 
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Abbreviations 
 
Abbreviation Description 
aa Amino acid 
ARF ADP ribosylation factor 
ARL ARF like 
BFA Brefeldin A 
CCP Clathrin coated pit 
CCV Clathrin coated vesicle 
CGN Cis-Golgi network 
COP Coat protein 
C-terminus Carboxyl terminus 
EE Early endosome 
EEA1 Early endosomal antigen 1 
EGF Epidermal growth factor  
EGFR EGF receptor 
ER Endoplasmic reticulum 
ERGIC ER-Golgi intermediate compartment 
GAP GTPase activating protein 
GDF GDI displacement factor 
GDI GDP dissociation inhibitor 
GDP Gunanosineine 5’diphosphate 
GEF Gunanine nucleotide exchange factor 
GFP Green fluorescent protein 
GTP Gunanosine 5’triphosphate 
Gyp GAP for Ypt 
HGF Hepatocyte growth factor 
Hrs HGF regulated tyrosine kinase substrate 
kDa Kilo Dalton 
LE Late endosome 
LY Lysosome 
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MPR Mannose 6-phosphate receptor 
MVB Multivesicular body 
NEM N-ethyl malemide 
Ni-NTA Nickel-nitriloacetic acid 
NSF NEM sensitive factor 
N-terminus Amino terminus 
PM Plasma membrane 
QDO Quadruple dropout 
Rab Ras like from brain 
RE Recycling endosome 
siRNA Small interfering RNA 
SNAP Soluble NSF acceptor protein 
SNARE SNAP receptor 
TGN Trans-Golgi network 
TMD Transmembrane Domain 
VSV-G Vesicular stomatitis virus G protein 
VTC Vesicular tubular cluster 
x Any amino acid 
Ypt Yeast protein transport 
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